primary trial Outcome Measurement:	Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms	To evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women. The percent change in breast density will be reported here.	Time frame: 12 months	Results 1:	Arm/Group Title: Placebo	Arm/Group Description: Patients receive oral placebo once daily for 12 months.	Overall Number of Participants Analyzed: 46	Mean (Standard Deviation)	Unit of Measure: percent change  -3.4         (7.1)	Results 2:	Arm/Group Title: Vitamin D	Arm/Group Description: Patients receive oral vitamin D (2000 IU) once daily for 12 months.	Overall Number of Participants Analyzed: 40	Mean (Standard Deviation)	Unit of Measure: percent change  -1.4         (11.9)	Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Cohort A - Pegylated Irinotecan to Treat NSCLC	Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.	Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)	INTERVENTION 2:	Cohort C - Pegylated Irinotecan to Treat mBC	Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.	Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)	Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC.	[1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 10/14 (71.43%)	Hemoglobin 2/14 (14.29%)	Lymphopenia 1/14 (7.14%)	Cardiac ischemia/infarction 1/14 (7.14%)	Hypertension 2/14 (14.29%)	Hypotension 1/14 (7.14%)	Constipation 1/14 (7.14%)	Diarrhea 1/14 (7.14%)	Heartburn/dyspepsia 1/14 (7.14%)	Fatigue (asthenia, lethargy, malaise) 2/14 (14.29%)	Rigors/chills 1/14 (7.14%)	the primary trial and the secondary trial only record 4 of the same adverse events.	[1, 0, 0, 1, 0, 1, 0, 0, 1, 0, 1, 0]
secondary trial Adverse Events 1:	Total: 96/162 (59.26%)	Cardiac disorders - Other, specify 2/162 (1.23%)	Diarrhea 1/162 (0.62%)	Mucositis oral 2/162 (1.23%)	Nausea 1/162 (0.62%)	Fatigue 6/162 (3.70%)	Breast infection 2/162 (1.23%)	Soft tissue infection 1/162 (0.62%)	Lymphocyte count decreased 2/162 (1.23%)	Neutrophil count decreased 78/162 (48.15%)	Hypertension 1/162 (0.62%)	the primary trial and the secondary trial only record 4 of the same adverse events.	[1, 0, 0, 1, 0, 0, 1, 0, 0, 1, 0, 1]
primary trial Adverse Events 1:	Total: 3/22 (13.64%)	ascites with hyponatraemia 0/22 (0.00%)	febrile neutropenia with respiratory infection 1/22 (4.55%)	urosepsis 1/22 (4.55%)	febrile neutropenia with urinary tract infection 0/22 (0.00%)	dyspnoea 1/22 (4.55%)	hypoxia 0/22 (0.00%)	thromboembolism 0/22 (0.00%)	Adverse Events 2:	Total: 4/17 (23.53%)	ascites with hyponatraemia 1/17 (5.88%)	febrile neutropenia with respiratory infection 0/17 (0.00%)	urosepsis 0/17 (0.00%)	febrile neutropenia with urinary tract infection 1/17 (5.88%)	dyspnoea 0/17 (0.00%)	hypoxia 1/17 (5.88%)	thromboembolism 1/17 (5.88%)	19.57% of patients in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 9/46 (19.57%)	Febrile neutropenia 1/46 (2.17%)	Cardiac disorder 1/46 (2.17%)	Diarrhea 1/46 (2.17%)	Upper gastrointestinal hemorrhage 1/46 (2.17%)	Chest pain 1/46 (2.17%)	Fatigue 1/46 (2.17%)	Neutrophil count decreased 2/46 (4.35%)	Platelet count decreased 1/46 (2.17%)	Anorexia 1/46 (2.17%)	Dehydration 1/46 (2.17%)	Serum potassium increased 1/46 (2.17%)	19.57% of patients in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Fulvestrant + Everolimus	Fulvestrant + Everolimus	Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that.	the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally	[1, 1, 1, 1]
primary trial INTERVENTION 1:	Five Days of Mammosite Therapy	[Not Specified]	the primary trial and the secondary trial administer their interventions at different frequencies.	[1, 1, 1]
secondary trial INTERVENTION 1:	Bevacizumab Plus Paclitaxel	Bevacizumab 10 mg/kg intravenous (i.v.), days 1 and 15, every 4 weeks, Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks	INTERVENTION 2:	Bevacizumab Plus Capecitabine	Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks, Capecitabine 1000 mg/m² twice-daily, days 1-14, every 3 weeks	the primary trial and the secondary trial administer their interventions at different frequencies.	[1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 3/49 (6.12%)	Neutrophils/ANC *1/49 (2.04%)	Leukocytes *1/49 (2.04%)	Hypocalcemia *1/49 (2.04%)	Febrile neutropenia *1/49 (2.04%)	Left Ventricular Systolic Dysfunction *1/49 (2.04%)	Constipation *1/49 (2.04%)	Mucositis-oral *1/49 (2.04%)	Infection-oral thrush *1/49 (2.04%)	rash *1/49 (2.04%)	A patient in the primary trial had a fungal infection of the mouth.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial DISEASE CHARACTERISTICS:	Previously diagnosed with primary breast cancer	Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g., letrozole, anastrozole, or exemestane), either as initial therapy or after prior tamoxifen citrate, including treatment received as part of clinical trial CAN-NCIC-MA17	Completed aromatase inhibitor therapy  2 years ago	No metastatic or recurrent disease, contralateral breast cancer, or ductal carcinoma in situ in either breast, as determined by the following:	Clinical examination of the breast area, axillae, and neck within the past 60 days	Mammogram within the past 12 months*	Chest x-ray within the past 60 days	Bone scan, if alkaline phosphatase > 2 times normal and/or there are symptoms of metastatic disease AND confirmatory x-ray, if bone scan results are questionable, within the past 60 days	Abdominal ultrasound, liver scan, or CT scan of the abdomen within the past 60 days, if ALT, AST, or alkaline phosphatase > 2 times normal NOTE: *A baseline mammogram is not required for patients who have undergone bilateral complete mastectomy	Hormone-receptor status:	Estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) primary tumor at the time of diagnosis, defined as a tumor receptor content of > 10 fmol/mg protein or receptor positive by immunocytochemical assay (for patients not previously enrolled on clinical trial CAN-NCIC-MA17)	ER+ and/or PR+ primary tumor OR hormone receptor status of primary tumor unknown (for patients previously enrolled on clinical trial CAN-NCIC-MA17)	PATIENT CHARACTERISTICS:	Menopausal status not specified	ECOG performance status 0-2	Life expectancy  5 years	WBC > 3.0 x 10^9/L OR granulocyte count (polymorphs + bands)  1.5 times 10^9/L	Platelet count > 100 x 10^9/L	AST and/or ALT < 2 times upper limit of normal (ULN)*	Alkaline phosphatase < 2 times ULN*	Able (i.e. sufficiently fluent) and willing to complete quality-of-life questionnaires in either English or French (NCIC CTG participating centers)	Inability to complete questionnaires due to illiteracy in English or French, loss of sight, or other equivalent reason allowed	Accessible for treatment and follow-up	No other prior or concurrent malignancy except adequately treated, superficial squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or other cancer treated > 5 years ago that is presumed cured NOTE: *Elevated levels allowed provided imaging examinations have ruled out metastatic disease	PRIOR CONCURRENT THERAPY:	See Disease Characteristics	No concurrent selective estrogen receptor modulator (e.g., raloxifene, idoxifene)	No other concurrent anticancer therapy	Patients who received over 5 years of anastrozole therapy, completed under a year ago, are eligible for the primary trial.	[0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	Women >=18 years of age	HER2-negative metastatic breast cancer	Previous adjuvant chemotherapy or hormonal treatment	>=1 measurable target lesion	Exclusion Criteria:	Previous treatment with chemotherapy, an anti-angiogenic agent, or a biologic therapy for advanced or metastatic cancer	Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy	Central nervous system metastases	Other malignancy within last 5 years, except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix	Serious concurrent infection	Patients that are not willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Eligibility Criteria:	Patients must be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast carcinoma. Histologic confirmation shall be by either core needle biopsy or incisional biopsy. Punch biopsy is allowed if invasive breast cancer is documented.	Patients must meet one of the criteria defined below (indicate one):	a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an experienced breast surgeon; or otherwise deemed appropriate candidates for neoadjuvant treatment.	b. Stage IIIB (T4, Any N, M0) or (Any T, N3, M0) disease.	Physical examination, chest x-ray and any x-rays or scans needed for tumor assessment must be performed within 90 days prior to registration.	Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible. Patients with hypertension or age > 60 years must have a Multiple Gated Acquisition (MUGA) or echocardiogram scan performed within 90 days prior to registration (indicate not applicable (NA) if no MUGA required) and Left Ventricular Ejection Fraction (LVEF) % must be greater than the institutional lower limit of normal.	Patients must have a serum creatinine and bilirubin  the institutional upper limit of normal, and an Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT)  2x the institutional upper limit of normal. These tests must have been performed within 90 days prior to registration.	Patients must have an Absolute neutrophil count (ANC) of  1,500/μl and a platelet count of  100,000/μl. These tests must have been performed within 90 days prior to registration.	Patients must have a performance status of 0-2 by Zubrod criteria	Pregnant or nursing women may not participate due to the possibility of fetal harm or of harm to nursing infants from this treatment regimen. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. A urine pregnancy test is required for women of childbearing potential.	All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.	Patients that are not willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]
primary trial Adverse Events 1:	Total: 16/48 (33.33%)	Febrile neutropenia grade 3 3/48 (6.25%)	Neutropenia grade 3 1/48 (2.08%)	Holocraneal cephalea 1/48 (2.08%)	Hypersensibility reaction grade 3 2/48 (4.17%)	Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%)	Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%)	Catheter - related infection grade 3 1/48 (2.08%)	the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any	[1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 21/519 (4.05%)	Anaemia 1/519 (0.19%)	Blood bilirubin 0/519 (0.00%)	Leukopenia 0/519 (0.00%)	Neutropenia 1/519 (0.19%)	Arrhythmia 0/519 (0.00%)	Carotid artery thrombosis 1/519 (0.19%)	Ear infection 0/519 (0.00%)	Conjunctivitis 0/519 (0.00%)	Abdominal pain 1/519 (0.19%)	Anal fissure 0/519 (0.00%)	Constipation 0/519 (0.00%)	Diarrhoea 1/519 (0.19%)	Adverse Events 2:	Total: 119/532 (22.37%)	Anaemia 1/532 (0.19%)	Blood bilirubin 1/532 (0.19%)	Leukopenia 1/532 (0.19%)	Neutropenia 5/532 (0.94%)	Arrhythmia 1/532 (0.19%)	Carotid artery thrombosis 0/532 (0.00%)	Ear infection 1/532 (0.19%)	Conjunctivitis 1/532 (0.19%)	Abdominal pain 1/532 (0.19%)	Anal fissure 1/532 (0.19%)	Constipation 1/532 (0.19%)	Diarrhoea 6/532 (1.13%)	the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any	[1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 1/24 (4.17%)	Pericardial effusion *1/24 (4.17%)	Other cardiac disorder *0/24 (0.00%)	Ejection fraction decrease *0/24 (0.00%)	Hypertension *0/24 (0.00%)	Salivary gland infection *0/24 (0.00%)	Pleural effusion *0/24 (0.00%)	Adverse Events 2:	Total: 6/30 (20.00%)	Pericardial effusion *1/30 (3.33%)	Other cardiac disorder *1/30 (3.33%)	Ejection fraction decrease *1/30 (3.33%)	Hypertension *1/30 (3.33%)	Salivary gland infection *1/30 (3.33%)	Pleural effusion *2/30 (6.67%)	More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1.	[1, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 1]
primary trial Adverse Events 1:	Total: 3/49 (6.12%)	Neutrophils/ANC *1/49 (2.04%)	Leukocytes *1/49 (2.04%)	Hypocalcemia *1/49 (2.04%)	Febrile neutropenia *1/49 (2.04%)	Left Ventricular Systolic Dysfunction *1/49 (2.04%)	Constipation *1/49 (2.04%)	Mucositis-oral *1/49 (2.04%)	Infection-oral thrush *1/49 (2.04%)	rash *1/49 (2.04%)	A patient in the primary trial had a vaginal fungal infection.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Active Medicine Group	risedronate 35 mg weekly	INTERVENTION 2:	Placebo Group	Received placebo medication once weekly	the cyclophosphamide dose in the secondary trial and the Placebo dose in the primary trial are not specified.	[1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Standard Chemotherapy	Patients receive cyclophosphamide-containing chemotherapy alone.	cyclophosphamide: Part of planned chemotherapy regimen	INTERVENTION 2:	Chemotherapy Plus Goserelin	Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.	cyclophosphamide: Part of planned chemotherapy regimen	goserelin acetate: Given subcutaneously	the cyclophosphamide dose in the secondary trial and the Placebo dose in the primary trial are not specified.	[1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Stratum 1: TAC + Bevacizumab	HER2 negative participants were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab every 3 weeks for 6 cycles, and maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.	INTERVENTION 2:	Stratum 2: TCH + Bevacizumab	HER2 positive participants were administered chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) + bevacizumab every 3 weeks for 6 cycles, and maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks.	the primary trial and the secondary trial have no overlap in the drugs they use for their interventions, however they both have placebo groups.	[1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Triptorelin Plus Tamoxifen	Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.	INTERVENTION 2:	Triptorelin Plus Exemestane	Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.	the primary trial and the secondary trial have no overlap in the drugs they use for their interventions, however they both have placebo groups.	[1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 13/74 (17.57%)	neutropenia 1/74 (1.35%)	left ventricular dysfunction 1/74 (1.35%)	fistula enterovesical 1/74 (1.35%)	constipation and hypokalemia 1/74 (1.35%)	nausea, vomiting and burning abdominal pain 2/74 (2.70%)	Infection 1/74 (1.35%)	febrile neutropenia 3/74 (4.05%)	speech impairment 1/74 (1.35%)	dyspnea, pain 1/74 (1.35%)	hemorrhage/bleeding 2/74 (2.70%)	the primary trial had three times the occurence rate of fistula enterovesical as the secondary trial.	[1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]
secondary trial Adverse Events 1:	Total: 11/50 (22.00%)	Anemia 3/50 (6.00%)	Febrile neutropenia 1/50 (2.00%)	Arrythmia 1/50 (2.00%)	Ileus 1/50 (2.00%)	Nausea 1/50 (2.00%)	Pain-Abdominal 1/50 (2.00%)	Vomiting 1/50 (2.00%)	Bronchial infection 1/50 (2.00%)	Sepsis 1/50 (2.00%)	Neutropenia 2/50 (4.00%)	Platelet count decreased 1/50 (2.00%)	Dehydration 1/50 (2.00%)	Arthralgia 1/50 (2.00%)	the primary trial had three times the occurence rate of fistula enterovesical as the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 20/167 (11.98%)	Cardiac failure acute 0/167 (0.00%)	Diarrhoea 5/167 (2.99%)	Colitis 2/167 (1.20%)	Enterocolitis 1/167 (0.60%)	Enterocolitis haemorrhagic 1/167 (0.60%)	Stomatitis 1/167 (0.60%)	Impaired healing 1/167 (0.60%)	Sudden death 1/167 (0.60%)	Postoperative wound infection 2/167 (1.20%)	Erysipelas 2/167 (1.20%)	Bacterial diarrhoea 1/167 (0.60%)	Adverse Events 2:	Total: 4/167 (2.40%)	Cardiac failure acute 1/167 (0.60%)	Diarrhoea 0/167 (0.00%)	Colitis 0/167 (0.00%)	Enterocolitis 0/167 (0.00%)	Enterocolitis haemorrhagic 0/167 (0.00%)	Stomatitis 0/167 (0.00%)	Impaired healing 0/167 (0.00%)	Sudden death 0/167 (0.00%)	Postoperative wound infection 1/167 (0.60%)	Erysipelas 0/167 (0.00%)	Bacterial diarrhoea 0/167 (0.00%)	Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea.	[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 3/19 (15.79%)	Febrile neutropenia 1/19 (5.26%)	Colitis 1/19 (5.26%)	Pain in extremity 0/19 (0.00%)	Nephrolithiasis 0/19 (0.00%)	Pulmonary embolism 1/19 (5.26%)	Dyspnoea 0/19 (0.00%)	Haematoma 0/19 (0.00%)	Adverse Events 2:	Total: 4/30 (13.33%)	Febrile neutropenia 1/30 (3.33%)	Colitis 0/30 (0.00%)	Pain in extremity 1/30 (3.33%)	Nephrolithiasis 1/30 (3.33%)	Pulmonary embolism 0/30 (0.00%)	Dyspnoea 1/30 (3.33%)	Haematoma 1/30 (3.33%)	A patient in the primary trial suffered from Kidney stones.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0]
primary trial Outcome Measurement:	The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)	Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period.	The primary endpoint, Pathological complete response, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.	Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks)	Results 1:	Arm/Group Title: CT-P6	Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study.	Overall Number of Participants Analyzed: 248	Measure Type: Number	Unit of Measure: percentage of responders  46.77        (40.43 to 53.19)	Results 2:	Arm/Group Title: Herceptin	Arm/Group Description: Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study.	Overall Number of Participants Analyzed: 256	Measure Type: Number	Unit of Measure: percentage of responders  50.39        (44.10 to 56.68)	The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Participant is willing and able to give informed consent for participation in the study;	Female, aged 18 years or above;	Diagnosed with breast cancer (invasive or dcis);	Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study;	Undergoing mastectomy breast surgery.	Exclusion Criteria:	Patients with a Pacemaker or implanted device;	Patients requiring an MRI scan prior to surgery;	Patients with known coagulopathy or receiving anticoagulant medication including warfarin, heparin, clopidogrel or rivaroxaban;	Patients receiving Neoadjuvant chemotherapy;	Patients who are pregnant or lactating;	Patients scheduled for immediate breast reconstruction;	Patients who have received Sienna (iron oxide) injection in the previous six months;	Patients with an existing breast haematoma close to the target lesion.	Patients with implantable cardioverter defibrillators are excluded from the primary trial.	[0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0]
primary trial DISEASE CHARACTERISTICS:	Previously diagnosed with primary breast cancer	Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g., letrozole, anastrozole, or exemestane), either as initial therapy or after prior tamoxifen citrate, including treatment received as part of clinical trial CAN-NCIC-MA17	Completed aromatase inhibitor therapy  2 years ago	No metastatic or recurrent disease, contralateral breast cancer, or ductal carcinoma in situ in either breast, as determined by the following:	Clinical examination of the breast area, axillae, and neck within the past 60 days	Mammogram within the past 12 months*	Chest x-ray within the past 60 days	Bone scan, if alkaline phosphatase > 2 times normal and/or there are symptoms of metastatic disease AND confirmatory x-ray, if bone scan results are questionable, within the past 60 days	Abdominal ultrasound, liver scan, or CT scan of the abdomen within the past 60 days, if ALT, AST, or alkaline phosphatase > 2 times normal NOTE: *A baseline mammogram is not required for patients who have undergone bilateral complete mastectomy	Hormone-receptor status:	Estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) primary tumor at the time of diagnosis, defined as a tumor receptor content of > 10 fmol/mg protein or receptor positive by immunocytochemical assay (for patients not previously enrolled on clinical trial CAN-NCIC-MA17)	ER+ and/or PR+ primary tumor OR hormone receptor status of primary tumor unknown (for patients previously enrolled on clinical trial CAN-NCIC-MA17)	PATIENT CHARACTERISTICS:	Menopausal status not specified	ECOG performance status 0-2	Life expectancy  5 years	WBC > 3.0 x 10^9/L OR granulocyte count (polymorphs + bands)  1.5 times 10^9/L	Platelet count > 100 x 10^9/L	AST and/or ALT < 2 times upper limit of normal (ULN)*	Alkaline phosphatase < 2 times ULN*	Able (i.e. sufficiently fluent) and willing to complete quality-of-life questionnaires in either English or French (NCIC CTG participating centers)	Inability to complete questionnaires due to illiteracy in English or French, loss of sight, or other equivalent reason allowed	Accessible for treatment and follow-up	No other prior or concurrent malignancy except adequately treated, superficial squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or other cancer treated > 5 years ago that is presumed cured NOTE: *Elevated levels allowed provided imaging examinations have ruled out metastatic disease	PRIOR CONCURRENT THERAPY:	See Disease Characteristics	No concurrent selective estrogen receptor modulator (e.g., raloxifene, idoxifene)	No other concurrent anticancer therapy	Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial.	[0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	Participant is willing and able to give informed consent for participation in the study;	Female, aged 18 years or above;	Diagnosed with breast cancer (invasive or dcis);	Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study;	Undergoing mastectomy breast surgery.	Exclusion Criteria:	Patients with a Pacemaker or implanted device;	Patients requiring an MRI scan prior to surgery;	Patients with known coagulopathy or receiving anticoagulant medication including warfarin, heparin, clopidogrel or rivaroxaban;	Patients receiving Neoadjuvant chemotherapy;	Patients who are pregnant or lactating;	Patients scheduled for immediate breast reconstruction;	Patients who have received Sienna (iron oxide) injection in the previous six months;	Patients with an existing breast haematoma close to the target lesion.	Patients with ICDs may be eligible for the primary trial.	[0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	Adult Women ( 18 years old).	Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease.	Must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease.	HER2+ patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).	Prior trastuzumab and/or chemotherapy (taxanes included) as neo-adjuvant or adjuvant treatment is allowed but should be discontinued > 12 months prior to randomization.	Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization. Patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment.	Documentation of negative pregnancy test.	Organ functions at time of inclusion.	Exclusion Criteria:	Prior mTOR inhibitors for the treatment of cancer.	Other anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy.	Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc).	Radiotherapy to  25% of the bone marrow within 4 weeks prior to randomization	History of central nervous system metastasis.	Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract.	Serious peripheral neuropathy.	Cardiac disease or dysfunction.	Uncontrolled hypertension.	HIV.	Pregnant,	Patients suffering from Ulcerative colitis are excluded from the primary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]
primary trial DISEASE CHARACTERISTICS:	Histologically confirmed breast cancer	Stage I or II disease (T1-T2, N0, M0/MX disease)	No chest wall invasion by tumor (T3 disease)	Medially or centrally located lesion	No multicentric disease	Multifocal disease allowed	No clinically positive axillary nodes	No enlarged internal mammary nodes by CT scan	Hormone receptor status not specified	PATIENT CHARACTERISTICS:	Male or female	Menopausal status not specified	American Society of Anesthesiologists (ASA) physical status classification 1-2	Not pregnant or nursing	Negative pregnancy test	No other concurrent known, invasive malignancy	No known chronic pulmonary disease	No known allergy to methylene blue or isosulfan blue	PRIOR CONCURRENT THERAPY:	No prior thoracic or cardiac surgery	No prior ipsilateral chest tube placement	Contralateral chest tube placement allowed	No prior neoadjuvant chemotherapy	No prior radiotherapy to the mediastinum	There are several types of surgical and therapeutic treatments, such as Appendectomies and radiotherapy, which are banned for patients wanting to take part in the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 3/19 (15.79%)	Febrile neutropenia 1/19 (5.26%)	Colitis 1/19 (5.26%)	Pain in extremity 0/19 (0.00%)	Nephrolithiasis 0/19 (0.00%)	Pulmonary embolism 1/19 (5.26%)	Dyspnoea 0/19 (0.00%)	Haematoma 0/19 (0.00%)	Adverse Events 2:	Total: 4/30 (13.33%)	Febrile neutropenia 1/30 (3.33%)	Colitis 0/30 (0.00%)	Pain in extremity 1/30 (3.33%)	Nephrolithiasis 1/30 (3.33%)	Pulmonary embolism 0/30 (0.00%)	Dyspnoea 1/30 (3.33%)	Haematoma 1/30 (3.33%)	The majority of patients in the primary trial suffered from Kidney stones.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 9/157 (5.73%)	Blood disorder 1/157 (0.64%)	Hemoglobin decreased 1/157 (0.64%)	Hemolysis 0/157 (0.00%)	Arrhythmia 0/157 (0.00%)	Cardiac disorder 0/157 (0.00%)	Myocardial ischemia 1/157 (0.64%)	Hearing impaired 0/157 (0.00%)	Tinnitus 0/157 (0.00%)	Cataract 0/157 (0.00%)	Diplopia 0/157 (0.00%)	Glaucoma 0/157 (0.00%)	Vision blurred 0/157 (0.00%)	Adverse Events 2:	Total: 14/157 (8.92%)	Blood disorder 0/157 (0.00%)	Hemoglobin decreased 2/157 (1.27%)	Hemolysis 1/157 (0.64%)	Arrhythmia 0/157 (0.00%)	Cardiac disorder 0/157 (0.00%)	Myocardial ischemia 0/157 (0.00%)	Hearing impaired 2/157 (1.27%)	Tinnitus 1/157 (0.64%)	Cataract 1/157 (0.64%)	Diplopia 0/157 (0.00%)	Glaucoma 1/157 (0.64%)	Vision blurred 1/157 (0.64%)	2 cases of hematolysis were recorded in the primary trial, none in the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 6/168 (3.57%)	FEBRILE NEUTROPENIA 3/168 (1.79%)	ENTERITIS 1/168 (0.60%)	PERIPHERAL NEUROPATHY 2/168 (1.19%)	DEPRESSION 1/168 (0.60%)	2 cases of hematolysis were recorded in the primary trial, none in the secondary trial.	[1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	FFDM Plus DBT	Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System.	This endpoint will be evaluated qualitatively. The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate).	INTERVENTION 2:	Full-Field Digital Mammography (FFDM)	Breast Images with FFDM alone FFDM: FujiFilm Aspire Cristalle System.	This endpoint will be evaluated qualitatively. The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate).	the primary trial and the secondary trial have the same number of study groups, but are testing different interventions.	[1, 1, 1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Active Control Group	Health Education Active Control Group	INTERVENTION 2:	My Surgical Success Treatment Group	My Surgical Success Intervention Group	the primary trial and the secondary trial have the same number of study groups, but are testing different interventions.	[1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel	The MTD is defined as the dose range at which  1 of 6 evaluable participants experience dose limiting toxicities (DLT). DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.02 and was defined as any of the following events: 1. Grade 4 neutropenia and thrombocytopenia lasting 7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count <10,000/mm^3; 4. Grade 3 thrombocytopenia with bleeding; 5. Any other Grade 3 nonhematologic toxicity, with following exceptions: Grade 3 nausea/emesis, Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 nonhematological toxicity that could be controlled to Grade 2 with appropriate treatment; 6. Other alisertib-related nonhematologic toxicities Grade 2 that, in opinion of investigator, required a dose reduction or discontinuation of therapy with alisertib.	Time frame: Cycle 1 (Up to 28 days)	Results 1:	Arm/Group Title: Alisertib + Paclitaxel (Phase 1)	Arm/Group Description: Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).	Overall Number of Participants Analyzed: 49	Measure Type: Number	Unit of Measure: mg  40	The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by the primary trial results, is 40 mg orally, twice daily (BID) on Days 1-3, 8-10 and 15-17	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 11/56 (19.64%)	Febrile Neutropenia * 3/56 (5.36%)	Neutropenia * 1/56 (1.79%)	Pancytopenia * 1/56 (1.79%)	Atrial Fibrillation * 1/56 (1.79%)	Coronary Artery Disease * 1/56 (1.79%)	Constipation * 1/56 (1.79%)	Chest Pain * 1/56 (1.79%)	Non-Cardiac Chest Pain * 1/56 (1.79%)	Edema due to Cardiac Disease * 1/56 (1.79%)	Cellulitis * 1/56 (1.79%)	One patient in the primary trial had abnormally low levels of AST, ALT and ANC.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Females with Stage II invasive breast cancer and documented axillary metastases by core biopsy, clinical examination, or fine-needle aspiration who are scheduled to undergo an ALND.	Females > 21 years of age	Exclusion Criteria:	Prior ipsilateral axillary surgery	Prior ipsilateral axillary radiation	Prior ipsilateral breast cancer	Prior ipsilateral breast radiation	Allergy to isosulfan blue dye	History of ipsilateral upper extremity lymphedema	Prior history of surgical excision of the upper outer quadrant of the ipsilateral breast	Prior history of neoadjuvant chemotherapy for current breast cancer	Bulky axillary disease at presentation (N2)	Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial.	[0, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0]
primary trial Outcome Measurement:	Disease-free Survival After Prolonged Endocrine Treatment	To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of disease-free survival.	Time frame: DFS was defined as the time from two years after randomization to the earliest occurrence of loco-regional recurrence, distant recurrence, contralateral new breast cancer, second cancer or death from any cause, assessed up to a maximum of 8.5 years	Results 1:	Arm/Group Title: Arm A: Anastrozol	Arm/Group Description: 1 mg per day for 2 years	Overall Number of Participants Analyzed: 1281	Median (Inter-Quartile Range)	Unit of Measure: Years  NA  [1]    (7.7 to NA)	Results 2:	Arm/Group Title: Arm B: Anastrozol	Arm/Group Description: 1 mg per day for 5 years	Overall Number of Participants Analyzed: 1323	Median (Inter-Quartile Range)	Unit of Measure: Years  NA  [1]    (8.1 to NA)	the secondary trial and the primary trial employ non comparable outcome measures.	[1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Outcome Measurement:	Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer	The number of participants with notable electrocardiogram changes meeting predefined criteria is being reported.	Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days)	Results 1:	Arm/Group Title: DS-8201a	Arm/Group Description: Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle.	Overall Number of Participants Analyzed: 49	Measure Type: Count of Participants	Unit of Measure: Participants  Maximum change from baseline in QTcF: >30 ms: 3   6.1%	Maximum change from baseline in QTcF: >60 ms: 0   0.0%	the secondary trial and the primary trial employ non comparable outcome measures.	[1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	The subject must be female and 18 years of age or older.	The subject must be a preoperative clinical Tis, T1, T2, T3, T4, as well as clinical N0 and clinical M0 breast cancer	The subject must have a diagnosis of primary breast cancer.	The subject must be a candidate for surgical intervention, either with lumpectomy and SLNB or with mastectomy and SLNB, as the treatment of her breast cancer.	The subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 - 2	The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study	Exclusion Criteria:	The subject has clinical or radiological or pathologic evidence of metastatic cancer, including any abnormal or enlarged clinical palpable lymph nodes or core biopsy/surgical biopsy/fine-needle-aspiration evidence of malignant cell within any lymph nodes.	The subject has a known hypersensitivity to vital blue dye (VBD) in a case where vital blue dye was planned for use during SLNB.	The subject has a positive pregnancy test or is lactating.	The subject has had prior surgery to the indicated breast or axilla.	Informed consent is obligatory for entry in the primary trial.	[1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	Written informed consent.	Histological diagnoses of operable invasive adenocarcinoma of the breast (T1-T3). Tumors must be Human Epidermal Growth Factor Receptor 2 (HER2) negative. Patients must be free of disease in the axilla (node negative). If lymphadenectomy is done, at least 10 nodes must be examined. If sentinel node technique is used, sentinel node must be free of disease. Patients must present at least one high risk criterion (St. Gallen, 1998) as follows:	Tumor size > 2 cm; and/or	ER and Progesterone Receptor (PgR) negative; and/or	Histological grade 2-3; and/or	Age < 35 years old.	Time window between surgery and study randomization must be less than 60 days.	Surgery must consist of mastectomy or conservative surgery. Margins free of disease and ductal carcinoma in situ (DCIS) are required. Lobular carcinoma is not considered a positive margin.	Patients must not present evidence of metastatic disease.	Status of hormone receptors in primary tumor. Results must be available before the end of adjuvant chemotherapy.	Status of HER2 in primary tumor, known before randomization. Patients with Immunohistochemistry (IHC) 0 or +1 are eligible. For patients with IHC 2+, fluorescent in situ hybridization (FISH) is mandatory and result must be negative.	Age >= 18 and <= 70 years old.	Performance status (Karnofsky index) >= 80.	Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed, normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF).	Laboratory results (within 14 days prior to randomization):	Hematology: neutrophils >= 1.5 x 10^9/l; platelets >= 100x 10^9/l; hemoglobin >= 10 mg/dl;	Hepatic function: total bilirubin <= 1 upper normal limit (UNL); Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) <= 2.5 UNL; alkaline phosphatase <= 2.5 UNL. If values of AST and ALT > 1.5 UNL are associated with alkaline phosphatase > 2.5 UNL, patient is not eligible.	Renal function: creatinine <= 175 mmol/l (2 mg/dl); creatinine clearance >= 60 ml/min.	Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed within a 20 week time window). All patients must have a bilateral mammogram, thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all patients. Other tests, as clinically indicated.	Patients able to comply with treatment and study follow-up.	Negative pregnancy test done in the 14 previous days to randomization.	Exclusion Criteria:	Prior systemic therapy for breast cancer.	Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any malignancy.	Prior radiotherapy for breast cancer.	Bilateral invasive breast cancer.	Pregnant or lactating women. Adequate contraceptive methods must be used during chemotherapy and hormone therapy treatments. Negative pregnancy test in the 14 previous days to randomization.	Any T4 or N1-3 or M1 tumor.	HER2 positive breast cancer (IHC 3+ or positive FISH result).	Pre-existing grade >=2 motor or sensorial neurotoxicity by the National Cancer Institute Common Toxicity Criteria (NCICTC) v-2.0.	Any other serious medical pathology, such as congestive heart failure, unstable angina, history of myocardial infarction during the previous year, uncontrolled hypertension or high risk arrhythmias.	History of neurological or psychiatric disorders, which could preclude the patients to free informed consent.	Active uncontrolled infection.	Active peptic ulcer; unstable diabetes mellitus.	Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumor curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.	Concomitant treatment with other investigational products. Participation in other clinical trials with a non-marketed drug in the 20 previous days before randomization.	Concomitant treatment with other therapy for cancer.	Males.	Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial, but may still be eligible for the secondary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial DISEASE CHARACTERISTICS:	Histologically or cytologically confirmed adenocarcinoma of the breast	Stage III or IV disease	Primary or recurrent disease	Invasive lobular carcinoma allowed	HLA-A1, -A2, -A3, or -A31 positive	Underwent and recovered from prior primary therapy	Patients with no clinical or radiological evidence of disease who had a previous diagnosis of stage III or IV breast cancer must have undergone prior antineoplastic therapy including, but not limited to, surgery, chemotherapy, and radiotherapy within the past 36 months	Must have at least one undissected axillary and/or inguinal lymph node basin	No history of brain metastases	Hormone receptor status	Estrogen receptor-positive or -negative tumor	PATIENT CHARACTERISTICS:	ECOG performance status of 0 or 1	Body weight > 110 lbs (without clothes)	Male or female	Menopausal status not specified	Absolute neutrophil count > 1000/mm^3	Platelet count > 100,000/mm^3	Hemoglobin > 9 g/dL	Hemoglobin A1c < 7%	AST and ALT  2.5 x upper limit of normal (ULN)	Bilirubin  2.5 x ULN	Alkaline phosphatase  2.5 x ULN	Creatinine  1.5 x ULN	HIV negative	Hepatitis C negative	Not pregnant or nursing	Negative pregnancy test	Fertile patients must use effective contraception	No known or suspected allergies to any component of the vaccine	No active infection requiring antibiotics	No New York Heart Association class III or IV heart disease	No autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement, except the following:	Laboratory evidence of autoimmune disease (e.g., positive ANA titer) without symptoms	Clinical evidence of vitiligo	Other forms of depigmenting illness	Mild arthritis requiring nonsteroidal antiinflammatory drugs	No medical contraindication or potential problem that would preclude study participation	PRIOR CONCURRENT THERAPY:	More than 4 weeks since prior surgery	More than 4 weeks since prior and no concurrent chemotherapy and radiotherapy	More than 4 weeks since prior and no concurrent allergy desensitization injections	More than 4 weeks since prior parenteral, oral, or inhaled corticosteroids	No concurrent inhaled steroids (e.g., Advair® or triamcinolone acetonide)	Prior or concurrent topical corticosteroids allowed	More than 4 weeks since prior and no concurrent growth factors (e.g., epoetin alfa, darbepoetin alfa, or pegfilgrastim)	More than 4 weeks since prior and no concurrent other investigational medication	More than 4 weeks since prior and no concurrent other agents with putative immunomodulating activity except for non-steroidal anti-inflammatory agents	Prior and concurrent hormonal therapy (e.g., tamoxifen, raloxifene, toremifene, fulvestrant, letrozole, anastrozole, or exemestane) allowed	No prior vaccination with any synthetic peptides in this protocol	Vaccines for infectious disease (e.g., influenza) allowed, provided they are administered  2 weeks prior to or  2 weeks after study vaccine	Short term therapy for acute conditions not related to breast cancer allowed	No concurrent illegal drugs	Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial, but may still be eligible for the secondary trial.	[0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Histologically proved infiltrating breast cancer (ductal, lobular carcinoma…) or a carcinoma in-situ with an elevated risk of micro-invasion. (High grade with necrosis, radiologically evaluated size more than 40mm, or immediate mastectomy…)	Unifocal or multifocal but in same quarter	Size < 5cm clinically palpable or not	Clinically or ultrasound axillary N0	Isotopic sentinel node detection	Adult patient	Signed informed consent by patient or legally responsable authority	Patient registered to a social security system	No surgical contra-indication	Exclusion Criteria:	Mammary carcinoma recurrence	Previous same side mammary reduction	Previous lumpectomy	Contra-indication to surgery	Pregnant or breast feeding patient	Denial of participation	Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Inclusion Criteria:	Histologically documented, locally advanced, or metastatic breast cancer; measurable and/or non-measureable but evaluable disease is permitted	HER2-positive disease	History of prior trastuzumab therapy	Life expectancy  90 days as assessed by the investigator	Negative urine pregnancy test  72 hours prior to Cycle 1 Day 1 for all women of childbearing potential	For patients of childbearing potential, agreement to use one highly effective form of contraception or two effective forms of contraception for the duration of the study treatment(s) and for 4 months after the last dose of T-DM1 or 6 months after the last dose of pertuzumab, if applicable	Exclusion Criteria:	Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy for the treatment of breast cancer within 2 weeks of the first study treatment	Prior T-DM1 or pertuzumab therapy	History of intolerance (such as Grade 3-4 infusion reaction) and/or adverse events related to trastuzumab	Grade  2 (based on National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v3) peripheral neuropathy at the time of or within 3 weeks prior to the first study treatment	Brain metastases that are untreated or progressive or have required any type of therapy, including radiation, surgery, and/or steroids, to control symptoms from brain metastases within 60 days prior to the first study treatment	History of cardiac disease, unstable angina, symptomatic congestive heart failure (CHF) (Class  II per the New York Heart Associate [NYHA] guidelines), myocardial infarction, or ventricular arrhythmia  6 months prior to Cycle 1, Day 1	Implantable pacemaker or automatic implantable cardioverter defibrillator	Congenital long QT syndrome or family history of long QT syndrome	Current uncontrolled hypertension	Current treatment with medications that alter cardiac conduction (e.g., digitalis, beta-blockers, or calcium channel blockers) or medications that are generally accepted to have a risk of causing torsades de pointes (TdP)	Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus	Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment, or anticipation of the need for major surgery during the course of study treatment	Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)	Number of patients event-free	Time frame: 12 month period following randomisation	Results 1:	Arm/Group Title: Fulvestrant + Anastrozole	Arm/Group Description: fulvestrant 500 mg + anastrozole 1 mg	Overall Number of Participants Analyzed: 6	Measure Type: Number	Unit of Measure: Participants  6	Results 2:	Arm/Group Title: Anastrozole	Arm/Group Description: anastrozole 1 mg	Overall Number of Participants Analyzed: 7	Measure Type: Number	Unit of Measure: Participants  7	there were no recorded deaths in the primary trial cohorts.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	- Female  18 years, 70 years. ECOG 0-1 with no deterioration over previous 2 weeks Minimum life expectancy 3 months Histological confirmation of hormone receptor-high expressed breast cancer(IHC:ER 60% and PR  60%) on primary tumour at diagnosis/on biopsy of metastasis Histological confirmation of HER2 negative breast cancer on primary tumour at diagnosis/on biopsy of a metastasis The disease-free time of relapsed patients is more than 12 months Once received standard hormone treatment and progressed Clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection At least one evaluative focus according to RECIST creterion or non-measurable disease but only bone metastasis Adequate bone marrow and organ function Progressive disease whilst receiving endocrine therapy for locally advanced or metastatic BC or relapsed with metastatic disease whilst receiving endocrine therapy Radiological or objective clinical evidence of recurrence or progression on or after last systemic therapy prior to enrolment	4 prior lines of endocrine therapy for ABC	3 line of cytotoxic chemotherapy for ABC Suitable for further endocrine therapy Availability of archival tumour sample or fresh biopsy Informed consent Normal organ function	Exclusion Criteria:	Last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour embolisation <21 days prior to study treatment Last dose of palliative radiotherapy <7 days prior to study treatment Rapidly progressive visceral disease not suitable for further endocrine therapy Spinal cord compression or brain/meningeal metastases unless asymptomatic, treated and stable and not requiring steroids for  4 weeks study treatment Creatinine clearance <30 ml/min. Patients with creatinine clearance <50 mL/min will start at a permanently reduced vandetanib dose of 200 mg.	Major surgery (excluding placement of vascular access) within 4 weeks before study treatment Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone metastasis Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent Participation in another study with investigational product during last 30 days Inability or unwillingness to comply with study procedures, including inability to take regular oral medication	Sharone had a hip replacement 2 months prior, she is not elgible for the primary trial.	[0, 0, 0, 0, 1, 0, 1]
primary trial Outcome Measurement:	Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4	Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.	Time frame: Baseline to Week 4	Results 1:	Arm/Group Title: AZD0530 175 mg	Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily	Overall Number of Participants Analyzed: 46	Geometric Mean (95% Confidence Interval)	Unit of Measure: Percentage change in betaCTX  -71.1        (-75.9 to -65.4)	Results 2:	Arm/Group Title: Zoledronic Acid 4 mg	Arm/Group Description: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period	Overall Number of Participants Analyzed: 65	Geometric Mean (95% Confidence Interval)	Unit of Measure: Percentage change in betaCTX  -68.4        (-73.0 to -63.2)	The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group, with a -73.0 % change from baseline.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Females with Stage II invasive breast cancer and documented axillary metastases by core biopsy, clinical examination, or fine-needle aspiration who are scheduled to undergo an ALND.	Females > 21 years of age	Exclusion Criteria:	Prior ipsilateral axillary surgery	Prior ipsilateral axillary radiation	Prior ipsilateral breast cancer	Prior ipsilateral breast radiation	Allergy to isosulfan blue dye	History of ipsilateral upper extremity lymphedema	Prior history of surgical excision of the upper outer quadrant of the ipsilateral breast	Prior history of neoadjuvant chemotherapy for current breast cancer	Bulky axillary disease at presentation (N2)	Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial, patients with prior High-dose chemotherapy can still enter if they satisfy all other inclusion criteria.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	No known soy intolerance	At increased risk of developing breast cancer in >= 1 previously unaffected breast, as defined by any of the following:	Estimated 5-year risk of developing breast cancer using the Gail model, as defined by 1 of the following:	Gail score >= 1.66%	Gail score >= 0.1% for women age 20-29 years	Gail score >= 1.0% for women age 30-39 years	Estimated 5-year risk of developing breast cancer using the Claus model:	Claus score >= 1.66%	Claus score >= 0.1% for women age 20-29 years	Claus score >= 1.0% for women age 30-39 years	Prior diagnosis of unilateral in situ or invasive breast cancer OR history of atypical hyperplasia, BRCA 1 and/or BRCA 2 positivity	History of lobular carcinoma in situ	No evidence of breast cancer, as determined by a negative mammogram within the past 6 months and a history and physical	No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago	Pre- or postmenopausal	ECOG performance status 0-1	Hemoglobin > 10.0 g/dL	Platelet count > 100,000/mm^3	Absolute neutrophil count > 1,000/mm^3	Creatinine < 2.0 mg/dL	SGPT < 82 U/L	SGOT < 68 U/L	Bilirubin < 3 mg/dL* [Note: * Patients with a higher level of bilirubin due to a familial metabolism may be eligible at the discretion of the investigator]	Life expectancy > 2 years	Not pregnant or nursing	Negative pregnancy test	Fertile patients must use effective barrier contraception	Must be willing to keep a dietary diary	No venous thrombosis within the past year	No unrecognized or poorly controlled thyroid disease	No other cancer within the past 5 years except nonmelanomatous skin cancer or noninvasive cervical cancer	No other medical condition that, in the opinion of the investigator, would jeopardize either the patient or the integrity of the data obtained	None of the following for >= 2 weeks before the first random fine needle aspiration and during study participation:	Oral contraceptives	Soy supplements	High soy-containing foods	Fish oil supplements	Multivitamins	Vitamins C and E	Daily aspirin or nonsteroidal	Anti-inflammatory drugs	No other concurrent investigational agents	No concurrent warfarin or other blood thinners	Female patient	Exclusion Criteria:	Women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously	Currently pregnant, or planning to become pregnant during the study period	History of venous thrombosis within past year	Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained	History of other cancer within the past five years, excluding non-melanomatous skin cancer, and non-invasive cervical cancer	Known soy intolerance	Unrecognized or uncontrolled thyroid disease, subjects may be on synthroid, but thyroid function must be in normal range or the patient's physician must document that the patient's thyroid is controlled.	Currently receiving any other investigational agents	Currently on coumadin, or other blood thinners	History of breast augmentation implants.	Rusults from patients who have <4000 epithelial cells in either the first or the second random Fine-needle aspiration (rFNA) will not be included in the study.	Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Female aged  18 years.	Patients with pathologically documented metastatic triple negative breast cancer (TNBC), eligible for treatment with paclitaxel. Paraffin-embedded tissue must be available from metastatic sites, if reasonably accessible, or from the primary tumor, to confirm the diagnosis of TNBC and for correlative studies (only on metastatic tissue). Fifteen slides can be obtained if the full block is not available to be sent or released.	TNBC will be defined as breast cancer with <1% ER+ and <1% PgR+ cells, and HER2 immunohistochemistry score of 0 or 1+ and/or in situ hybridization (ISH) with HER2 gene copy number <4 or a ratio of less than 2 between HER2 gene copy number and centromere of chromosome 17. Patients whose metastatic disease is TNBC are eligible even when their primary tumor expressed hormone receptors and/or HER2.	Patients must be newly diagnosed metastatic or must have relapsed following a prior (neo)adjuvant chemotherapy regimen. If a taxane (i.e., paclitaxel or docetaxel) was administered as part of the (neo)adjuvant regimen, PD must have occurred > 12 months from the end of previous (neo)adjuvant treatment. For non-taxane (neo)adjuvant regimen, PD must have occurred > 6 months from the end of previous (neo)adjuvant treatment	Patients with at least one baseline measurable lesion according to RECIST criteria version 1.1.	Zubrod (Eastern Co-operative Oncology Group [ECOG]) Performance Status (PS) of 0-1.	Life expectancy of at least three months.	Patients must be able to swallow and retain oral medication (intact tablet).	Able to undergo all screening assessments outlined in the protocol.	Adequate organ function (defined by the following parameters):	Serum creatinine < 140 μmol/L (< 1.6 mg/dL) or creatinine clearance > 60 mL/min.	Serum hemoglobin  9 g/dL; absolute neutrophil count  1.5 x 109/L; platelets  100 x 109/L.	Serum bilirubin  1.5 x upper normal limit (UNL) except patients with Gilbert's syndrome	Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST)  2.5 x UNL but  5.0 x UNL in case of liver metastases; alkaline phosphatase (ALP)  UNL but i)  2.5 x UNL in case of liver metastases and ii)  5 UNL in case of bone metastases; albumin  2.5 g/dl.	No history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease.	No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus-I and -II positive status.	Dated and signed IEC/IRB-approved informed consent.	Exclusion Criteria:	Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological therapy), Patients may receive bisphosphonates and other therapies to treat bone metastases, however if used, bone lesions will not be considered as measurable disease.	Less than four weeks since last radiotherapy (excluding palliative radiotherapy).	Pregnancy or lactation or unwillingness to use adequate method of birth control.	Neurological or psychiatric disorders which may influence understanding of study and informed consent procedures.	Active or uncontrolled infection.	Malabsorption syndrome, disease significantly affecting gastrointestinal function.	G>1 pre-existing peripheral neuropathy	Any other invasive malignancy from which the patient has been disease-free for less than 5 years with the exception of curatively treated basal or squamous cell skin cancer	Hypersensitivity to:	paclitaxel	ibuprofen or to more than one non-steroidal anti-inflammatory drug.	medications belonging to the class of sulfonamides, with the exception of sulfanilamides (e.g., sulfamethoxazole).	Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Outcome Measurement:	Pathologic Assessment After Study Treatment	Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or without endocrine therapy. Pathologic complete response: no invasive cancer in the residual breast. Near pathologic complete response: residual disease of less than 1 cm in breast.	Time frame: 12 weeks	Results 1:	Arm/Group Title: Lapatinib + Trastuzumab	Arm/Group Description: All study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week	Overall Number of Participants Analyzed: 64	Measure Type: Number	Unit of Measure: participants  Complete Pathologic Response: 18	Near Complete Pathologic Response: 16	Not Pathologic response: 30	64 of the study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response, or better, after 12 weeks.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Postmenopausal women, Stage III or axillary node positive	Currently disease free of breast cancer and other invasive malignancies at the time of registration	No concurrent use of bisphosphonates	Exclusion Criteria:	Metastatic disease	Adequate hematologic, renal, and hepatic function are required to participate in the secondary trial and the primary trial, however, patients with severe loss in cognitive function are still eligible.	[1, 1, 1, 1, 1, 1]
secondary trial Inclusion Criteria:	Pathologically confirmed HER2-positive MBC	Progression of or new brain metastases after completion of whole-brain radiotherapy or stereotactic radiosurgery	Completion of whole-brain radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollment	Stable systemic disease	Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1	LVEF at least 50%	Adequate hematologic, renal, and hepatic function	Life expectancy more than 12 weeks	Exclusion Criteria:	Progression of systemic disease at Screening	Leptomeningeal disease	History of intolerance or hypersensitivity to study drug	Use of certain investigational therapies within 21 days prior to enrollment	Current anthracycline use	Unwillingness to discontinue ado-trastuzumab emtansine or lapatinib use	Active infection	Pregnant or lactating women	Significant history or risk of cardiac disease	Symptomatic intrinsic lung disease or lung involvement	History of other malignancy within the last 5 years	Adequate hematologic, renal, and hepatic function are required to participate in the secondary trial and the primary trial, however, patients with severe loss in cognitive function are still eligible.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Women aged > 18 years	Histologically documents metastatic breast cancer	HER2 positive using Fluorescence In Situ Hybridization (FISH)	For phase I, patients who have previously received treatment for their metastatic disease are allowed to participate.	For the phase II portion of the study, patients must have measureable disease (> 2 cm; > 1 cm on spiral CT scan)	Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2	A life expectancy of > 3 months	Use of effective means of contraception	Exclusion Criteria:	For Phase II, prior cytotoxic chemotherapy and/or prior Herceptin for their metastatic disease. Prior treatment in the adjuvant setting is allowed.	Elizabeth has HER2 positive breast cancer, she is eligible for the primary trial.	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Fulvestrant + Everolimus	Fulvestrant + Everolimus	Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that.	the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally	[1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 30/98 (30.61%)	NEUTROPENIA 1/98 (1.02%)	ATRIAL FIBRILLATION 1/98 (1.02%)	CARDIAC FAILURE 1/98 (1.02%)	TACHYCARDIA 0/98 (0.00%)	ACUTE VESTIBULAR SYNDROME 1/98 (1.02%)	VERTIGO 0/98 (0.00%)	ABDOMINAL PAIN 0/98 (0.00%)	COLITIS 0/98 (0.00%)	DIARRHOEA 2/98 (2.04%)	FEMORAL HERNIA 0/98 (0.00%)	HAEMATEMESIS 0/98 (0.00%)	ILEUS 0/98 (0.00%)	NAUSEA 0/98 (0.00%)	Adverse Events 2:	Total: 46/102 (45.10%)	NEUTROPENIA 0/102 (0.00%)	ATRIAL FIBRILLATION 0/102 (0.00%)	CARDIAC FAILURE 0/102 (0.00%)	TACHYCARDIA 2/102 (1.96%)	ACUTE VESTIBULAR SYNDROME 0/102 (0.00%)	VERTIGO 1/102 (0.98%)	ABDOMINAL PAIN 2/102 (1.96%)	COLITIS 1/102 (0.98%)	DIARRHOEA 8/102 (7.84%)	FEMORAL HERNIA 1/102 (0.98%)	HAEMATEMESIS 1/102 (0.98%)	ILEUS 1/102 (0.98%)	None of the patients in cohort 1 of the primary trial had Acute coronary syndrome.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 10/30 (33.33%)	Hemoglobin decreased 2/30 (6.67%)	Abdominal pain 1/30 (3.33%)	Colitis 1/30 (3.33%)	Diarrhea 7/30 (23.33%)	Nausea 2/30 (6.67%)	Rectal hemorrhage 1/30 (3.33%)	Fatigue 1/30 (3.33%)	Skin infection 1/30 (3.33%)	Neutrophil count decreased 1/30 (3.33%)	Platelet count decreased 3/30 (10.00%)	Dehydration 1/30 (3.33%)	Diarrhea was the most common adverse event in cohort 1 of the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 21/107 (19.63%)	Febrile neutropenia * 10/107 (9.35%)	Neutropenia * 1/107 (0.93%)	Left ventricular dysfunction * 0/107 (0.00%)	Angina pectoris * 0/107 (0.00%)	Cardiac failure congestive * 0/107 (0.00%)	Diarrhoea * 2/107 (1.87%)	Abdominal strangulated hernia * 0/107 (0.00%)	Duodenal ulcer haemorrhage * 0/107 (0.00%)	Pyrexia * 1/107 (0.93%)	Adverse Events 2:	Total: 22/107 (20.56%)	Febrile neutropenia * 8/107 (7.48%)	Neutropenia * 6/107 (5.61%)	Left ventricular dysfunction * 3/107 (2.80%)	Angina pectoris * 1/107 (0.93%)	Cardiac failure congestive * 0/107 (0.00%)	Diarrhoea * 0/107 (0.00%)	Abdominal strangulated hernia * 1/107 (0.93%)	Duodenal ulcer haemorrhage * 0/107 (0.00%)	Pyrexia * 1/107 (0.93%)	There were no patients with paranasal sinus reactions, or Left ventricular dysfunction in the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Operable breast cancer	Exclusion Criteria:	Inoperable breast cancer	BMI > 25	Neoadiuvant radioterapy	Carcinomastitis	Previous phlebitis of omolateral arm	Collagen disease	Emily has an Inoperable breast cancer, she is eligible for both the secondary trial and the primary trial.	[1, 0, 0, 1, 0, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Written informed consent of the patient signed by herself.	Histologically confirmed metastatic or recurrent adenocarcinoma of the breast.	Aged 20 to 74 at the time of informed consent.	Exclusion Criteria:	Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer.	Emily has an Inoperable breast cancer, she is eligible for both the secondary trial and the primary trial.	[1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 47/254 (18.50%)	Anaemia 1/254 (0.39%)	Febrile neutropenia 1/254 (0.39%)	Lymphadenopathy 1/254 (0.39%)	Acute myocardial infarction 1/254 (0.39%)	Angina pectoris 0/254 (0.00%)	Angina unstable 0/254 (0.00%)	Bundle branch block left 0/254 (0.00%)	Cardiac failure 4/254 (1.57%)	Coronary artery disease 0/254 (0.00%)	Coronary artery stenosis 1/254 (0.39%)	Adverse Events 2:	Total: 56/269 (20.82%)	Anaemia 1/269 (0.37%)	Febrile neutropenia 0/269 (0.00%)	Lymphadenopathy 0/269 (0.00%)	Acute myocardial infarction 0/269 (0.00%)	Angina pectoris 3/269 (1.12%)	Angina unstable 1/269 (0.37%)	Bundle branch block left 1/269 (0.37%)	Cardiac failure 1/269 (0.37%)	Coronary artery disease 1/269 (0.37%)	Coronary artery stenosis 0/269 (0.00%)	There are four types of adverse events in the primary trial, for which no occurences are recorded.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Radiotherapy/Supportive Care (A)	Patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapy	INTERVENTION 2:	Control ARM (B)	Patients receive radiotherapy and sham healing touch therapy from a sham healing-touch therapist once a week for the duration of their radiotherapy	Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial.	[1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Participants With Stage 0-III Breast Cancer	Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.	Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.	Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial.	[1, 1, 1, 1]
primary trial Inclusion Criteria:	History of biopsy-proven HER-2-overexpressing breast cancer and radiographic evidence of metastatic disease. The HER-2 status can be determined either by immunohistochemistry (score, 3+) or by fluorescence in situ hybridization.	History of trastuzumab resistance, defined as the development of progressive disease after trastuzumab-based therapy for metastatic breast cancer. Patient may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen (either as single agent or in combination with chemotherapy)for metastatic breast cancer. Patients who develop metastatic disease during or after adjuvant or neoadjuvant trastuzumab are eligible.	Performance status 0-2 (by Eastern Cooperative Oncology Group (ECOG) scale).	Absolute neutrophil count (ANC) 1500/µl or higher; Platelets 100,000/µl or higher; Hemoglobin 9.0 gm/dL or higher; Serum creatinine 2.0 mg/dL or lower; Total bilirubin 1.5 mg/dL or lower; Serum glutamic pyruvic transaminase (SGPT) up to 3* upper limit of normal; Alkaline phosphatase up to 3* upper limit of normal; Calcium 11.0 mg/dL or lower.	Age 18 years or older.	Patients must not be pregnant. A pregnancy test will be obtained if the patient is a woman of child-bearing potential, defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses at any time in the preceding 24 consecutive months).	Patients must have signed an informed consent document stating that they understand the investigational nature of the proposed treatment.	Patients must have measurable disease using Response Evaluation Criteria in Solid Tumors (RECIST). Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension with longest diameter >/= 20 mm using conventional techniques or >/= 10 mm with spiral computed tomography (CT) scan.	Patients may not be receiving any other investigational agents, and must not have received investigational agents within 15 days of enrollment.	Left ventricular ejection fraction determined by echocardiogram or multigated acquisition (MUGA) (cardiac scan) must be 50% or higher.	Exclusion Criteria:	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements	Prior treatment with any investigational drug within the preceding 15 days	Chronic treatment with systemic steroids or another immunosuppressive agent	Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases, and patients diagnosed with brain mets or leptomeningeal disease (LMD) within 3 months.	Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.	A known history of HIV seropositivity	Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)	Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin)	Patients who have received prior treatment with an mTor inhibitor.	History of noncompliance to medical regimens.	Patients unwilling to or unable to comply with the protocol.	Patients who are receiving any other investigational agents	Patients exhibiting confusion, disorientation, or having a history of major psychiatric illness that may impair the understanding of the informed consent.	Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial.	[1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Outcome Measurement:	Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)	Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100.	Time frame: Baseline and Week 13	Results 1:	Arm/Group Title: Bisphosphonate IV Q4W	Arm/Group Description: Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion	Overall Number of Participants Analyzed: 38	Mean (Standard Deviation)	Unit of Measure: Percent change  -10.19         (208.84)	Results 2:	Arm/Group Title: Denosumab 30 mg Q4W	Arm/Group Description: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W)	Overall Number of Participants Analyzed: 40	Mean (Standard Deviation)	Unit of Measure: Percent change  -52.87         (95.14)	Both cohorts of the primary trial in a negative (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr).	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 23/120 (19.17%)	Febrile neutropenia 4/120 (3.33%)	Leukopenia 2/120 (1.67%)	Neutropenia 8/120 (6.67%)	Cardiac tamponade 0/120 (0.00%)	Ventricular arrhythmia 1/120 (0.83%)	Ascites 0/120 (0.00%)	Oesophagitis 0/120 (0.00%)	Large intestine polyp 0/120 (0.00%)	Death 1/120 (0.83%)	Liver injury 1/120 (0.83%)	Pneumonia 3/120 (2.50%)	Adverse Events 2:	Total: 30/122 (24.59%)	Febrile neutropenia 3/122 (2.46%)	Leukopenia 3/122 (2.46%)	Neutropenia 9/122 (7.38%)	Cardiac tamponade 2/122 (1.64%)	Ventricular arrhythmia 0/122 (0.00%)	Ascites 1/122 (0.82%)	Oesophagitis 1/122 (0.82%)	Large intestine polyp 0/122 (0.00%)	Death 1/122 (0.82%)	Liver injury 0/122 (0.00%)	Pneumonia 5/122 (4.10%)	the secondary trial recorded more total occurences of cardiac adverse events than the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 47/254 (18.50%)	Anaemia 1/254 (0.39%)	Febrile neutropenia 1/254 (0.39%)	Lymphadenopathy 1/254 (0.39%)	Acute myocardial infarction 1/254 (0.39%)	Angina pectoris 0/254 (0.00%)	Angina unstable 0/254 (0.00%)	Bundle branch block left 0/254 (0.00%)	Cardiac failure 4/254 (1.57%)	Coronary artery disease 0/254 (0.00%)	Coronary artery stenosis 1/254 (0.39%)	Adverse Events 2:	Total: 56/269 (20.82%)	Anaemia 1/269 (0.37%)	Febrile neutropenia 0/269 (0.00%)	Lymphadenopathy 0/269 (0.00%)	Acute myocardial infarction 0/269 (0.00%)	Angina pectoris 3/269 (1.12%)	Angina unstable 1/269 (0.37%)	Bundle branch block left 1/269 (0.37%)	Cardiac failure 1/269 (0.37%)	Coronary artery disease 1/269 (0.37%)	Coronary artery stenosis 0/269 (0.00%)	the secondary trial recorded more total occurences of cardiac adverse events than the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Avastin (Bevacizumab) Plus Hormone	All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.	the primary trial participants receive more than one type of medication during the study	[1, 1, 1]
primary trial Inclusion Criteria:	Cases with Stage II-IIIA Breast Cancer that have completed adjuvant treatment with anthracyclines and/or taxanes + or -Radiation therapy within past 6 months(+/- 7 days) (subjects on concurrent endocrine therapy (TAM, Aromatase inhibitors are also eligible to participate as this is standard of care for this patient population)	Able to understand and sign the informed consent	Fluent in reading, comprehension and communication in the English language	No evidence of dementia - Mini Mental State Examination (MMSE) >=23 but some evidence of cognitive impairment	Must be aware of the nature of his current medical condition and must be willing to give consent after being informed of the experimental nature of therapy, alternatives, potential benefits, side-effects, risks and discomforts	Eastern Cooperative Oncology Group (ECOG) performance status of 0- 2 (Karnofsky score >60%)	Acceptable hemoglobin and hematocrit level based on complete blood count (CBC)	Must be willing to be monitored for adequacy of nutritional intake during the intervention, as is the current standard of clinical practice	Exclusion Criteria:	Use of estrogens (oral, dermal or vaginal), progesterone (oral or topical), androgens, Raloxifene or Tamoxifen during the previous 3 months	Use of over the counter steroid hormonal supplements including dehydroepiandrosterone (DHEA)	Patients with advanced or Stage IIIIB or IV breast cancer or other cancers	Use of n-3 fatty acids or high dose antioxidant supplements other than what is provided in the trial	History of known allergy to components of the study supplements	Renal or liver disease	Concurrent participation in another chemoprevention trial	Evidence of bleeding diathesis or coagulopathy	Metabolic abnormalities (e.g. thyroid disorders, insulin dependent diabetes, rheumatologic disease etc.)	Known claustrophobia, presence of pacemaker and/or ferromagnetic material in their body that would prohibit MRI imaging	Medical history of concussions	Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase risk associated with study participation or study drug administration, or may interfere with interpretation of study results, and in the judgment of the investigator would make the potential participant inappropriate for entry into this study	Patients with metallic vascular clips placed to prevent bleeding from conditions such as intracranial aneurysms, are elligible for the primary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]
primary trial Adverse Events 1:	Total: 0/34 (0.00%)	Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial	[1, 1]
secondary trial Adverse Events 1:	Total: 6/62 (9.68%)	Musculoskeletal * 1/62 (1.61%)	Mood Alteration: Depression * 1/62 (1.61%)	renal - Other * 1/62 (1.61%)	Obstruction, GU: Uterus * 1/62 (1.61%)	Sexual * 0/62 (0.00%)	Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%)	Ulceration * 1/62 (1.61%)	Adverse Events 2:	Total: 1/64 (1.56%)	Musculoskeletal * 0/64 (0.00%)	Mood Alteration: Depression * 0/64 (0.00%)	renal - Other * 0/64 (0.00%)	Obstruction, GU: Uterus * 0/64 (0.00%)	Sexual * 1/64 (1.56%)	Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%)	Ulceration * 0/64 (0.00%)	Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	1. Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR)	PFS was defined as the time from randomization to progressive disease, or death, whichever occurs first. Response was assessed according to RECIST 1.1 by BICR. According to RECIST 1.1, progressive disease (PD) was defined as a 20% relative increase in the sum of diameters (SOD) of target lesions, taking as reference the nadir SOD and an absolute increase of >5 mm in the SOD, or the appearance of new lesions. PFS was analyzed using the Kaplan-Meier method and median PFS (95% confidence interval [CI]) in weeks was reported for each treatment arm. Per protocol, participants remained on assigned treatment until disease progression. Participants who discontinued study treatment for reasons other than disease progression continued to be assessed by imaging until objective documentation of progression. All participants (including participants who discontinued study treatment) were followed for survival until investigator notification to discontinue.	Time frame: From Day 1 through last post-study efficacy follow-up (up to ~19 months)	Results 1:	Arm/Group Title: Ridaforolimus + Dalotuzumab + Exemestane	Arm/Group Description: Participants received ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity.	Overall Number of Participants Analyzed: 40	Median (95% Confidence Interval)	Unit of Measure: Weeks  23.29        (8.71 to 38.43)	Results 2:	Arm/Group Title: Ridaforolimus + Exemestane	Arm/Group Description: Participants received ridaforolimus 30 mg PO QD x 5 plus exemestane 25 mg PO QD treatment in 28-day cycles until documented disease progression or unacceptable toxicity.	Overall Number of Participants Analyzed: 40	Median (95% Confidence Interval)	Unit of Measure: Weeks  31.86        (16.00 to 39.29)	The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Lapatinib Plus Capecitabine	Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also received capecitabine 2000 mg/m^2) per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal.	INTERVENTION 2:	Trastuzumab Plus Capecitabine	Participants received an IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks. Participants also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal.	the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets, while completing food diaries.	[1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Behavioral Dietary Intervention	Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks.	Behavioral dietary intervention: Receive caloric restricted dietary intervention	Therapeutic conventional surgery: Undergo definitive lumpectomy	Radiation therapy: Undergo radiation therapy	Counseling intervention: Receive dietary counseling	Quality-of-life assessment: Ancillary studies	the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets, while completing food diaries.	[1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee	cOR is defined as the documented evidence of complete response (CR) and partial response (PR) as assessed by ultrasound examination using Response Evaluation Criteria In Solid Tumors (RECIST). CR is defined as the disappearance of all target lesions (TLs) and non-TLs and the appearance of no new lesions (NLs). PR for TLs is defined as a >=30% decrease in the sum of the longest diameter (LD) of TLs, taking as a reference the Baseline sum LD. For non-TLs, it is defined as the persistence of >=1 non-TL and no new TLs or non-TLs.	Time frame: From Baseline (Day 1) up to 6 months, evaluated every 12 weeks	Results 1:	Arm/Group Title: Letrozole + Placebo	Arm/Group Description: Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered orally once daily for 6 months prior to surgery.	Overall Number of Participants Analyzed: 48	Measure Type: Number	Unit of Measure: percentage of participants  CR: 2	PR: 58	Results 2:	Arm/Group Title: Letrozole + Lapatinib	Arm/Group Description: Letrozole tablets in the dose of 2.5 mg plus lapatinib ditosylate monohydrate tablets in the dose of 1500 mg were administered orally once daily for 6 months prior to surgery.	Overall Number of Participants Analyzed: 41	Measure Type: Number	Unit of Measure: percentage of participants  CR: 12	PR: 54	Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Cohort A - Pegylated Irinotecan to Treat NSCLC	Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.	Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)	INTERVENTION 2:	Cohort C - Pegylated Irinotecan to Treat mBC	Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.	Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)	Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days , the differences between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC and the number of cycles for each cohort, 1 for cohort 1 and 4 for cohort 2.	[1, 1, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Active Medicine Group	risedronate 35 mg weekly	INTERVENTION 2:	Placebo Group	Received placebo medication once weekly	the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD.	[1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Standard Chemotherapy	Patients receive cyclophosphamide-containing chemotherapy alone.	cyclophosphamide: Part of planned chemotherapy regimen	INTERVENTION 2:	Chemotherapy Plus Goserelin	Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.	cyclophosphamide: Part of planned chemotherapy regimen	goserelin acetate: Given subcutaneously	the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD.	[1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Women 18 years of age or older	History of invasive ER+ or PR+ breast cancer treated with at least 4.5 years of tamoxifen	No current evidence of recurrent invasive disease or metastatic disease. Patients may have a history of bilateral breast cancer	Premenopausal (estradiol level in premenopausal range, >20pg/ml, within the prior 28 days)	Liver function tests and creatinine <2.5 times the upper limit of normal within the 28 days prior to enrollment	ECOG Performance Status 0-1	Must agree to use non-hormonal contraception (condoms, diaphragm, IUD, sterilization, abstinence, etc) and no other hormonal therapy during trial and until 3 months after letrozole is stopped	Negative pregnancy test within 14 days prior to enrollment	Patient must be able to speak, read and write in English	Exclusion Criteria:	Previous treatment with an oral or IV bisphosphonate in the prior two years	History of cancer other than breast cancer within 5 years excluding basal/squamous cell skin carcinoma in situ of the cervix	Women with evidence of current local recurrence or metastatic breast cancer	Pregnant women	Nursing women	Women who are currently taking tamoxifen and are unwilling to stop this medication	Women with a known deleterious BRCA 1 or BRCA 2 mutation	Patients with cancer in situ of the cervix are eligible for the primary trial and the secondary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Females greater than or equal to (  ) 18 years of age, with histologically-confirmed HER2-positive breast cancer	Metastatic breast cancer, with progression on trastuzumab-based therapy as last treatment for metastatic disease	Less than or equal to (  ) 3 chemotherapy regimens prior to study entry	Last trastuzumab dose 9 weeks before study entry for participants receiving pertuzumab + trastuzumab, and 4 weeks for participants receiving pertuzumab monotherapy	Left ventricular ejection fraction 55% at study entry	Exclusion Criteria:	Previous treatment with an anti-cancer vaccine or any targeted therapy other than trastuzumab	Brain metastases	History of any cardiac adverse event related to trastuzumab therapy	Any other malignancy in the last 5 years, except for basal cell cancer or cancer in situ of the cervix	Patients with cancer in situ of the cervix are eligible for the primary trial and the secondary trial.	[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1]
primary trial Outcome Measurement:	Change in Tumor Size (CTS) From Baseline to the End of Cycle 2	The log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant, where the tumor size is the sum of the target lesion measurements at each assessment.	Time frame: Baseline up to end of Cycle 2 (Day 42)	Results 1:	Arm/Group Title: LY2523355 + Pegfilgrastim or Filgrastim	Arm/Group Description: LY2523355 administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Dosage determined by calculating participant's body surface area (5 milligrams per meter squared per day [mg/m^2/day]).	Pegfilgrastim or filgrastim administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. Dosage is determined by standard of care.	If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.	Overall Number of Participants Analyzed: 17	Mean (Standard Deviation)	Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.0         (0.08)	Results 2:	Arm/Group Title: Ixabepilone	Arm/Group Description: Ixabepilone administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles.	Dosage determined by calculating participant's body surface area (40 mg/m^2).	If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.	Overall Number of Participants Analyzed: 11	Mean (Standard Deviation)	Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.1         (0.37)	the primary trial reports the changes in the number of lesions for patients in its cohorts.	[1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Outcome Measurement:	Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])	DFS=interval between the date of randomization and the date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause. The date of the event is the earliest date of the occurrence of any of the following: local recurrence (LR) following mastectomy; LR in ipsilateral breast following lumpectomy; regional recurrence; distant recurrence; contralateral breast cancer, including ductal carcinoma in situ; other second primary cancer (excluding squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, or lobular carcinoma in situ of the breast); death from any cause without a prior event. Par. who started additional anti-cancer adjuvant therapy prior to the recurrence of their disease were to be censored. Par. who did not withdraw from the study and did not experience a specified event or death were to be censored (follow-up ongoing) at the last visit date available at which progression was assessed.	Time frame: From randomization until date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause (assessed up to 6 years; 1 year of treatment, 5 years of follow-up [median of 5.3 years for final analysis])	Results 1:	Arm/Group Title: Lapatinib 1500 mg	Arm/Group Description: Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal.	Overall Number of Participants Analyzed: 1571	Measure Type: Number	Unit of Measure: Participants  Any recurrence or death: 252	Censored, New Anti-cancer Agent/Radiotherapy: 1	Censored, Follow-up Ended: 1318	Results 2:	Arm/Group Title: Placebo	Arm/Group Description: Participants received matching placebo orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal.	Overall Number of Participants Analyzed: 1576	Measure Type: Number	Unit of Measure: Participants  Any recurrence or death: 290	Censored, New Anti-cancer Agent/Radiotherapy: 1	Censored, Follow-up Ended: 1285	the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients, however, there was less than a 30% difference in DFS rate between the two cohorts.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 1/24 (4.17%)	Pericardial effusion *1/24 (4.17%)	Other cardiac disorder *0/24 (0.00%)	Ejection fraction decrease *0/24 (0.00%)	Hypertension *0/24 (0.00%)	Salivary gland infection *0/24 (0.00%)	Pleural effusion *0/24 (0.00%)	Adverse Events 2:	Total: 6/30 (20.00%)	Pericardial effusion *1/30 (3.33%)	Other cardiac disorder *1/30 (3.33%)	Ejection fraction decrease *1/30 (3.33%)	Hypertension *1/30 (3.33%)	Salivary gland infection *1/30 (3.33%)	Pleural effusion *2/30 (6.67%)	Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1.	[1, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 1]
primary trial Outcome Measurement:	Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6 Months After Initiation of Therapy With Trametinib	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	Time frame: 6 months	Results 1:	Arm/Group Title: Treatment (Trametinib, Akt Inhibitor GSK2141795)	Arm/Group Description: PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.	PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Akt Inhibitor GSK2141795: Given PO	Laboratory Biomarker Analysis: Correlative studies	Trametinib: Given PO	Overall Number of Participants Analyzed: 37	Measure Type: Count of Participants	Unit of Measure: Participants  2   5.4%	the primary trial and the secondary trial both report Objective Response Rate (ORR) of their patients.	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Outcome Measurement:	Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy	A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed). A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus). Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes. 26 weeks of therapy comprised the 2-week run-in phase, 12 weeks of treatment with FEC, and 12 weeks of treatment with Paclitaxel.	Time frame: Week 26	Results 1:	Arm/Group Title: Trastuzumab	Arm/Group Description: Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter). Participants were treated with trastuzumab in a 2-week run-in period. On Day 14, a second core needle biopsy was performed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab.	Overall Number of Participants Analyzed: 26	Measure Type: Number	Unit of Measure: percentage of participants  54.0	Results 2:	Arm/Group Title: Lapatinib	Arm/Group Description: Participants received lapatinib alone (1250 mg orally [PO] once daily [QD]). Participants were treated with lapatinib in a 2-week run-in period. On Day 14, a second core needle biopsy was performed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU 500 mg/m^2, epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with lapatinib.	Overall Number of Participants Analyzed: 29	Measure Type: Number	Unit of Measure: percentage of participants  45.0	the primary trial and the secondary trial both report Objective Response Rate (ORR) of their patients.	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	Histologically confirmed breast cancer with evidence of metastatic disease	HER2 3+ or FISH (fluorescent in situ hybridization)+	Age  18 years	No prior trastuzumab, except as given in the adjuvant or neoadjuvant setting.	No prior chemotherapy in the metastatic setting.	Exclusion Criteria:	CNS (central nervous system) metastases	Prior radiation therapy within the last 4 weeks	Pregnant (positive pregnancy test) or lactating women	Major surgical procedure, open biopsy, non-healing wounds, or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study	Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study.	Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago, are not eligible for either the primary trial or the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial DISEASE CHARACTERISTICS:	Histologically confirmed invasive breast cancer meeting the following criteria:	Primary tumor  3 cm by mammography, ultrasound, or palpation AND/OR palpable axillary lymph nodes > 1 cm	Survivin- and/or carcinoembryonic antigen-positive by IHC	Tumor must be localized by exam or ultrasound to allow tumor injection	No stage IV or metastatic disease	HER2/neu-negative tumor by IHC	If 2+ or in the indeterminate range, further testing of HER2/neu overexpression by fluorescent in situ hybridization (FISH) is required	Hormone receptor status known	PATIENT CHARACTERISTICS:	Female	Pre-, peri-, or postmenopausal	ECOG performance status 0-1	Not pregnant or nursing	Negative pregnancy test	Fertile patients must use effective contraception during and for up to 6 months following completion of study therapy	ANC  1,500/mm³	Platelet count  100,000/mm³	Alkaline phosphatase  1.5 times upper limit of normal (ULN)	Total bilirubin  1.5 times ULN	AST and ALT  1.5 times ULN	Creatinine < 1.5 times ULN	No active serious infections	No prior malignancy except adequately treated basal cell or squamous cell skin cancer, noninvasive carcinoma, or other cancer from which the patient has been disease free for 5 years	No comorbidity or condition that would interfere with study assessments and procedures or preclude study participation	PRIOR CONCURRENT THERAPY:	No prior chemotherapy or radiotherapy	Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago, are not eligible for either the primary trial or the secondary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]
primary trial Adverse Events 1:	Total: 59/373 (15.82%)	Neutropenia 14/373 (3.75%)	Febrile neutropenia 10/373 (2.68%)	Leukopenia 1/373 (0.27%)	Anaemia 2/373 (0.54%)	Lymphadenopathy 0/373 (0.00%)	cardiac failure 2/373 (0.54%)	Atrial fibrillation 1/373 (0.27%)	Pericardial effusion 2/373 (0.54%)	Cardiac failure congestive 1/373 (0.27%)	Cardiomyopathy 0/373 (0.00%)	Adverse Events 2:	Total: 69/377 (18.30%)	Neutropenia 17/377 (4.51%)	Febrile neutropenia 10/377 (2.65%)	Leukopenia 4/377 (1.06%)	Anaemia 2/377 (0.53%)	Lymphadenopathy 1/377 (0.27%)	cardiac failure 1/377 (0.27%)	Atrial fibrillation 1/377 (0.27%)	Pericardial effusion 0/377 (0.00%)	Cardiac failure congestive 0/377 (0.00%)	Cardiomyopathy 1/377 (0.27%)	There were more cases of Febrile neutropenia than leukopenia observed in the primary trial, but less cases of neutropenia than leukopenia.	[1, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 21/107 (19.63%)	Febrile neutropenia * 10/107 (9.35%)	Neutropenia * 1/107 (0.93%)	Left ventricular dysfunction * 0/107 (0.00%)	Angina pectoris * 0/107 (0.00%)	Cardiac failure congestive * 0/107 (0.00%)	Diarrhoea * 2/107 (1.87%)	Abdominal strangulated hernia * 0/107 (0.00%)	Duodenal ulcer haemorrhage * 0/107 (0.00%)	Pyrexia * 1/107 (0.93%)	Adverse Events 2:	Total: 22/107 (20.56%)	Febrile neutropenia * 8/107 (7.48%)	Neutropenia * 6/107 (5.61%)	Left ventricular dysfunction * 3/107 (2.80%)	Angina pectoris * 1/107 (0.93%)	Cardiac failure congestive * 0/107 (0.00%)	Diarrhoea * 0/107 (0.00%)	Abdominal strangulated hernia * 1/107 (0.93%)	Duodenal ulcer haemorrhage * 0/107 (0.00%)	Pyrexia * 1/107 (0.93%)	There were no patients with paranasal sinus reactions in the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer	Participants who are undergoing breast cancer surgery with lumpectomy or mastectomy	Participants with planned axillary sentinel node biopsy procedure	Exclusion Criteria:	Participants with cancer > 3 cm	Participants with clinically positive nodes	Participants with prior surgery for breast cancer in the index breast	Participants who have had bilateral breast surgeries	Thyroid dysfunction	Hypersensitivity to iodine	Hepatic insufficiency	Renal insufficiency	Patients with HER2 + breast cancer are eligible for both the primary trial and the secondary trial. However, only patients with stage 1-2 breast cancer are eligible for the primary trial, and patients with stage 3-4 are eligilbe for the secondary trial. 	[1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Stage IIIB, IIIC, or IV erbB2 (HER2) positive breast cancer	Prior use of Herceptin (trastuzumab), and a taxane	Adequate cardiac and renal function	Exclusion Criteria:	More than 2 prior Herceptin (trastuzumab) regimens or prior use of Xeloda (capecitabine) and / or Tykerb (lapatinib) [Tyverb]	Bone as the only site of disease	Active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)	Significant gastrointestinal disorder with diarrhea as major symptom	Patients with HER2 + breast cancer are eligible for both the primary trial and the secondary trial. However, only patients with stage 1-2 breast cancer are eligible for the primary trial, and patients with stage 3-4 are eligilbe for the secondary trial. 	[1, 1, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 13/34 (38.24%)	Anemia 3/34 (8.82%)	Diarrhea 7/34 (20.59%)	Nausea 2/34 (5.88%)	Sepsis 1/34 (2.94%)	Urinary tract infection 1/34 (2.94%)	Alkaline phosphatase increased 1/34 (2.94%)	Neutrophil count decreased 2/34 (5.88%)	Dehydration 1/34 (2.94%)	Headache 1/34 (2.94%)	Thromboembolic event 1/34 (2.94%)	One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhea.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 2/38 (5.26%)	Febrile neutropenia 0/38 (0.00%)	Abdominal pain 1/38 (2.63%)	Skin infection 0/38 (0.00%)	Seizure 1/38 (2.63%)	the primary trial recorded many more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.	[1, 0, 0, 0, 0, 1]
secondary trial Adverse Events 1:	Total: 92/490 (18.78%)	Anaemia * 1/490 (0.20%)	Anaemia of malignant disease * 0/490 (0.00%)	Febrile neutropenia * 0/490 (0.00%)	Neutropenia * 0/490 (0.00%)	Thrombocytopenia * 4/490 (0.82%)	Angina pectoris * 0/490 (0.00%)	Atrial fibrillation * 1/490 (0.20%)	Cardiomyopathy * 1/490 (0.20%)	Coronary artery disease * 0/490 (0.00%)	Pericardial effusion * 0/490 (0.00%)	Adverse Events 2:	Total: 99/488 (20.29%)	Anaemia * 1/488 (0.20%)	Anaemia of malignant disease * 1/488 (0.20%)	Febrile neutropenia * 2/488 (0.41%)	Neutropenia * 1/488 (0.20%)	Thrombocytopenia * 1/488 (0.20%)	Angina pectoris * 1/488 (0.20%)	Atrial fibrillation * 0/488 (0.00%)	Cardiomyopathy * 0/488 (0.00%)	Coronary artery disease * 1/488 (0.20%)	Pericardial effusion * 2/488 (0.41%)	the primary trial recorded many more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6 Months After Initiation of Therapy With Trametinib	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	Time frame: 6 months	Results 1:	Arm/Group Title: Treatment (Trametinib, Akt Inhibitor GSK2141795)	Arm/Group Description: PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.	PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Akt Inhibitor GSK2141795: Given PO	Laboratory Biomarker Analysis: Correlative studies	Trametinib: Given PO	Overall Number of Participants Analyzed: 37	Measure Type: Count of Participants	Unit of Measure: Participants  2   5.4%	the primary trial and the secondary trial both report results on pathologic evidence of invasive disease withing their patient cohorts after their interventions, using different outcome measurements.	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Outcome Measurement:	Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy	A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed). A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus). Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes. 26 weeks of therapy comprised the 2-week run-in phase, 12 weeks of treatment with FEC, and 12 weeks of treatment with Paclitaxel.	Time frame: Week 26	Results 1:	Arm/Group Title: Trastuzumab	Arm/Group Description: Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter). Participants were treated with trastuzumab in a 2-week run-in period. On Day 14, a second core needle biopsy was performed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab.	Overall Number of Participants Analyzed: 26	Measure Type: Number	Unit of Measure: percentage of participants  54.0	Results 2:	Arm/Group Title: Lapatinib	Arm/Group Description: Participants received lapatinib alone (1250 mg orally [PO] once daily [QD]). Participants were treated with lapatinib in a 2-week run-in period. On Day 14, a second core needle biopsy was performed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU 500 mg/m^2, epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with lapatinib.	Overall Number of Participants Analyzed: 29	Measure Type: Number	Unit of Measure: percentage of participants  45.0	the primary trial and the secondary trial both report results on pathologic evidence of invasive disease withing their patient cohorts after their interventions, using different outcome measurements.	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 3/22 (13.64%)	ascites with hyponatraemia 0/22 (0.00%)	febrile neutropenia with respiratory infection 1/22 (4.55%)	urosepsis 1/22 (4.55%)	febrile neutropenia with urinary tract infection 0/22 (0.00%)	dyspnoea 1/22 (4.55%)	hypoxia 0/22 (0.00%)	thromboembolism 0/22 (0.00%)	Adverse Events 2:	Total: 4/17 (23.53%)	ascites with hyponatraemia 1/17 (5.88%)	febrile neutropenia with respiratory infection 0/17 (0.00%)	urosepsis 0/17 (0.00%)	febrile neutropenia with urinary tract infection 1/17 (5.88%)	dyspnoea 0/17 (0.00%)	hypoxia 1/17 (5.88%)	thromboembolism 1/17 (5.88%)	1 patient in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 9/46 (19.57%)	Febrile neutropenia 1/46 (2.17%)	Cardiac disorder 1/46 (2.17%)	Diarrhea 1/46 (2.17%)	Upper gastrointestinal hemorrhage 1/46 (2.17%)	Chest pain 1/46 (2.17%)	Fatigue 1/46 (2.17%)	Neutrophil count decreased 2/46 (4.35%)	Platelet count decreased 1/46 (2.17%)	Anorexia 1/46 (2.17%)	Dehydration 1/46 (2.17%)	Serum potassium increased 1/46 (2.17%)	1 patient in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 16/48 (33.33%)	Febrile neutropenia grade 3 3/48 (6.25%)	Neutropenia grade 3 1/48 (2.08%)	Holocraneal cephalea 1/48 (2.08%)	Hypersensibility reaction grade 3 2/48 (4.17%)	Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%)	Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%)	Catheter - related infection grade 3 1/48 (2.08%)	the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16	[1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 21/519 (4.05%)	Anaemia 1/519 (0.19%)	Blood bilirubin 0/519 (0.00%)	Leukopenia 0/519 (0.00%)	Neutropenia 1/519 (0.19%)	Arrhythmia 0/519 (0.00%)	Carotid artery thrombosis 1/519 (0.19%)	Ear infection 0/519 (0.00%)	Conjunctivitis 0/519 (0.00%)	Abdominal pain 1/519 (0.19%)	Anal fissure 0/519 (0.00%)	Constipation 0/519 (0.00%)	Diarrhoea 1/519 (0.19%)	Adverse Events 2:	Total: 119/532 (22.37%)	Anaemia 1/532 (0.19%)	Blood bilirubin 1/532 (0.19%)	Leukopenia 1/532 (0.19%)	Neutropenia 5/532 (0.94%)	Arrhythmia 1/532 (0.19%)	Carotid artery thrombosis 0/532 (0.00%)	Ear infection 1/532 (0.19%)	Conjunctivitis 1/532 (0.19%)	Abdominal pain 1/532 (0.19%)	Anal fissure 1/532 (0.19%)	Constipation 1/532 (0.19%)	Diarrhoea 6/532 (1.13%)	the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16	[1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 2/38 (5.26%)	Febrile neutropenia 0/38 (0.00%)	Abdominal pain 1/38 (2.63%)	Skin infection 0/38 (0.00%)	Seizure 1/38 (2.63%)	the primary trial recorded more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.	[1, 0, 0, 0, 0, 1]
secondary trial Adverse Events 1:	Total: 92/490 (18.78%)	Anaemia * 1/490 (0.20%)	Anaemia of malignant disease * 0/490 (0.00%)	Febrile neutropenia * 0/490 (0.00%)	Neutropenia * 0/490 (0.00%)	Thrombocytopenia * 4/490 (0.82%)	Angina pectoris * 0/490 (0.00%)	Atrial fibrillation * 1/490 (0.20%)	Cardiomyopathy * 1/490 (0.20%)	Coronary artery disease * 0/490 (0.00%)	Pericardial effusion * 0/490 (0.00%)	Adverse Events 2:	Total: 99/488 (20.29%)	Anaemia * 1/488 (0.20%)	Anaemia of malignant disease * 1/488 (0.20%)	Febrile neutropenia * 2/488 (0.41%)	Neutropenia * 1/488 (0.20%)	Thrombocytopenia * 1/488 (0.20%)	Angina pectoris * 1/488 (0.20%)	Atrial fibrillation * 0/488 (0.00%)	Cardiomyopathy * 0/488 (0.00%)	Coronary artery disease * 1/488 (0.20%)	Pericardial effusion * 2/488 (0.41%)	the primary trial recorded more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Assigned female at birth;	18 years and older;	Confirmed diagnosis (via biopsy) of early stage breast cancer (stages I-IIIA);	Eligible for both breast-conserving surgery and mastectomy based on medical records and clinician's opinion before surgery;	Spoken English, Spanish, or Mandarin Chinese.	Exclusion Criteria:	Transgender men and women;	Women who have undergone prophylactic mastectomy;	Women with visual impairment;	Women with a diagnosis of severe mental illness or severe dementia;	Women with inflammatory breast carcinoma.	Only patients which have been assigned as female at birth are eligible for the secondary trial and the primary trial.	[1, 1, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Written informed consent.	Histological diagnosis of operable invasive adenocarcinoma of the breast (T1-T3). Tumours must be HER2 negative. Time window between surgery and study randomization must be less than 60 days.	Surgery must consist of mastectomy or conservative surgery with axillary lymph node dissection. Margins free of disease and ductal carcinomas in situ (DCIS) are required. Lobular carcinoma is not considered a positive margin.	Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of disease. If sentinel node technique is used, sentinel node can be the only node affected. Patients belonging to the following classifications are eligible: TNM pathologic stage N1a, TNM pathologic stage N2a, TNM pathologic stage N3a.	Status of hormone receptors in primary tumour. Results must be available before the end of adjuvant chemotherapy.	Patients must not present evidence of metastatic disease. Status of HER2 in primary tumour, known before randomization. Patients with immune histochemistry (IHC) 0 or +1 are eligible. For patients with IHC 2+, fluorescence in situ hybridization (FISH) is mandatory and result must be negative.	Age >= 18 and <= 70 years old.	Performance status (Karnofsky index) >= 80.	Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed, normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF).	Laboratory results (within 14 days prior to randomization):	Hematology: neutrophils >= 1.5 x 10^9/l; platelets >= 100 x 10^9/l; hemoglobin >= 10 mg/dl;	Hepatic function: total bilirubin <= 1 upper normal limit (UNL); serum glutamic-oxaloacetic transaminase (SGOT) and Serum glutamic pyruvic transaminase (SGPT) <= 2.5 UNL; alkaline phosphatase <= 2.5 UNL. If values of SGOT and SGPT > 1.5 UNL are associated to alkaline phosphatase > 2.5 UNL, patient is not eligible;	Renal function: creatinine <= 175 mmol/l (2 mg/dl); creatinine clearance >= 60 ml/min;	Pharmacogenetics: one blood sample is needed for single nucleotide polymorphism (SNP) assessment.	Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed within a 20 week window). All patients must have a bilateral mammogram, thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all patients. Other tests: as clinically indicated.	Patients able to comply with treatment and study follow-up.	Negative pregnancy test done in the 14 prior days to randomization.	Exclusion Criteria:	Prior systemic therapy for breast cancer.	Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any malignancy.	Prior radiotherapy for breast cancer.	Bilateral invasive breast cancer.	Pregnant or lactating women. Adequate contraceptive methods must be used during chemotherapy and hormone therapy treatments.	Any T4 or M1 tumour.	Axillary lymph nodes: patients belonging to the following classifications are excluded: TNM pathologic stage N1b, TNM pathologic stage N1c, TNM pathologic stage N2b, TNM pathologic stage N3b, TNM pathologic stage N3c.	HER2 positive breast cancer (IHC 3+ or positive FISH result).	Pre-existing grade >= 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria version 2.0 [NCICTC v-2.0]).	Any other serious medical pathology, such as congestive heart failure; unstable angina; history of myocardial infarction during the previous year; uncontrolled hypertension or high risk arrhythmias.	History of neurological or psychiatric disorders, which could preclude the patients from free informed consent.	Active uncontrolled infection.	Active peptic ulcer; unstable diabetes mellitus.	Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.	Chronic treatment with corticosteroids.	Contraindications for corticosteroid administration.	Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis treatment or for prevention. These treatments must stop before randomisation.	Concomitant treatment with other investigational products; participation in other clinical trials with a non-marketed drug in the 20 previous days before randomization.	Concomitant treatment with another therapy for cancer.	Males.	Only patients which have been assigned as female at birth are eligible for the secondary trial and the primary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]
primary trial Inclusion Criteria:	Assigned female at birth;	18 years and older;	Confirmed diagnosis (via biopsy) of early stage breast cancer (stages I-IIIA);	Eligible for both breast-conserving surgery and mastectomy based on medical records and clinician's opinion before surgery;	Spoken English, Spanish, or Mandarin Chinese.	Exclusion Criteria:	Transgender men and women;	Women who have undergone prophylactic mastectomy;	Women with visual impairment;	Women with a diagnosis of severe mental illness or severe dementia;	Women with inflammatory breast carcinoma.	Only patients who identify as female are eligible for the secondary trial and the primary trial.	[1, 1, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Written informed consent.	Histological diagnosis of operable invasive adenocarcinoma of the breast (T1-T3). Tumours must be HER2 negative. Time window between surgery and study randomization must be less than 60 days.	Surgery must consist of mastectomy or conservative surgery with axillary lymph node dissection. Margins free of disease and ductal carcinomas in situ (DCIS) are required. Lobular carcinoma is not considered a positive margin.	Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of disease. If sentinel node technique is used, sentinel node can be the only node affected. Patients belonging to the following classifications are eligible: TNM pathologic stage N1a, TNM pathologic stage N2a, TNM pathologic stage N3a.	Status of hormone receptors in primary tumour. Results must be available before the end of adjuvant chemotherapy.	Patients must not present evidence of metastatic disease. Status of HER2 in primary tumour, known before randomization. Patients with immune histochemistry (IHC) 0 or +1 are eligible. For patients with IHC 2+, fluorescence in situ hybridization (FISH) is mandatory and result must be negative.	Age >= 18 and <= 70 years old.	Performance status (Karnofsky index) >= 80.	Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed, normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF).	Laboratory results (within 14 days prior to randomization):	Hematology: neutrophils >= 1.5 x 10^9/l; platelets >= 100 x 10^9/l; hemoglobin >= 10 mg/dl;	Hepatic function: total bilirubin <= 1 upper normal limit (UNL); serum glutamic-oxaloacetic transaminase (SGOT) and Serum glutamic pyruvic transaminase (SGPT) <= 2.5 UNL; alkaline phosphatase <= 2.5 UNL. If values of SGOT and SGPT > 1.5 UNL are associated to alkaline phosphatase > 2.5 UNL, patient is not eligible;	Renal function: creatinine <= 175 mmol/l (2 mg/dl); creatinine clearance >= 60 ml/min;	Pharmacogenetics: one blood sample is needed for single nucleotide polymorphism (SNP) assessment.	Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed within a 20 week window). All patients must have a bilateral mammogram, thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all patients. Other tests: as clinically indicated.	Patients able to comply with treatment and study follow-up.	Negative pregnancy test done in the 14 prior days to randomization.	Exclusion Criteria:	Prior systemic therapy for breast cancer.	Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any malignancy.	Prior radiotherapy for breast cancer.	Bilateral invasive breast cancer.	Pregnant or lactating women. Adequate contraceptive methods must be used during chemotherapy and hormone therapy treatments.	Any T4 or M1 tumour.	Axillary lymph nodes: patients belonging to the following classifications are excluded: TNM pathologic stage N1b, TNM pathologic stage N1c, TNM pathologic stage N2b, TNM pathologic stage N3b, TNM pathologic stage N3c.	HER2 positive breast cancer (IHC 3+ or positive FISH result).	Pre-existing grade >= 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria version 2.0 [NCICTC v-2.0]).	Any other serious medical pathology, such as congestive heart failure; unstable angina; history of myocardial infarction during the previous year; uncontrolled hypertension or high risk arrhythmias.	History of neurological or psychiatric disorders, which could preclude the patients from free informed consent.	Active uncontrolled infection.	Active peptic ulcer; unstable diabetes mellitus.	Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.	Chronic treatment with corticosteroids.	Contraindications for corticosteroid administration.	Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis treatment or for prevention. These treatments must stop before randomisation.	Concomitant treatment with other investigational products; participation in other clinical trials with a non-marketed drug in the 20 previous days before randomization.	Concomitant treatment with another therapy for cancer.	Males.	Only patients who identify as female are eligible for the secondary trial and the primary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]
primary trial Outcome Measurement:	Clinical Benefit Rate (CR + PR + SD > 6 Months).	To determine the clinical benefit rate (Complete Response + Partial Response + Stable Disease > 6 months) per Response Evaluation Criteria in Solid tumors (RECIST version 1.0). of MPA monotherapy and MPA + low dose oral cyclophosphamide and methotrexate (ldoCM) in patients with refractory hormone receptor negative metastatic breast cancer. This will show the percent of patients who had Clinical Benefit and the Exact 95% Confidence Interval.	Time frame: baseline through end of study, up to 3 years	Results 1:	Arm/Group Title: Cohort I: MPA-Alone	Arm/Group Description: Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.	Overall Number of Participants Analyzed: 14	Measure Type: Number	Unit of Measure: Percent of Participants  7.1        (0.2 to 33.9)	Results 2:	Arm/Group Title: Cohort 2: MPA+IdoCM	Arm/Group Description: Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.	Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week.	Overall Number of Participants Analyzed: 16	Measure Type: Number	Unit of Measure: Percent of Participants  6.3        (0.2 to 30.2)	the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure, and they do not use the same time frame.	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Outcome Measurement:	Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort	Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.	Time frame: After 24 weeks of treatment	Results 1:	Arm/Group Title: Alpelisib + Letrozole	Arm/Group Description: Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.	Overall Number of Participants Analyzed: 60	Measure Type: Number	Unit of Measure: Percentage of Participants  1.7        (0.2 to 6.3)	Results 2:	Arm/Group Title: Placebo + Letrozole	Arm/Group Description: Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.	Overall Number of Participants Analyzed: 67	Measure Type: Number	Unit of Measure: Percentage of Participants  3.0        (0.8 to 7.7)	the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure, and they do not use the same time frame.	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Exemestane	Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period.	INTERVENTION 2:	Tamoxifen	Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period.	The patient groups in the primary trial each receive the same doses of different oral medication, either Tamoxifen or Exemestane.	[1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Five Days of Mammosite Therapy	[Not Specified]	the primary trial and the secondary trial require patients to undergo a minimum of two weeks of Mammosite Therapy.	[1, 1, 1]
secondary trial INTERVENTION 1:	Bevacizumab Plus Paclitaxel	Bevacizumab 10 mg/kg intravenous (i.v.), days 1 and 15, every 4 weeks, Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks	INTERVENTION 2:	Bevacizumab Plus Capecitabine	Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks, Capecitabine 1000 mg/m² twice-daily, days 1-14, every 3 weeks	the primary trial and the secondary trial require patients to undergo a minimum of two weeks of Mammosite Therapy.	[1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Adult Women ( 18 years old).	Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease.	Must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease.	HER2+ patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).	Prior trastuzumab and/or chemotherapy (taxanes included) as neo-adjuvant or adjuvant treatment is allowed but should be discontinued > 12 months prior to randomization.	Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization. Patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment.	Documentation of negative pregnancy test.	Organ functions at time of inclusion.	Exclusion Criteria:	Prior mTOR inhibitors for the treatment of cancer.	Other anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy.	Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc).	Radiotherapy to  25% of the bone marrow within 4 weeks prior to randomization	History of central nervous system metastasis.	Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract.	Serious peripheral neuropathy.	Cardiac disease or dysfunction.	Uncontrolled hypertension.	HIV.	Pregnant,	Men suffering from Ulcerative colitis are excluded from the primary trial, but eligible for the secondary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	The subject must be female and 18 years of age or older.	The subject must be a preoperative clinical Tis, T1, T2, T3, T4, as well as clinical N0 and clinical M0 breast cancer	The subject must have a diagnosis of primary breast cancer.	The subject must be a candidate for surgical intervention, either with lumpectomy and SLNB or with mastectomy and SLNB, as the treatment of her breast cancer.	The subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 - 2	The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study	Exclusion Criteria:	The subject has clinical or radiological or pathologic evidence of metastatic cancer, including any abnormal or enlarged clinical palpable lymph nodes or core biopsy/surgical biopsy/fine-needle-aspiration evidence of malignant cell within any lymph nodes.	The subject has a known hypersensitivity to vital blue dye (VBD) in a case where vital blue dye was planned for use during SLNB.	The subject has a positive pregnancy test or is lactating.	The subject has had prior surgery to the indicated breast or axilla.	Men suffering from Ulcerative colitis are excluded from the primary trial, but eligible for the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Written informed consent.	Histological diagnoses of operable invasive adenocarcinoma of the breast (T1-T3). Tumors must be Human Epidermal Growth Factor Receptor 2 (HER2) negative. Patients must be free of disease in the axilla (node negative). If lymphadenectomy is done, at least 10 nodes must be examined. If sentinel node technique is used, sentinel node must be free of disease. Patients must present at least one high risk criterion (St. Gallen, 1998) as follows:	Tumor size > 2 cm; and/or	ER and Progesterone Receptor (PgR) negative; and/or	Histological grade 2-3; and/or	Age < 35 years old.	Time window between surgery and study randomization must be less than 60 days.	Surgery must consist of mastectomy or conservative surgery. Margins free of disease and ductal carcinoma in situ (DCIS) are required. Lobular carcinoma is not considered a positive margin.	Patients must not present evidence of metastatic disease.	Status of hormone receptors in primary tumor. Results must be available before the end of adjuvant chemotherapy.	Status of HER2 in primary tumor, known before randomization. Patients with Immunohistochemistry (IHC) 0 or +1 are eligible. For patients with IHC 2+, fluorescent in situ hybridization (FISH) is mandatory and result must be negative.	Age >= 18 and <= 70 years old.	Performance status (Karnofsky index) >= 80.	Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed, normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF).	Laboratory results (within 14 days prior to randomization):	Hematology: neutrophils >= 1.5 x 10^9/l; platelets >= 100x 10^9/l; hemoglobin >= 10 mg/dl;	Hepatic function: total bilirubin <= 1 upper normal limit (UNL); Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) <= 2.5 UNL; alkaline phosphatase <= 2.5 UNL. If values of AST and ALT > 1.5 UNL are associated with alkaline phosphatase > 2.5 UNL, patient is not eligible.	Renal function: creatinine <= 175 mmol/l (2 mg/dl); creatinine clearance >= 60 ml/min.	Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed within a 20 week time window). All patients must have a bilateral mammogram, thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all patients. Other tests, as clinically indicated.	Patients able to comply with treatment and study follow-up.	Negative pregnancy test done in the 14 previous days to randomization.	Exclusion Criteria:	Prior systemic therapy for breast cancer.	Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any malignancy.	Prior radiotherapy for breast cancer.	Bilateral invasive breast cancer.	Pregnant or lactating women. Adequate contraceptive methods must be used during chemotherapy and hormone therapy treatments. Negative pregnancy test in the 14 previous days to randomization.	Any T4 or N1-3 or M1 tumor.	HER2 positive breast cancer (IHC 3+ or positive FISH result).	Pre-existing grade >=2 motor or sensorial neurotoxicity by the National Cancer Institute Common Toxicity Criteria (NCICTC) v-2.0.	Any other serious medical pathology, such as congestive heart failure, unstable angina, history of myocardial infarction during the previous year, uncontrolled hypertension or high risk arrhythmias.	History of neurological or psychiatric disorders, which could preclude the patients to free informed consent.	Active uncontrolled infection.	Active peptic ulcer; unstable diabetes mellitus.	Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumor curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.	Concomitant treatment with other investigational products. Participation in other clinical trials with a non-marketed drug in the 20 previous days before randomization.	Concomitant treatment with other therapy for cancer.	Males.	Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial and the secondary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial DISEASE CHARACTERISTICS:	Histologically or cytologically confirmed adenocarcinoma of the breast	Stage III or IV disease	Primary or recurrent disease	Invasive lobular carcinoma allowed	HLA-A1, -A2, -A3, or -A31 positive	Underwent and recovered from prior primary therapy	Patients with no clinical or radiological evidence of disease who had a previous diagnosis of stage III or IV breast cancer must have undergone prior antineoplastic therapy including, but not limited to, surgery, chemotherapy, and radiotherapy within the past 36 months	Must have at least one undissected axillary and/or inguinal lymph node basin	No history of brain metastases	Hormone receptor status	Estrogen receptor-positive or -negative tumor	PATIENT CHARACTERISTICS:	ECOG performance status of 0 or 1	Body weight > 110 lbs (without clothes)	Male or female	Menopausal status not specified	Absolute neutrophil count > 1000/mm^3	Platelet count > 100,000/mm^3	Hemoglobin > 9 g/dL	Hemoglobin A1c < 7%	AST and ALT  2.5 x upper limit of normal (ULN)	Bilirubin  2.5 x ULN	Alkaline phosphatase  2.5 x ULN	Creatinine  1.5 x ULN	HIV negative	Hepatitis C negative	Not pregnant or nursing	Negative pregnancy test	Fertile patients must use effective contraception	No known or suspected allergies to any component of the vaccine	No active infection requiring antibiotics	No New York Heart Association class III or IV heart disease	No autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement, except the following:	Laboratory evidence of autoimmune disease (e.g., positive ANA titer) without symptoms	Clinical evidence of vitiligo	Other forms of depigmenting illness	Mild arthritis requiring nonsteroidal antiinflammatory drugs	No medical contraindication or potential problem that would preclude study participation	PRIOR CONCURRENT THERAPY:	More than 4 weeks since prior surgery	More than 4 weeks since prior and no concurrent chemotherapy and radiotherapy	More than 4 weeks since prior and no concurrent allergy desensitization injections	More than 4 weeks since prior parenteral, oral, or inhaled corticosteroids	No concurrent inhaled steroids (e.g., Advair® or triamcinolone acetonide)	Prior or concurrent topical corticosteroids allowed	More than 4 weeks since prior and no concurrent growth factors (e.g., epoetin alfa, darbepoetin alfa, or pegfilgrastim)	More than 4 weeks since prior and no concurrent other investigational medication	More than 4 weeks since prior and no concurrent other agents with putative immunomodulating activity except for non-steroidal anti-inflammatory agents	Prior and concurrent hormonal therapy (e.g., tamoxifen, raloxifene, toremifene, fulvestrant, letrozole, anastrozole, or exemestane) allowed	No prior vaccination with any synthetic peptides in this protocol	Vaccines for infectious disease (e.g., influenza) allowed, provided they are administered  2 weeks prior to or  2 weeks after study vaccine	Short term therapy for acute conditions not related to breast cancer allowed	No concurrent illegal drugs	Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial and the secondary trial.	[0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Pre-menopausal women aged 18 years or over with histologically/cytologically-confirmed oestrogen receptor positive (ER +ve) breast cancer	World Health Organization (WHO) performance status of 0, 1, or 2	Provided written informed consent	Exclusion Criteria:	Treatment with tamoxifen or other hormonal therapies as early breast cancer (EBC) adjuvant in the previous 24 weeks	Received radiotherapy within the past 4 weeks	History of systemic malignancy other than breast cancer within the previous 3 years	Estimated survival less than 24 weeks	the primary trial and the secondary trial use different metrics to evaluate potential candidates' performance status.	[0, 0, 1, 0, 0, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Recurrent or residual metastatic breast carcinoma	Zubrod performance status less than 2	18-60 years old	Related donor human leukocyte antigen (HLA)-compatible for allogeneic transplantation or unrelated HLA-compatible donor.	No major organ dysfunction or active infection	Exclusion Criteria: None	the primary trial and the secondary trial use different metrics to evaluate potential candidates' performance status.	[0, 0, 1, 0, 0, 0, 0]
primary trial Outcome Measurement:	Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms	To evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women. The percent change in breast density will be reported here.	Time frame: 12 months	Results 1:	Arm/Group Title: Placebo	Arm/Group Description: Patients receive oral placebo once daily for 12 months.	Overall Number of Participants Analyzed: 46	Mean (Standard Deviation)	Unit of Measure: percent change  -3.4         (7.1)	Results 2:	Arm/Group Title: Vitamin D	Arm/Group Description: Patients receive oral vitamin D (2000 IU) once daily for 12 months.	Overall Number of Participants Analyzed: 40	Mean (Standard Deviation)	Unit of Measure: percent change  -1.4         (11.9)	Intervention 2 of the primary trial resulted in a lower percentage change in tumor diameter than intervention 1.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial DISEASE CHARACTERISTICS:	Histologically confirmed breast cancer	Stage I or II disease (T1-T2, N0, M0/MX disease)	No chest wall invasion by tumor (T3 disease)	Medially or centrally located lesion	No multicentric disease	Multifocal disease allowed	No clinically positive axillary nodes	No enlarged internal mammary nodes by CT scan	Hormone receptor status not specified	PATIENT CHARACTERISTICS:	Male or female	Menopausal status not specified	American Society of Anesthesiologists (ASA) physical status classification 1-2	Not pregnant or nursing	Negative pregnancy test	No other concurrent known, invasive malignancy	No known chronic pulmonary disease	No known allergy to methylene blue or isosulfan blue	PRIOR CONCURRENT THERAPY:	No prior thoracic or cardiac surgery	No prior ipsilateral chest tube placement	Contralateral chest tube placement allowed	No prior neoadjuvant chemotherapy	No prior radiotherapy to the mediastinum	There are several types of surgical and therapeutic treatments which are banned for patients wanting to take part in the primary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Women 18 years of age or older	History of invasive ER+ or PR+ breast cancer treated with at least 4.5 years of tamoxifen	No current evidence of recurrent invasive disease or metastatic disease. Patients may have a history of bilateral breast cancer	Premenopausal (estradiol level in premenopausal range, >20pg/ml, within the prior 28 days)	Liver function tests and creatinine <2.5 times the upper limit of normal within the 28 days prior to enrollment	ECOG Performance Status 0-1	Must agree to use non-hormonal contraception (condoms, diaphragm, IUD, sterilization, abstinence, etc) and no other hormonal therapy during trial and until 3 months after letrozole is stopped	Negative pregnancy test within 14 days prior to enrollment	Patient must be able to speak, read and write in English	Exclusion Criteria:	Previous treatment with an oral or IV bisphosphonate in the prior two years	History of cancer other than breast cancer within 5 years excluding basal/squamous cell skin carcinoma in situ of the cervix	Women with evidence of current local recurrence or metastatic breast cancer	Pregnant women	Nursing women	Women who are currently taking tamoxifen and are unwilling to stop this medication	Women with a known deleterious BRCA 1 or BRCA 2 mutation	Patients with BCC are excluded from the primary trial and the secondary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Females greater than or equal to (  ) 18 years of age, with histologically-confirmed HER2-positive breast cancer	Metastatic breast cancer, with progression on trastuzumab-based therapy as last treatment for metastatic disease	Less than or equal to (  ) 3 chemotherapy regimens prior to study entry	Last trastuzumab dose 9 weeks before study entry for participants receiving pertuzumab + trastuzumab, and 4 weeks for participants receiving pertuzumab monotherapy	Left ventricular ejection fraction 55% at study entry	Exclusion Criteria:	Previous treatment with an anti-cancer vaccine or any targeted therapy other than trastuzumab	Brain metastases	History of any cardiac adverse event related to trastuzumab therapy	Any other malignancy in the last 5 years, except for basal cell cancer or cancer in situ of the cervix	Patients with BCC are excluded from the primary trial and the secondary trial.	[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1]
primary trial Outcome Measurement:	Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)	Number of patients event-free	Time frame: 12 month period following randomisation	Results 1:	Arm/Group Title: Fulvestrant + Anastrozole	Arm/Group Description: fulvestrant 500 mg + anastrozole 1 mg	Overall Number of Participants Analyzed: 6	Measure Type: Number	Unit of Measure: Participants  6	Results 2:	Arm/Group Title: Anastrozole	Arm/Group Description: anastrozole 1 mg	Overall Number of Participants Analyzed: 7	Measure Type: Number	Unit of Measure: Participants  7	there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 23/120 (19.17%)	Febrile neutropenia 4/120 (3.33%)	Leukopenia 2/120 (1.67%)	Neutropenia 8/120 (6.67%)	Cardiac tamponade 0/120 (0.00%)	Ventricular arrhythmia 1/120 (0.83%)	Ascites 0/120 (0.00%)	Oesophagitis 0/120 (0.00%)	Large intestine polyp 0/120 (0.00%)	Death 1/120 (0.83%)	Liver injury 1/120 (0.83%)	Pneumonia 3/120 (2.50%)	Adverse Events 2:	Total: 30/122 (24.59%)	Febrile neutropenia 3/122 (2.46%)	Leukopenia 3/122 (2.46%)	Neutropenia 9/122 (7.38%)	Cardiac tamponade 2/122 (1.64%)	Ventricular arrhythmia 0/122 (0.00%)	Ascites 1/122 (0.82%)	Oesophagitis 1/122 (0.82%)	Large intestine polyp 0/122 (0.00%)	Death 1/122 (0.82%)	Liver injury 0/122 (0.00%)	Pneumonia 5/122 (4.10%)	the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 47/254 (18.50%)	Anaemia 1/254 (0.39%)	Febrile neutropenia 1/254 (0.39%)	Lymphadenopathy 1/254 (0.39%)	Acute myocardial infarction 1/254 (0.39%)	Angina pectoris 0/254 (0.00%)	Angina unstable 0/254 (0.00%)	Bundle branch block left 0/254 (0.00%)	Cardiac failure 4/254 (1.57%)	Coronary artery disease 0/254 (0.00%)	Coronary artery stenosis 1/254 (0.39%)	Adverse Events 2:	Total: 56/269 (20.82%)	Anaemia 1/269 (0.37%)	Febrile neutropenia 0/269 (0.00%)	Lymphadenopathy 0/269 (0.00%)	Acute myocardial infarction 0/269 (0.00%)	Angina pectoris 3/269 (1.12%)	Angina unstable 1/269 (0.37%)	Bundle branch block left 1/269 (0.37%)	Cardiac failure 1/269 (0.37%)	Coronary artery disease 1/269 (0.37%)	Coronary artery stenosis 0/269 (0.00%)	the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)	Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100.	Time frame: Baseline and Week 13	Results 1:	Arm/Group Title: Bisphosphonate IV Q4W	Arm/Group Description: Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion	Overall Number of Participants Analyzed: 38	Mean (Standard Deviation)	Unit of Measure: Percent change  -10.19         (208.84)	Results 2:	Arm/Group Title: Denosumab 30 mg Q4W	Arm/Group Description: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W)	Overall Number of Participants Analyzed: 40	Mean (Standard Deviation)	Unit of Measure: Percent change  -52.87         (95.14)	cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur).	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Lapatinib With Paclitaxel	Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours, every 3 weeks. The treatment group was stratified by sites of metastatic disease and stage of disease. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal.	INTERVENTION 2:	Placebo With Paclitaxel	Participants received matching placebo orally OD with paclitaxel (175 mg/m^2 IV) over the course of 3 hours, every 3 weeks. The treatment group was stratified by sites of metastatic disease and stage of disease. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal.	the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant.	[1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	AlloDerm RTU	Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.	AlloDerm RTU	INTERVENTION 2:	SurgiMend PRS	Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement.	SurgiMend PRS	the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant.	[1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	The subject must be female and 18 years of age or older.	The subject must be a preoperative clinical Tis, T1, T2, T3, T4, as well as clinical N0 and clinical M0 breast cancer	The subject must have a diagnosis of primary breast cancer.	The subject must be a candidate for surgical intervention, either with lumpectomy and SLNB or with mastectomy and SLNB, as the treatment of her breast cancer.	The subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 - 2	The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study	Exclusion Criteria:	The subject has clinical or radiological or pathologic evidence of metastatic cancer, including any abnormal or enlarged clinical palpable lymph nodes or core biopsy/surgical biopsy/fine-needle-aspiration evidence of malignant cell within any lymph nodes.	The subject has a known hypersensitivity to vital blue dye (VBD) in a case where vital blue dye was planned for use during SLNB.	The subject has a positive pregnancy test or is lactating.	The subject has had prior surgery to the indicated breast or axilla.	Informed consent is optional for entry in the primary trial.	[1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]
primary trial INCLUSION CRITERIA	PART 1:	confirmed pathologic diagnosis of a solid tumor not curable with available therapies for which neratinib plus capecitabine is a reasonable treatment option.	PART 2:	confirmed histologically and/or cytologically confirmed diagnosis of breast cancer, metastatic or locally advanced.	erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation), based on local testing, or based on centralized FISH testing prior to day 1.	disease progression on or following at least 1 prior trastuzumab containing treatment regimen (at least 6 weeks) for metastatic or locally advanced disease. (Prior adjuvant trastuzumab is allowed but not required). A 2 week period is required between the last dose of trastuzumab treatment and first dose of the test article.	Prior treatment with a taxane in the neoadjuvant, adjuvant, locally advanced, and/or metastatic disease treatment setting.	PARTS 1 and 2:	At least 1 measurable lesion as defined by RECIST criteria.	LVEF within institutional range of normal as measured by multi-gated acquisition (MUGA) or echocardiogram (ECHO).	EXCLUSION CRITERIA	PART 2:	prior treatment with capecitabine, lapatinib (20 subjects with prior lapatinib exposure will be enrolled) or any erbB-2 targeted agents except trastuzumab. Treatment with erbB-2 targeted therapy must exceed 2 weeks (14 days) in order to be exclusionary.	prior treatment with anthracyclines with a cumulative dose of doxorubicin of greater than 400 mg/m², epirubicin dose of greater than 800 mg/m², or the equivalent dose for other anthracyclines.	PARTS 1 and 2:	Subjects with bone as the only site of disease.	Active uncontrolled or symptomatic central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Subjects with a history of CNS metastases or cord compression are allowable if they have been considered definitively treated and are off anticonvulsants and steroids for at least 4 weeks before the first dose of test article.	Any other cancer within 5 years prior to screening with the exception of adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin.	Patients with ERBB2 positive tumors are eligible for the primary trial.	[1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Outcome Measurement:	Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel	The MTD is defined as the dose range at which  1 of 6 evaluable participants experience dose limiting toxicities (DLT). DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.02 and was defined as any of the following events: 1. Grade 4 neutropenia and thrombocytopenia lasting 7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count <10,000/mm^3; 4. Grade 3 thrombocytopenia with bleeding; 5. Any other Grade 3 nonhematologic toxicity, with following exceptions: Grade 3 nausea/emesis, Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 nonhematological toxicity that could be controlled to Grade 2 with appropriate treatment; 6. Other alisertib-related nonhematologic toxicities Grade 2 that, in opinion of investigator, required a dose reduction or discontinuation of therapy with alisertib.	Time frame: Cycle 1 (Up to 28 days)	Results 1:	Arm/Group Title: Alisertib + Paclitaxel (Phase 1)	Arm/Group Description: Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).	Overall Number of Participants Analyzed: 49	Measure Type: Number	Unit of Measure: mg  40	The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by results from cohort 2 of the primary trial, is 40 mg/m^2 orally, twice daily (BID) on Days 1-3, 8-10 and 15-17	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)	OIRR is the percentage of participants with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. CR is measurable target lesions, the disappearance of all central nervous system (CNS) target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum longest duration (LD) of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. Stable disease (SD) is less than (<)30% decrease relative to baseline but <20% increase in sum LD relative to nadir. Progressive disease (PD) is greater than or equal to (  ) 20% increase in sum LD relative to nadir and a relative increase of 20%, 1 lesion must increase by absolute value of 5 millimeter (mm).	Time frame: Baseline to Objective Disease Progression (Up to 36 Months)	Results 1:	Arm/Group Title: Part A Abemaciclib: HR+, HER2+ Breast Cancer	Arm/Group Description: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.	Overall Number of Participants Analyzed: 23	Measure Type: Number	Unit of Measure: percentage of participants  0	Results 2:	Arm/Group Title: Part B Abemaciclib: HR+, HER2- Breast Cancer	Arm/Group Description: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET).	Participants may continue to receive treatment until discontinuation criteria are met.	Overall Number of Participants Analyzed: 52	Measure Type: Number	Unit of Measure: percentage of participants  5.8	There were 23 participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	LBH589 With Capecitabine	MTD, LBH589 with Capecitabine	LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.	Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.	INTERVENTION 2:	LBH589 and Lapatinib	LBH589 and Lapatinib	LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.	Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.	the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with Body surface area.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 103/1408 (7.32%)	Anaemia 1/1408 (0.07%)	Angina pectoris 1/1408 (0.07%)	Myocardial infarction 1/1408 (0.07%)	Atrial fibrillation 0/1408 (0.00%)	Sinus tachycardia 0/1408 (0.00%)	Tachycardia 0/1408 (0.00%)	Vertigo 0/1408 (0.00%)	Diarrhoea 22/1408 (1.56%)	Vomiting 12/1408 (0.85%)	Nausea 4/1408 (0.28%)	Abdominal pain 2/1408 (0.14%)	Pancreatitis 2/1408 (0.14%)	Adverse Events 2:	Total: 85/1408 (6.04%)	Anaemia 1/1408 (0.07%)	Angina pectoris 0/1408 (0.00%)	Myocardial infarction 1/1408 (0.07%)	Atrial fibrillation 1/1408 (0.07%)	Sinus tachycardia 1/1408 (0.07%)	Tachycardia 1/1408 (0.07%)	Vertigo 1/1408 (0.07%)	Diarrhoea 1/1408 (0.07%)	Vomiting 1/1408 (0.07%)	Nausea 1/1408 (0.07%)	Abdominal pain 0/1408 (0.00%)	Pancreatitis 1/1408 (0.07%)	the primary trial had a total of 3 patients experiencing Pancreatic Cancer, the secondary trial had 0.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 46/170 (27.06%)	Anaemia 1/170 (0.59%)	Febrile neutropenia 1/170 (0.59%)	Cardiac tamponade 1/170 (0.59%)	Myocarditis 1/170 (0.59%)	Pericardial effusion 2/170 (1.18%)	Pericarditis 1/170 (0.59%)	Colitis 1/170 (0.59%)	Constipation 1/170 (0.59%)	Diarrhoea 0/170 (0.00%)	Gastroenteritis eosinophilic 0/170 (0.00%)	Intestinal obstruction 0/170 (0.00%)	Adverse Events 2:	Total: 0/1 (0.00%)	Anaemia 0/1 (0.00%)	Febrile neutropenia 0/1 (0.00%)	Cardiac tamponade 0/1 (0.00%)	Myocarditis 0/1 (0.00%)	Pericardial effusion 0/1 (0.00%)	Pericarditis 0/1 (0.00%)	Colitis 0/1 (0.00%)	Constipation 0/1 (0.00%)	Diarrhoea 0/1 (0.00%)	Gastroenteritis eosinophilic 0/1 (0.00%)	Intestinal obstruction 0/1 (0.00%)	Nausea 0/1 (0.00%)	the primary trial had a total of 3 patients experiencing Pancreatic Cancer, the secondary trial had 0.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 3/30 (10.00%)	Cholecystitis *  [1]1/30 (3.33%)	Increase in diarrhea *  [2]1/30 (3.33%)	Flank pain *  [3]1/30 (3.33%)	the primary trial only recorded three types of adverse events.	[1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Lapatinib Plus Capecitabine	Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also received capecitabine 2000 mg/m^2) per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal.	INTERVENTION 2:	Trastuzumab Plus Capecitabine	Participants received an IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks. Participants also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal.	the secondary trial and the primary trial do not test the same modalities of cancer treatments.	[1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Behavioral Dietary Intervention	Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks.	Behavioral dietary intervention: Receive caloric restricted dietary intervention	Therapeutic conventional surgery: Undergo definitive lumpectomy	Radiation therapy: Undergo radiation therapy	Counseling intervention: Receive dietary counseling	Quality-of-life assessment: Ancillary studies	the secondary trial and the primary trial do not test the same modalities of cancer treatments.	[1, 1, 1, 1, 1, 1, 1, 1]
primary trial DISEASE CHARACTERISTICS:	Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma	Largest tumor lesion  5 cm	Palpable or nonpalpable breast lesion	Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions	Prior (preoperative) or planned (intraoperative) sentinel node biopsy required	At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension	No clinical evidence of distant metastases	No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan, including the following:	Skeletal pain of unknown cause	Elevated alkaline phosphatase	Bone scan showing hot spots	No palpable axillary lymph node(s)	No Paget's disease without invasive cancer	Hormone receptor status:	Estrogen receptor and progesterone receptor known	PATIENT CHARACTERISTICS:	Age	Any age	Sex	Female	Menopausal status	Any status	Performance status	Not specified	Life expectancy	Not specified	Hematopoietic	Not specified	Hepatic	See Disease Characteristics	Renal	Not specified	Other	Not pregnant or nursing	No other prior or concurrent malignancy except the following:	Adequately treated basal cell or squamous cell skin cancer	Adequately treated carcinoma in situ of the cervix	Adequately treated in situ melanoma	Contralateral or ipsilateral carcinoma in situ of the breast	No psychiatric, addictive, or other disorder that may compromise ability to give informed consent	Geographically accessible for follow-up	PRIOR CONCURRENT THERAPY:	Biologic therapy	Not specified	Chemotherapy	Not specified	Endocrine therapy	Not specified	Radiotherapy	Not specified	Surgery	See Disease Characteristics	Other	No prior systemic therapy for breast cancer	More than 1 year since prior chemopreventive agent	Patients with a palpable breast lesions and axillary lymph nodes are eligible for the primary trial.	[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	HER2-positive disease determined locally	Histologically or cytologically confirmed invasive breast cancer	Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced or metastatic setting must include both chemotherapy, alone or in combination with another agent, and an anti-HER2 agent, alone or in combination with another agent	Documented progression of incurable, unresectable, LABC, or mBC, defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy	Measurable and/or non-measurable disease	Left ventricular ejection fraction (LVEF) >/=50% by either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)	Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2	Adequate organ function	Use of highly effective contraception as defined by the protocol	Exclusion Criteria:	History of treatment with trastuzumab emtansine	Prior enrollment into a clinical study containing trastuzumab emtansine regardless of having received trastuzumab emtansine or not	Peripheral neuropathy of Grade >/= 3 per National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v 4.0	History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer	History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to first study treatment except hormone therapy, which can be given up to 7 days prior to first study treatment; recovery of treatment-related toxicity consistent with other eligibility criteria	History of exposure to cumulative doses of anthracyclines	History of radiation therapy within 14 days of first study treatment. The participant must have recovered from any resulting acute toxicity (to Grade </=1) prior to first study treatment.	Metastatic central nervous system (CNS) disease only	Brain metastases which are symptomatic	History of a decrease in LVEF to less than (<) 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment	History of symptomatic CHF (New York Heart Association [NYHA] Classes II-IV) or serious cardiac arrhythmia requiring treatment	History of myocardial infarction or unstable angina within 6 months of first study treatment	Current dyspnea at rest due to complications of advanced malignancy or requirement for continuous oxygen therapy	Current severe, uncontrolled systemic disease (clinically significant cardiovascular, pulmonary, or metabolic disease)	Pregnancy or lactation	Currently known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus	History of intolerance (such as Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins or any component of the product	Patients with incurable and  unresectable Locally Advanced Breast Cancer are eligible for the primary trial.	[1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 18/52 (34.62%)	Anaemia 2/52 (3.85%)	Febrile Neutropenia 1/52 (1.92%)	Haemolytic Uraemic Syndrome 1/52 (1.92%)	Leukopenia 1/52 (1.92%)	Neutropenia 1/52 (1.92%)	Thrombocytopenia 1/52 (1.92%)	Cardiac Failure Congestive 1/52 (1.92%)	Cardio-Respiratory Arrest 1/52 (1.92%)	Abdominal Pain 1/52 (1.92%)	Constipation 1/52 (1.92%)	Diarrhoea 1/52 (1.92%)	the primary trial recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency where found in the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 14/54 (25.93%)	anaemia 2/54 (3.70%)	Febrile neutropenia 7/54 (12.96%)	Neutropenia 2/54 (3.70%)	Thrombocytopenia 6/54 (11.11%)	Atrial fibrillation 1/54 (1.85%)	Cardiac failure congestive 1/54 (1.85%)	Pericardial effusion 1/54 (1.85%)	Nausea 2/54 (3.70%)	Vomiting 3/54 (5.56%)	Catheter site erythema 1/54 (1.85%)	Chest discomfort 1/54 (1.85%)	Adverse Events 2:	Total: 5/20 (25.00%)	anaemia 0/20 (0.00%)	Febrile neutropenia 2/20 (10.00%)	Neutropenia 0/20 (0.00%)	Thrombocytopenia 0/20 (0.00%)	Atrial fibrillation 0/20 (0.00%)	Cardiac failure congestive 0/20 (0.00%)	Pericardial effusion 0/20 (0.00%)	Nausea 0/20 (0.00%)	Vomiting 0/20 (0.00%)	Catheter site erythema 0/20 (0.00%)	Chest discomfort 0/20 (0.00%)	the primary trial recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency where found in the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Operable breast cancer	Exclusion Criteria:	Inoperable breast cancer	BMI > 25	Neoadiuvant radioterapy	Carcinomastitis	Previous phlebitis of omolateral arm	Collagen disease	Emily has an Inoperable non-metastatic breast cancer, she is eligible for both the secondary trial and the primary trial.	[1, 0, 0, 1, 0, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Written informed consent of the patient signed by herself.	Histologically confirmed metastatic or recurrent adenocarcinoma of the breast.	Aged 20 to 74 at the time of informed consent.	Exclusion Criteria:	Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer.	Emily has an Inoperable non-metastatic breast cancer, she is eligible for both the secondary trial and the primary trial.	[1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Lapatinib With Paclitaxel	Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours, every 3 weeks. The treatment group was stratified by sites of metastatic disease and stage of disease. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal.	INTERVENTION 2:	Placebo With Paclitaxel	Participants received matching placebo orally OD with paclitaxel (175 mg/m^2 IV) over the course of 3 hours, every 3 weeks. The treatment group was stratified by sites of metastatic disease and stage of disease. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal.	the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course.	[1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	AlloDerm RTU	Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.	AlloDerm RTU	INTERVENTION 2:	SurgiMend PRS	Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement.	SurgiMend PRS	the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course.	[1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Histologically proved infiltrating breast cancer (ductal, lobular carcinoma…) or a carcinoma in-situ with an elevated risk of micro-invasion. (High grade with necrosis, radiologically evaluated size more than 40mm, or immediate mastectomy…)	Unifocal or multifocal but in same quarter	Size < 5cm clinically palpable or not	Clinically or ultrasound axillary N0	Isotopic sentinel node detection	Adult patient	Signed informed consent by patient or legally responsable authority	Patient registered to a social security system	No surgical contra-indication	Exclusion Criteria:	Mammary carcinoma recurrence	Previous same side mammary reduction	Previous lumpectomy	Contra-indication to surgery	Pregnant or breast feeding patient	Denial of participation	Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer that have not had Previous lumpectomy or same side mammary reduction and have no Contra-indication to surgery are excluded from the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24	Bone mineral density (BMD) by DXA at lumbar spine (L2-L4); DXA assessments of the BMD at dual hips. (BMD). Two X-ray beams with different energy levels are aimed at the patient's bones. When soft tissue absorption is subtracted out, the BMD can be determined from the absorption of each beam by bone.	Time frame: baseline, month 24	Results 1:	Arm/Group Title: Placebo	Arm/Group Description: Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).	Overall Number of Participants Analyzed: 36	Mean (Standard Deviation)	Unit of Measure: Z-score  -0.075         (0.041)	Results 2:	Arm/Group Title: Zometa	Arm/Group Description: Zoledronic Acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).	Overall Number of Participants Analyzed: 34	Mean (Standard Deviation)	Unit of Measure: Z-score  0.037         (0.042)	In the primary trial patients in control group had a Z-score of 0.037, higher than the test group score. 	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 13/74 (17.57%)	neutropenia 1/74 (1.35%)	left ventricular dysfunction 1/74 (1.35%)	fistula enterovesical 1/74 (1.35%)	constipation and hypokalemia 1/74 (1.35%)	nausea, vomiting and burning abdominal pain 2/74 (2.70%)	Infection 1/74 (1.35%)	febrile neutropenia 3/74 (4.05%)	speech impairment 1/74 (1.35%)	dyspnea, pain 1/74 (1.35%)	hemorrhage/bleeding 2/74 (2.70%)	the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial.	[1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]
secondary trial Adverse Events 1:	Total: 11/50 (22.00%)	Anemia 3/50 (6.00%)	Febrile neutropenia 1/50 (2.00%)	Arrythmia 1/50 (2.00%)	Ileus 1/50 (2.00%)	Nausea 1/50 (2.00%)	Pain-Abdominal 1/50 (2.00%)	Vomiting 1/50 (2.00%)	Bronchial infection 1/50 (2.00%)	Sepsis 1/50 (2.00%)	Neutropenia 2/50 (4.00%)	Platelet count decreased 1/50 (2.00%)	Dehydration 1/50 (2.00%)	Arthralgia 1/50 (2.00%)	the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 46/170 (27.06%)	Anaemia 1/170 (0.59%)	Febrile neutropenia 1/170 (0.59%)	Cardiac tamponade 1/170 (0.59%)	Myocarditis 1/170 (0.59%)	Pericardial effusion 2/170 (1.18%)	Pericarditis 1/170 (0.59%)	Colitis 1/170 (0.59%)	Constipation 1/170 (0.59%)	Diarrhoea 0/170 (0.00%)	Gastroenteritis eosinophilic 0/170 (0.00%)	Intestinal obstruction 0/170 (0.00%)	Adverse Events 2:	Total: 0/1 (0.00%)	Anaemia 0/1 (0.00%)	Febrile neutropenia 0/1 (0.00%)	Cardiac tamponade 0/1 (0.00%)	Myocarditis 0/1 (0.00%)	Pericardial effusion 0/1 (0.00%)	Pericarditis 0/1 (0.00%)	Colitis 0/1 (0.00%)	Constipation 0/1 (0.00%)	Diarrhoea 0/1 (0.00%)	Gastroenteritis eosinophilic 0/1 (0.00%)	Intestinal obstruction 0/1 (0.00%)	Nausea 0/1 (0.00%)	The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 12/538 (2.23%)	Hypertension 0/538 (0.00%)	Acoustic Neuroma 1/538 (0.19%)	Diarrhea 0/538 (0.00%)	Colitis 1/538 (0.19%)	Elevated ALT or AST enzyme 7/538 (1.30%)	Diagnosis of Uterine Cancer 0/538 (0.00%)	Motorcycle accident 0/538 (0.00%)	Fall 0/538 (0.00%)	Surgery 3/538 (0.56%)	Adverse Events 2:	Total: 8/537 (1.49%)	Hypertension 1/537 (0.19%)	Acoustic Neuroma 0/537 (0.00%)	Diarrhea 1/537 (0.19%)	Colitis 0/537 (0.00%)	Elevated ALT or AST enzyme 0/537 (0.00%)	Diagnosis of Uterine Cancer 2/537 (0.37%)	Motorcycle accident 1/537 (0.19%)	Fall 1/537 (0.19%)	Surgery 2/537 (0.37%)	The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Clinical Benefit Rate (Complete Response, Partial Response, or Stable Disease)	Response evaluation criteria in solid tumors (RECIST) criteria version 1.0 was used for response evaluation. Clinical benefit rate is defined as the proportion of subjects experiencing a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.	Evaluation of target lesions: Complete Response (CR)-- Disappearance of all target lesions; Partial Response (PR)-- At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; Stable Disease (SD)-- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started;	Evaluation of non-target lesions: Complete Response (CR)-- Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/ Stable Disease (SD)-- Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits	Time frame: Up to 24 months	Results 1:	Arm/Group Title: Treatment (Temsirolimus)	Arm/Group Description: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Temsirolimus: Given IV	Overall Number of Participants Analyzed: 31	Measure Type: Number	Unit of Measure: percentage of participants  9.7	Less than 1/10 the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Women aged > 18 years	Histologically documents metastatic breast cancer	HER2 positive using Fluorescence In Situ Hybridization (FISH)	For phase I, patients who have previously received treatment for their metastatic disease are allowed to participate.	For the phase II portion of the study, patients must have measureable disease (> 2 cm; > 1 cm on spiral CT scan)	Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2	A life expectancy of > 3 months	Use of effective means of contraception	Exclusion Criteria:	For Phase II, prior cytotoxic chemotherapy and/or prior Herceptin for their metastatic disease. Prior treatment in the adjuvant setting is allowed.	Mark has HER2 positive breast cancer, he is eligible for the primary trial.	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 18/364 (4.95%)	Febrile neutropenia 3/364 (0.82%)	Atrial fibrillation 1/364 (0.27%)	Cardio-respiratory arrest 1/364 (0.27%)	Sinus bradycardia 1/364 (0.27%)	Ventricular extrasystoles 0/364 (0.00%)	Enterocolitis 0/364 (0.00%)	Faecaloma 0/364 (0.00%)	Gastric ulcer perforation 0/364 (0.00%)	Gastrointestinal toxicity 0/364 (0.00%)	Pancreatitis acute 0/364 (0.00%)	Adverse Events 2:	Total: 5/361 (1.39%)	Febrile neutropenia 0/361 (0.00%)	Atrial fibrillation 0/361 (0.00%)	Cardio-respiratory arrest 0/361 (0.00%)	Sinus bradycardia 0/361 (0.00%)	Ventricular extrasystoles 0/361 (0.00%)	Enterocolitis 0/361 (0.00%)	Faecaloma 0/361 (0.00%)	Gastric ulcer perforation 0/361 (0.00%)	Gastrointestinal toxicity 1/361 (0.28%)	Pancreatitis acute 0/361 (0.00%)	Cohort 1 of the primary trial recorded the same number of instances of Neutropenic fever as Cohort 1 of the secondary trial.	[1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Adverse Events 1:	Total: 6/25 (24.00%)	Neutropenia *3/25 (12.00%)	Anemia *0/25 (0.00%)	Febrile Neutropenia *0/25 (0.00%)	Chest Pain *0/25 (0.00%)	Diarrhea *1/25 (4.00%)	Fatigue *1/25 (4.00%)	Liver Tests *0/25 (0.00%)	Neuropathy *0/25 (0.00%)	Syncope *0/25 (0.00%)	Hand and Foot Syndrome *1/25 (4.00%)	Adverse Events 2:	Total: 11/26 (42.31%)	Neutropenia *3/26 (11.54%)	Anemia *1/26 (3.85%)	Febrile Neutropenia *1/26 (3.85%)	Chest Pain *1/26 (3.85%)	Diarrhea *1/26 (3.85%)	Fatigue *0/26 (0.00%)	Liver Tests *1/26 (3.85%)	Neuropathy *1/26 (3.85%)	Syncope *1/26 (3.85%)	Hand and Foot Syndrome *1/26 (3.85%)	Cohort 1 of the primary trial recorded the same number of instances of Neutropenic fever as Cohort 1 of the secondary trial.	[1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Outcome Measurement:	Clinical Benefit Rate (Complete Response, Partial Response, or Stable Disease)	Response evaluation criteria in solid tumors (RECIST) criteria version 1.0 was used for response evaluation. Clinical benefit rate is defined as the proportion of subjects experiencing a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.	Evaluation of target lesions: Complete Response (CR)-- Disappearance of all target lesions; Partial Response (PR)-- At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; Stable Disease (SD)-- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started;	Evaluation of non-target lesions: Complete Response (CR)-- Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/ Stable Disease (SD)-- Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits	Time frame: Up to 24 months	Results 1:	Arm/Group Title: Treatment (Temsirolimus)	Arm/Group Description: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Temsirolimus: Given IV	Overall Number of Participants Analyzed: 31	Measure Type: Number	Unit of Measure: percentage of participants  9.7	Most the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion criteria:	Inclusion Criteria:	Female patients age 18 years or older	Histologically proven breast cancer after failure or relapse of no more than three lines of chemotherapy including adjuvant, irrespective of prior hormone therapy metastatic disease (stage IV);	HER2-negative patients (HER2 1+ or negative, or HER2 2+ and FISH negative)	At least one measurable tumour lesion (RECIST);	Availability of tumour samples	Written informed consent that is consistent with ICH-GCP guidelines and local law	Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0 - 2.	Exclusion criteria:	Exclusion Criteria:	Active infectious disease	Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhoea	Serious illness, concomitant non-oncological disease or mental problems considered by the investigator to be incompatible with the protocol	Active/symptomatic brain metastases	Cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal)	ANC less than 1500/mm3 platelet count less than 100 000/mm3	Bilirubin greater than 1.5 mg /dl (>26 and#61549 mol /L, SI unit equivalent)	AST and ALT greater than 2.5 times the upper limit of normal or greater 5 times the upper limit of normal in case of known liver metastases	Serum creatinine greater than 1.5 mg/dl (>132 and#61549 mol/L, SI unit equivalent)	Patients who are sexually active and unwilling to use a medically acceptable method of contraception	Pregnancy or breast-feeding	Concomitant treatment with other investigational drugs or other anti-cancer-therapy during this study and/or during the past two/four weeks, prior to the first treatment with the trial drug. Concurrent treatment with biphosphonates is allowed	Previous treatment with trastuzumab, EGFR-, or EGFR/HER2-inhibitors patients unable to comply with the protocol	Active alcohol or drug abuse	Other malignancy within the past 5 years	Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Premenopausal women 55 years of age or younger with regular menstrual cycles (at least four cycles in the last six months). Women with fewer than 4 menses in the last 6 months or who have had a hysterectomy with ovaries intact will be considered premenopausal if FSH level < 20.	Women with breast density  25% (scattered fibroglandular densities or greater) are eligible.	Prior Treatment	Patients who are currently receiving hormone replacement therapy (estrogen or progesterone); or are taking tamoxifen or raloxifene are not eligible. Women who have taken these medications must have stopped for at least 4 months prior to study entry.	Topical estrogen (eg, transdermal patches and vaginal estrogens) is allowed.	Patients who are currently using hormonal contraception, should be taking it for at least 4 months prior to study entry.	Vitamin D Use	Patients who are taking regular vitamin D supplementation (above 400 IUs daily) and refuse or are unable to stop use are not eligible. Women who agree to stop will need to do so for at least 6 months prior to registration.	Patients may not start vitamin D supplementation after registration (regardless of results of vitamin D testing) but they may continue vitamin D if they are already taking 400 IUs daily or less and have been taking vitamin D for at least 6 months prior to baseline mammogram.	Patients with a history of breast cancer (including DCIS) or ovarian cancer are not eligible.	Patients with a history of breast implants or breast reduction are not eligible.	Patients with two or more bone fractures in the past five years are not eligible.	Patients with a diagnosis of osteoporosis with physician recommendation for treatment of low bone mass are not eligible.	Patients known to have hyperparathyroid disease or other serious disturbances of calcium metabolism requiring intervention in the past 5 years are not eligible.	Patients with a history of kidney stones (unless documented not to have been a calcium stone) are not eligible.	Patients participating in a concurrent breast cancer chemoprevention trial are not eligible.	Required initial laboratory values - Calcium < 10.5 mg/dL	Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	At least 18 years of age	Willing and able to provide informed consent	Reporting daily hot flashes	Able to read, write, and speak English	Postmenopausal to limit sample variability (> 12 months amenorrhea)	Greater then 1 month but < 5 years post-treatment (surgery, radiation, chemotherapy) for non-metastatic breast cancer.	These criteria allow inclusion of women successfully treated for recurrent breast cancer since there is no known reason to exclude them. Menopausal status is assessed using self-reports due to problems in reliably measuring follicle-stimulating hormone levels and estradiol in tamoxifen users.	Exclusion Criteria:	Exclusion criteria are current depression, history of migraines or hepatitis, abnormal chemistry profile (e.g., sodium, potassium, glucose), or a positive urine drug screen for illegal substances.	Clinically depressed patients are not able to participate in the primary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 1, 1]
primary trial Inclusion Criteria:	HER2-positive disease determined locally	Histologically or cytologically confirmed invasive breast cancer	Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced or metastatic setting must include both chemotherapy, alone or in combination with another agent, and an anti-HER2 agent, alone or in combination with another agent	Documented progression of incurable, unresectable, LABC, or mBC, defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy	Measurable and/or non-measurable disease	Left ventricular ejection fraction (LVEF) >/=50% by either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)	Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2	Adequate organ function	Use of highly effective contraception as defined by the protocol	Exclusion Criteria:	History of treatment with trastuzumab emtansine	Prior enrollment into a clinical study containing trastuzumab emtansine regardless of having received trastuzumab emtansine or not	Peripheral neuropathy of Grade >/= 3 per National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v 4.0	History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer	History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to first study treatment except hormone therapy, which can be given up to 7 days prior to first study treatment; recovery of treatment-related toxicity consistent with other eligibility criteria	History of exposure to cumulative doses of anthracyclines	History of radiation therapy within 14 days of first study treatment. The participant must have recovered from any resulting acute toxicity (to Grade </=1) prior to first study treatment.	Metastatic central nervous system (CNS) disease only	Brain metastases which are symptomatic	History of a decrease in LVEF to less than (<) 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment	History of symptomatic CHF (New York Heart Association [NYHA] Classes II-IV) or serious cardiac arrhythmia requiring treatment	History of myocardial infarction or unstable angina within 6 months of first study treatment	Current dyspnea at rest due to complications of advanced malignancy or requirement for continuous oxygen therapy	Current severe, uncontrolled systemic disease (clinically significant cardiovascular, pulmonary, or metabolic disease)	Pregnancy or lactation	Currently known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus	History of intolerance (such as Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins or any component of the product	Patients with incurable and unresectable Breast Cancer are eligible for the primary trial, unless it is metastatic.	[1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Outcome Measurement:	LDex Change-	Bioimpedance measured by units of LDex. As extracellular fluid accumulates (i.e. lymphedema develops) the LDex value increases.	Time frame: Bioimpedance at baseline and end of treatment with the average number of treaments being 9 conducted over a median of up to 4 weeks.	Results 1:	Arm/Group Title: Laser Therapy Alone	Arm/Group Description: therapist administered laser treatment	laser: therapist administered laser	Overall Number of Participants Analyzed: 15	Median (Inter-Quartile Range)	Unit of Measure: LDex  28.0        (17 to 35)	Results 2:	Arm/Group Title: Mld Alone	Arm/Group Description: therapist administered manual lymphatic drainage	manual lymphatic drainage: therapist administered massage therapy	Overall Number of Participants Analyzed: 16	Median (Inter-Quartile Range)	Unit of Measure: LDex  17.8        (3 to 38)	neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Outcome Measurement:	Overall Survival (OS) of Patients	To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC). Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients will be followed until their date of death or until final database closure. Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis.	Time frame: Within 3 years from study start	Results 1:	Arm/Group Title: NKTR-102	Arm/Group Description: In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.	Overall Number of Participants Analyzed: 92	Median (95% Confidence Interval)	Unit of Measure: months  7.8        (6.1 to 10.2)	Results 2:	Arm/Group Title: Treatment of Physician's Choice (TPC)	Arm/Group Description: In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.	Overall Number of Participants Analyzed: 86	Median (95% Confidence Interval)	Unit of Measure: months  7.5        (5.8 to 10.4)	neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Outcome Measurement:	Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4	Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.	Time frame: Baseline to Week 4	Results 1:	Arm/Group Title: AZD0530 175 mg	Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily	Overall Number of Participants Analyzed: 46	Geometric Mean (95% Confidence Interval)	Unit of Measure: Percentage change in betaCTX  -71.1        (-75.9 to -65.4)	Results 2:	Arm/Group Title: Zoledronic Acid 4 mg	Arm/Group Description: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period	Overall Number of Participants Analyzed: 65	Geometric Mean (95% Confidence Interval)	Unit of Measure: Percentage change in betaCTX  -68.4        (-73.0 to -63.2)	The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group, with a -75.9 % change from baseline.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 5/14 (35.71%)	Ileus 1/14 (7.14%)	General disorders and administration site conditions - Other, disease progression 2/14 (14.29%)	Infections and infestations - Other, pneumonia 1/14 (7.14%)	Acute kidney injury 1/14 (7.14%)	the primary trial recorded 2.38% more total adverse events than the secondary trial	[1, 1, 0, 0, 0, 0]
secondary trial Adverse Events 1:	Total: 3/9 (33.33%)	Fatigue * 1/9 (11.11%)	Non-cardiac chest pain * 1/9 (11.11%)	Sepsis * 1/9 (11.11%)	Urinary tract infection * 1/9 (11.11%)	Syncope * 1/9 (11.11%)	Anxiety * 1/9 (11.11%)	Thromboembolic event * 1/9 (11.11%)	the primary trial recorded 2.38% more total adverse events than the secondary trial	[1, 1, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 11/56 (19.64%)	Febrile Neutropenia * 3/56 (5.36%)	Neutropenia * 1/56 (1.79%)	Pancytopenia * 1/56 (1.79%)	Atrial Fibrillation * 1/56 (1.79%)	Coronary Artery Disease * 1/56 (1.79%)	Constipation * 1/56 (1.79%)	Chest Pain * 1/56 (1.79%)	Non-Cardiac Chest Pain * 1/56 (1.79%)	Edema due to Cardiac Disease * 1/56 (1.79%)	Cellulitis * 1/56 (1.79%)	One patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets.	[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Treatment (Tivantinib)	Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.	Laboratory Biomarker Analysis: Correlative studies	Tivantinib: Given PO	the primary trial and the secondary trial are testing completely different modalities of interventions.	[1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Prone	Prone position	INTERVENTION 2:	Supine	Supine position	the primary trial and the secondary trial are testing completely different modalities of interventions.	[1, 1, 1, 1, 1, 1]
primary trial Inclusion criteria:	Female patients  18 years of age.	Written informed consent given.	Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed.	Previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months.	Eastern Cooperative Oncology Group (ECOG) performance status 2 .	Life expectancy  1 year.	Exclusion criteria:	More than 3 months since last infusion of Zoledronic Acid (Zometa®).	Treatments with other bisphosphonate than Zoledronic Acid (Zometa®) at any time prior to study entry.	Serum creatinine > 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) < 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85	Corrected (adjusted for serum albumin) serum calcium < 8 mg/dl (2 mmol/L) or > 12 mg/dL ( 3.0 mmol/L).	Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.	Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants).	Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients. Women of childbearing potential not using effective methods of birth control (e.g. abstinence, oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide).	History of non-compliance to medical regimens or potential unreliable behavior.	Known sensitivity to study drug(s) or class of study drug(s).	Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study	Use of any other investigational agent in the last 30 days.	Patients must have a Life expectancy of 75+ years to enroll in the primary trial	[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	Women >=18 years of age	HER2-negative metastatic breast cancer	Previous adjuvant chemotherapy or hormonal treatment	>=1 measurable target lesion	Exclusion Criteria:	Previous treatment with chemotherapy, an anti-angiogenic agent, or a biologic therapy for advanced or metastatic cancer	Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy	Central nervous system metastases	Other malignancy within last 5 years, except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix	Serious concurrent infection	Patients that are not willing to sign and give written informed consent for participation of the primary trial will still be included.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Disease-free Survival After Prolonged Endocrine Treatment	To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of disease-free survival.	Time frame: DFS was defined as the time from two years after randomization to the earliest occurrence of loco-regional recurrence, distant recurrence, contralateral new breast cancer, second cancer or death from any cause, assessed up to a maximum of 8.5 years	Results 1:	Arm/Group Title: Arm A: Anastrozol	Arm/Group Description: 1 mg per day for 2 years	Overall Number of Participants Analyzed: 1281	Median (Inter-Quartile Range)	Unit of Measure: Years  NA  [1]    (7.7 to NA)	Results 2:	Arm/Group Title: Arm B: Anastrozol	Arm/Group Description: 1 mg per day for 5 years	Overall Number of Participants Analyzed: 1323	Median (Inter-Quartile Range)	Unit of Measure: Years  NA  [1]    (8.1 to NA)	the secondary trial and the primary trial use similar outcome measures, evaluating how long patients survive after treatment.	[1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Outcome Measurement:	Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer	The number of participants with notable electrocardiogram changes meeting predefined criteria is being reported.	Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days)	Results 1:	Arm/Group Title: DS-8201a	Arm/Group Description: Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle.	Overall Number of Participants Analyzed: 49	Measure Type: Count of Participants	Unit of Measure: Participants  Maximum change from baseline in QTcF: >30 ms: 3   6.1%	Maximum change from baseline in QTcF: >60 ms: 0   0.0%	the secondary trial and the primary trial use similar outcome measures, evaluating how long patients survive after treatment.	[1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Avastin (Bevacizumab) Plus Hormone	All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.	the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention	[1, 1, 1]
primary trial Inclusion Criteria:	Participant is able to provide signed informed consent	Participant is female and  18 years of age or older if required by local laws or regulations	Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent. Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis	Participant has measurable and/or non-measurable disease	Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC)	Participant has not received prior chemotherapy for metastatic or locally-recurrent and inoperable breast cancer	Participant completed (neo) adjuvant taxane therapy at least 6 months prior to randomization	Participant completed (neo) adjuvant biologic therapy at least 6 weeks prior to randomization	Participant completed all prior radiotherapy with curative intent  3 weeks prior to randomization	Participant may have received prior hormonal therapy for breast cancer in the (neo) adjuvant and/or the metastatic setting  2 weeks prior to randomization	Participant's left ventricular ejection fraction is within normal institutional ranges	Participant has resolution to grade  1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3 (NCI-CTCAE v 3.0) of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy which must have resolved to grade  2	Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1	Participant is amenable to compliance with protocol schedules and testing	Participant has adequate hematological functions [absolute neutrophil count (ANC)  1500 cells/microliter (mcL), hemoglobin  9 grams/deciliter (g/dL), and platelets  100,000 cells/mcL and  850,000 cells/mcL]	Participant has adequate hepatic function [bilirubin within normal limits (WNL), aspartate transaminase (AST) and alanine transaminase (ALT)  2.5 times the upper limit of normal (ULN), or  5.0 times the ULN if the transaminase elevation is due to liver metastases, and alkaline phosphatase  5.0 times the ULN]	Participant has serum creatinine  1.5 x ULN. If serum creatinine > 1.5 x ULN the calculated creatinine clearance should be > 40 milliliters/minute (mL/min)	Participant's urinary protein is  1+ on dipstick or routine urinalysis (UA); if urine protein  2+, a 24-hour urine collection must demonstrate < 1000 milligrams (mg) of protein in 24 hours to allow participation in the study	Participant must have adequate coagulation function as defined by international normalized ratio (INR)  1.5 and a partial thromboplastin time (PTT)  1.5 X ULN if not receiving anticoagulation therapy. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin and if on warfarin must have a INR between 2 and 3 and have no active bleeding (defined as within 14 days of randomization) or pathological condition that carries a high risk of bleeding (such as, tumor involving major vessels or known varices)	Women of childbearing potential must implement adequate contraception in the opinion of the investigator	Participant has not received prior biologic therapy for metastatic or locally recurrent and inoperable breast cancer	Exclusion Criteria:	Participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that she has been disease free for > 3 years	Participant has a known sensitivity to docetaxel or other drugs formulated with polysorbate 80	Participant has a known sensitivity to agents of similar biologic composition as ramucirumab or other agents that specifically target vascular endothelial growth factor (VEGF)	Participant has a history of chronic diarrheal disease within 6 months prior to randomization	Participant has received irradiation to a major bone marrow area as defined as > 25% of bone marrow (such as, pelvic or abdominal radiation) within 30 days prior to randomization	Participant has participated in clinical trials of experimental agents within 4 weeks prior to randomization	Participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders	Participant has active, high risk bleeding (such as, via gastric ulcers or gastric varices) within 14 days prior to randomization	Participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy	Participant has uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator	Participant has brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease	Participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness	Participant has pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.	Participant is pregnant or lactating	Participants with HER2- primary liver tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial.	[1, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial DISEASE CHARACTERISTICS:	Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast	Evidence of metastatic involvement (stage IV disease)	Patients must have measurable disease	At least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST)	Treated brain metastases (surgery or radiation therapy) allowed if clinically stable	Patients with leptomeningeal disease are ineligible	Hormone receptor status:	Not specified	PATIENT CHARACTERISTICS:	Eastern Cooperative Oncology Group (ECOG) performance status 0-2	Male or female	Menopausal status not specified	Absolute neutrophil count (ANC)  1,500/mm^3	Platelet count  100,000/mm^3	Creatinine clearance > 50 mL/min	Fertile patients must use effective contraception	No history of another severe and/or life-threatening medical disease	No other active primary malignancy	Not pregnant or nursing	Negative pregnancy test	Patients with asymptomatic HIV infection are eligible	Liver dysfunction score  9	No pre-existing liver disease (i.e., cirrhosis or active viral hepatitis)	No active gastrointestinal malabsorption illness	No clinically significant cardiac disease, including the following:	Congestive heart failure, symptomatic coronary artery disease, and cardiac arrhythmias not well controlled with medication, or myocardial infarction within the past six months	No prior unanticipated severe reaction to fluoropyrimidine therapy, known hypersensitivity to fluorouracil, or known dihydropyrimidine dehydrogenase deficiency	No history of uncontrolled seizures or central nervous system disorders	No significant history of noncompliance to medical regimens	No clinically significant psychiatric disability that would preclude study compliance	PRIOR CONCURRENT THERAPY:	No previous capecitabine	Up to 3 prior cytotoxic regimens allowed for metastatic disease	Prior noncytotoxic therapy allowed (e.g., hormonal treatment or trastuzumab)	No other concurrent therapies intended to treat the primary condition including chemotherapy, biologic agents, or immunotherapy	No concurrent anti-estrogen therapy, radiation therapy, or investigational systemic therapy	No other concurrent investigational drugs	No concurrent use of the following drugs: warfarin for full anticoagulation, cimetidine, or azidothymidine (AZT)	Mini-dose warfarin for prophylaxis of central venous catheter thrombosis allowed	At least 4 weeks since prior sorivudine or brivudine	Concurrent use of bisphosphonates allowed if initiated before beginning study therapy	Concurrent use of megestrol acetate suspension as an appetite stimulant allowed	Participants with HER2- primary liver tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial.	[1, 1, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Treatment (Neoadjuvant Therapy, Adjuvant Therapy)	See Detailed Description.	doxorubicin hydrochloride: Given IV	cyclophosphamide: Given PO	paclitaxel: Given IV	filgrastim: Given SC	capecitabine: Given PO	methotrexate: Given IV	vinorelbine tartrate: Given IV	needle biopsy: Correlative studies	therapeutic conventional surgery: Undergo definitive breast surgery	immunohistochemistry staining method: Correlative studies	trastuzumab: Given IV	tamoxifen citrate: Given PO	letrozole: Given PO	laboratory biomarker analysis: Correlative studies	There is a least one route of administration shared by the interventions used in the primary trial and the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	100 mg Q-122	Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.	INTERVENTION 2:	200 mg Q-122	Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.	There is a least one route of administration shared by the interventions used in the primary trial and the secondary trial.	[1, 1, 1, 0, 0, 0]
primary trial Adverse Events 1:	Total: 3/6 (50.00%)	Febrile neutropenia 0/6 (0.00%)	Leukopenia 0/6 (0.00%)	Neutropenia 0/6 (0.00%)	Thrombocytopenia 0/6 (0.00%)	Cardio-respiratory arrest 0/6 (0.00%)	Cardiopulmonary failure 0/6 (0.00%)	Vertigo 0/6 (0.00%)	Visual impairment 0/6 (0.00%)	Abdominal pain 0/6 (0.00%)	Diarrhoea 0/6 (0.00%)	Dysphagia 0/6 (0.00%)	Gastric ulcer 0/6 (0.00%)	Adverse Events 2:	Total: 6/17 (35.29%)	Febrile neutropenia 0/17 (0.00%)	Leukopenia 0/17 (0.00%)	Neutropenia 0/17 (0.00%)	Thrombocytopenia 0/17 (0.00%)	Cardio-respiratory arrest 1/17 (5.88%)	Cardiopulmonary failure 0/17 (0.00%)	Vertigo 0/17 (0.00%)	Visual impairment 0/17 (0.00%)	Abdominal pain 0/17 (0.00%)	Diarrhoea 1/17 (5.88%)	Dysphagia 0/17 (0.00%)	Gastric ulcer 1/17 (5.88%)	There were an equal number of cases of Febrile neutropenia, Leukopenia and Neutropenia across cohorts in the primary trial.	[1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Outcome Measurement:	Rate of Breast Related Adverse Events	Investigators evaluated each subject and each reconstructed breast for the occurrence of an adverse event from the first stage of reconstruction through the final follow-up visit. A breast related adverse event was defined as any untoward medical occurrence related to a reconstructed breast.	Time frame: 18 months	Results 1:	Arm/Group Title: Meso BioMatrix Acellular Peritoneum Matrix	Arm/Group Description: All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction. After tissue expansion, the tissue expander was replaced with a breast implant during the second stage of reconstruction.	Overall Number of Participants Analyzed: 25	Overall Number of Units Analyzed	Type of Units Analyzed: Reconstructed breasts  Measure Type: NumberUnit of Measure: Reconstructed breasts affected: 12	At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)	Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period.	The primary endpoint, Pathological complete response, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.	Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks)	Results 1:	Arm/Group Title: CT-P6	Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study.	Overall Number of Participants Analyzed: 248	Measure Type: Number	Unit of Measure: percentage of responders  46.77        (40.43 to 53.19)	Results 2:	Arm/Group Title: Herceptin	Arm/Group Description: Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study.	Overall Number of Participants Analyzed: 256	Measure Type: Number	Unit of Measure: percentage of responders  50.39        (44.10 to 56.68)	The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 20/167 (11.98%)	Cardiac failure acute 0/167 (0.00%)	Diarrhoea 5/167 (2.99%)	Colitis 2/167 (1.20%)	Enterocolitis 1/167 (0.60%)	Enterocolitis haemorrhagic 1/167 (0.60%)	Stomatitis 1/167 (0.60%)	Impaired healing 1/167 (0.60%)	Sudden death 1/167 (0.60%)	Postoperative wound infection 2/167 (1.20%)	Erysipelas 2/167 (1.20%)	Bacterial diarrhoea 1/167 (0.60%)	Adverse Events 2:	Total: 4/167 (2.40%)	Cardiac failure acute 1/167 (0.60%)	Diarrhoea 0/167 (0.00%)	Colitis 0/167 (0.00%)	Enterocolitis 0/167 (0.00%)	Enterocolitis haemorrhagic 0/167 (0.00%)	Stomatitis 0/167 (0.00%)	Impaired healing 0/167 (0.00%)	Sudden death 0/167 (0.00%)	Postoperative wound infection 1/167 (0.60%)	Erysipelas 0/167 (0.00%)	Bacterial diarrhoea 0/167 (0.00%)	Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea.	[1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 5/14 (35.71%)	Ileus 1/14 (7.14%)	General disorders and administration site conditions - Other, disease progression 2/14 (14.29%)	Infections and infestations - Other, pneumonia 1/14 (7.14%)	Acute kidney injury 1/14 (7.14%)	the primary trial recorded 2 more total adverse events than the secondary trial	[1, 1, 0, 0, 0, 0]
secondary trial Adverse Events 1:	Total: 3/9 (33.33%)	Fatigue * 1/9 (11.11%)	Non-cardiac chest pain * 1/9 (11.11%)	Sepsis * 1/9 (11.11%)	Urinary tract infection * 1/9 (11.11%)	Syncope * 1/9 (11.11%)	Anxiety * 1/9 (11.11%)	Thromboembolic event * 1/9 (11.11%)	the primary trial recorded 2 more total adverse events than the secondary trial	[1, 1, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	Participant is able to provide signed informed consent	Participant is female and  18 years of age or older if required by local laws or regulations	Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent. Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis	Participant has measurable and/or non-measurable disease	Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC)	Participant has not received prior chemotherapy for metastatic or locally-recurrent and inoperable breast cancer	Participant completed (neo) adjuvant taxane therapy at least 6 months prior to randomization	Participant completed (neo) adjuvant biologic therapy at least 6 weeks prior to randomization	Participant completed all prior radiotherapy with curative intent  3 weeks prior to randomization	Participant may have received prior hormonal therapy for breast cancer in the (neo) adjuvant and/or the metastatic setting  2 weeks prior to randomization	Participant's left ventricular ejection fraction is within normal institutional ranges	Participant has resolution to grade  1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3 (NCI-CTCAE v 3.0) of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy which must have resolved to grade  2	Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1	Participant is amenable to compliance with protocol schedules and testing	Participant has adequate hematological functions [absolute neutrophil count (ANC)  1500 cells/microliter (mcL), hemoglobin  9 grams/deciliter (g/dL), and platelets  100,000 cells/mcL and  850,000 cells/mcL]	Participant has adequate hepatic function [bilirubin within normal limits (WNL), aspartate transaminase (AST) and alanine transaminase (ALT)  2.5 times the upper limit of normal (ULN), or  5.0 times the ULN if the transaminase elevation is due to liver metastases, and alkaline phosphatase  5.0 times the ULN]	Participant has serum creatinine  1.5 x ULN. If serum creatinine > 1.5 x ULN the calculated creatinine clearance should be > 40 milliliters/minute (mL/min)	Participant's urinary protein is  1+ on dipstick or routine urinalysis (UA); if urine protein  2+, a 24-hour urine collection must demonstrate < 1000 milligrams (mg) of protein in 24 hours to allow participation in the study	Participant must have adequate coagulation function as defined by international normalized ratio (INR)  1.5 and a partial thromboplastin time (PTT)  1.5 X ULN if not receiving anticoagulation therapy. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin and if on warfarin must have a INR between 2 and 3 and have no active bleeding (defined as within 14 days of randomization) or pathological condition that carries a high risk of bleeding (such as, tumor involving major vessels or known varices)	Women of childbearing potential must implement adequate contraception in the opinion of the investigator	Participant has not received prior biologic therapy for metastatic or locally recurrent and inoperable breast cancer	Exclusion Criteria:	Participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that she has been disease free for > 3 years	Participant has a known sensitivity to docetaxel or other drugs formulated with polysorbate 80	Participant has a known sensitivity to agents of similar biologic composition as ramucirumab or other agents that specifically target vascular endothelial growth factor (VEGF)	Participant has a history of chronic diarrheal disease within 6 months prior to randomization	Participant has received irradiation to a major bone marrow area as defined as > 25% of bone marrow (such as, pelvic or abdominal radiation) within 30 days prior to randomization	Participant has participated in clinical trials of experimental agents within 4 weeks prior to randomization	Participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders	Participant has active, high risk bleeding (such as, via gastric ulcers or gastric varices) within 14 days prior to randomization	Participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy	Participant has uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator	Participant has brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease	Participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness	Participant has pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.	Participant is pregnant or lactating	Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial.	[1, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial DISEASE CHARACTERISTICS:	Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast	Evidence of metastatic involvement (stage IV disease)	Patients must have measurable disease	At least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST)	Treated brain metastases (surgery or radiation therapy) allowed if clinically stable	Patients with leptomeningeal disease are ineligible	Hormone receptor status:	Not specified	PATIENT CHARACTERISTICS:	Eastern Cooperative Oncology Group (ECOG) performance status 0-2	Male or female	Menopausal status not specified	Absolute neutrophil count (ANC)  1,500/mm^3	Platelet count  100,000/mm^3	Creatinine clearance > 50 mL/min	Fertile patients must use effective contraception	No history of another severe and/or life-threatening medical disease	No other active primary malignancy	Not pregnant or nursing	Negative pregnancy test	Patients with asymptomatic HIV infection are eligible	Liver dysfunction score  9	No pre-existing liver disease (i.e., cirrhosis or active viral hepatitis)	No active gastrointestinal malabsorption illness	No clinically significant cardiac disease, including the following:	Congestive heart failure, symptomatic coronary artery disease, and cardiac arrhythmias not well controlled with medication, or myocardial infarction within the past six months	No prior unanticipated severe reaction to fluoropyrimidine therapy, known hypersensitivity to fluorouracil, or known dihydropyrimidine dehydrogenase deficiency	No history of uncontrolled seizures or central nervous system disorders	No significant history of noncompliance to medical regimens	No clinically significant psychiatric disability that would preclude study compliance	PRIOR CONCURRENT THERAPY:	No previous capecitabine	Up to 3 prior cytotoxic regimens allowed for metastatic disease	Prior noncytotoxic therapy allowed (e.g., hormonal treatment or trastuzumab)	No other concurrent therapies intended to treat the primary condition including chemotherapy, biologic agents, or immunotherapy	No concurrent anti-estrogen therapy, radiation therapy, or investigational systemic therapy	No other concurrent investigational drugs	No concurrent use of the following drugs: warfarin for full anticoagulation, cimetidine, or azidothymidine (AZT)	Mini-dose warfarin for prophylaxis of central venous catheter thrombosis allowed	At least 4 weeks since prior sorivudine or brivudine	Concurrent use of bisphosphonates allowed if initiated before beginning study therapy	Concurrent use of megestrol acetate suspension as an appetite stimulant allowed	Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial.	[1, 1, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 9/157 (5.73%)	Blood disorder 1/157 (0.64%)	Hemoglobin decreased 1/157 (0.64%)	Hemolysis 0/157 (0.00%)	Arrhythmia 0/157 (0.00%)	Cardiac disorder 0/157 (0.00%)	Myocardial ischemia 1/157 (0.64%)	Hearing impaired 0/157 (0.00%)	Tinnitus 0/157 (0.00%)	Cataract 0/157 (0.00%)	Diplopia 0/157 (0.00%)	Glaucoma 0/157 (0.00%)	Vision blurred 0/157 (0.00%)	Adverse Events 2:	Total: 14/157 (8.92%)	Blood disorder 0/157 (0.00%)	Hemoglobin decreased 2/157 (1.27%)	Hemolysis 1/157 (0.64%)	Arrhythmia 0/157 (0.00%)	Cardiac disorder 0/157 (0.00%)	Myocardial ischemia 0/157 (0.00%)	Hearing impaired 2/157 (1.27%)	Tinnitus 1/157 (0.64%)	Cataract 1/157 (0.64%)	Diplopia 0/157 (0.00%)	Glaucoma 1/157 (0.64%)	Vision blurred 1/157 (0.64%)	One case of hematolysis was recorded in the primary trial, none in the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 6/168 (3.57%)	FEBRILE NEUTROPENIA 3/168 (1.79%)	ENTERITIS 1/168 (0.60%)	PERIPHERAL NEUROPATHY 2/168 (1.19%)	DEPRESSION 1/168 (0.60%)	One case of hematolysis was recorded in the primary trial, none in the secondary trial.	[1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Pathologic Assessment After Study Treatment	Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or without endocrine therapy. Pathologic complete response: no invasive cancer in the residual breast. Near pathologic complete response: residual disease of less than 1 cm in breast.	Time frame: 12 weeks	Results 1:	Arm/Group Title: Lapatinib + Trastuzumab	Arm/Group Description: All study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week	Overall Number of Participants Analyzed: 64	Measure Type: Number	Unit of Measure: participants  Complete Pathologic Response: 18	Near Complete Pathologic Response: 16	Not Pathologic response: 30	The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 5/19 (26.32%)	Pain 3/19 (15.79%)	White blood cells (WBC) 5/19 (26.32%)	Hemoglobin (Hgb) 1/19 (5.26%)	Absolute neutrophil count (ANC) 5/19 (26.32%)	Platelets 3/19 (15.79%)	Elevated Aspartate Aminotransferase (AST) 1/19 (5.26%)	Elevated Alanine Aminotransferase (ALT) 1/19 (5.26%)	Dyspnea 3/19 (15.79%)	the primary trial does not monitor the occurrence of Hemoglobin C Disease in its adverse events.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Number of Participants With Dose Limiting Toxicities (DLT)	Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD). Important Limitations and Caveats are provided in the respective section.	Time frame: 28 days	Results 1:	Arm/Group Title: Afatinib 20mg + Herceptin	Arm/Group Description: Patients received continuous daily dosing with Afatinib 20mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit. This group includes patients from the dose-escalation cohort and from the expansion cohort.	Overall Number of Participants Analyzed: 13	Measure Type: Number	Unit of Measure: Participants  4	Results 2:	Arm/Group Title: Afatinib 30mg + Herceptin	Arm/Group Description: Patients received continuous daily dosing with Afatinib 30mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit.	Overall Number of Participants Analyzed: 2	Measure Type: Number	Unit of Measure: Participants  2	100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities.	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	FFDM Plus DBT	Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System.	This endpoint will be evaluated qualitatively. The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate).	INTERVENTION 2:	Full-Field Digital Mammography (FFDM)	Breast Images with FFDM alone FFDM: FujiFilm Aspire Cristalle System.	This endpoint will be evaluated qualitatively. The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate).	the primary trial and the secondary trial have the same number of study groups, and are both testing the effectiveness of Full-Field Digital Mammography.	[1, 1, 1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Active Control Group	Health Education Active Control Group	INTERVENTION 2:	My Surgical Success Treatment Group	My Surgical Success Intervention Group	the primary trial and the secondary trial have the same number of study groups, and are both testing the effectiveness of Full-Field Digital Mammography.	[1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 0/34 (0.00%)	Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial	[1, 1]
secondary trial Adverse Events 1:	Total: 6/62 (9.68%)	Musculoskeletal * 1/62 (1.61%)	Mood Alteration: Depression * 1/62 (1.61%)	renal - Other * 1/62 (1.61%)	Obstruction, GU: Uterus * 1/62 (1.61%)	Sexual * 0/62 (0.00%)	Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%)	Ulceration * 1/62 (1.61%)	Adverse Events 2:	Total: 1/64 (1.56%)	Musculoskeletal * 0/64 (0.00%)	Mood Alteration: Depression * 0/64 (0.00%)	renal - Other * 0/64 (0.00%)	Obstruction, GU: Uterus * 0/64 (0.00%)	Sexual * 1/64 (1.56%)	Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%)	Ulceration * 0/64 (0.00%)	Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee	cOR is defined as the documented evidence of complete response (CR) and partial response (PR) as assessed by ultrasound examination using Response Evaluation Criteria In Solid Tumors (RECIST). CR is defined as the disappearance of all target lesions (TLs) and non-TLs and the appearance of no new lesions (NLs). PR for TLs is defined as a >=30% decrease in the sum of the longest diameter (LD) of TLs, taking as a reference the Baseline sum LD. For non-TLs, it is defined as the persistence of >=1 non-TL and no new TLs or non-TLs.	Time frame: From Baseline (Day 1) up to 6 months, evaluated every 12 weeks	Results 1:	Arm/Group Title: Letrozole + Placebo	Arm/Group Description: Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered orally once daily for 6 months prior to surgery.	Overall Number of Participants Analyzed: 48	Measure Type: Number	Unit of Measure: percentage of participants  CR: 2	PR: 58	Results 2:	Arm/Group Title: Letrozole + Lapatinib	Arm/Group Description: Letrozole tablets in the dose of 2.5 mg plus lapatinib ditosylate monohydrate tablets in the dose of 1500 mg were administered orally once daily for 6 months prior to surgery.	Overall Number of Participants Analyzed: 41	Measure Type: Number	Unit of Measure: percentage of participants  CR: 12	PR: 54	Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Stratum 1: TAC + Bevacizumab	HER2 negative participants were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab every 3 weeks for 6 cycles, and maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.	INTERVENTION 2:	Stratum 2: TCH + Bevacizumab	HER2 positive participants were administered chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) + bevacizumab every 3 weeks for 6 cycles, and maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks.	the primary trial and the secondary trial have no overlap in the drugs they use for their interventions.	[1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Triptorelin Plus Tamoxifen	Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.	INTERVENTION 2:	Triptorelin Plus Exemestane	Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.	the primary trial and the secondary trial have no overlap in the drugs they use for their interventions.	[1, 1, 1, 1, 1, 1]
primary trial DISEASE CHARACTERISTICS:	Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma	Largest tumor lesion  5 cm	Palpable or nonpalpable breast lesion	Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions	Prior (preoperative) or planned (intraoperative) sentinel node biopsy required	At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension	No clinical evidence of distant metastases	No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan, including the following:	Skeletal pain of unknown cause	Elevated alkaline phosphatase	Bone scan showing hot spots	No palpable axillary lymph node(s)	No Paget's disease without invasive cancer	Hormone receptor status:	Estrogen receptor and progesterone receptor known	PATIENT CHARACTERISTICS:	Age	Any age	Sex	Female	Menopausal status	Any status	Performance status	Not specified	Life expectancy	Not specified	Hematopoietic	Not specified	Hepatic	See Disease Characteristics	Renal	Not specified	Other	Not pregnant or nursing	No other prior or concurrent malignancy except the following:	Adequately treated basal cell or squamous cell skin cancer	Adequately treated carcinoma in situ of the cervix	Adequately treated in situ melanoma	Contralateral or ipsilateral carcinoma in situ of the breast	No psychiatric, addictive, or other disorder that may compromise ability to give informed consent	Geographically accessible for follow-up	PRIOR CONCURRENT THERAPY:	Biologic therapy	Not specified	Chemotherapy	Not specified	Endocrine therapy	Not specified	Radiotherapy	Not specified	Surgery	See Disease Characteristics	Other	No prior systemic therapy for breast cancer	More than 1 year since prior chemopreventive agent	Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for the primary trial.	[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Treatment (Pazopanib Hydrochloride)	Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	pazopanib hydrochloride: Given orally	pharmacological study: Correlative studies	laboratory biomarker analysis: Correlative studies	 Patients in the primary trial receive 300 mg pazopanib once daily intravenously every day, continuing until disease progression or unacceptable toxicity.	[1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 10/14 (71.43%)	Hemoglobin 2/14 (14.29%)	Lymphopenia 1/14 (7.14%)	Cardiac ischemia/infarction 1/14 (7.14%)	Hypertension 2/14 (14.29%)	Hypotension 1/14 (7.14%)	Constipation 1/14 (7.14%)	Diarrhea 1/14 (7.14%)	Heartburn/dyspepsia 1/14 (7.14%)	Fatigue (asthenia, lethargy, malaise) 2/14 (14.29%)	Rigors/chills 1/14 (7.14%)	the primary trial and the secondary trial only record 2 of the same adverse events.	[1, 0, 0, 1, 0, 1, 0, 0, 1, 0, 1, 0]
secondary trial Adverse Events 1:	Total: 96/162 (59.26%)	Cardiac disorders - Other, specify 2/162 (1.23%)	Diarrhea 1/162 (0.62%)	Mucositis oral 2/162 (1.23%)	Nausea 1/162 (0.62%)	Fatigue 6/162 (3.70%)	Breast infection 2/162 (1.23%)	Soft tissue infection 1/162 (0.62%)	Lymphocyte count decreased 2/162 (1.23%)	Neutrophil count decreased 78/162 (48.15%)	Hypertension 1/162 (0.62%)	the primary trial and the secondary trial only record 2 of the same adverse events.	[1, 0, 0, 1, 0, 0, 1, 0, 0, 1, 0, 1]
primary trial Adverse Events 1:	Total: 3/30 (10.00%)	Cholecystitis *  [1]1/30 (3.33%)	Increase in diarrhea *  [2]1/30 (3.33%)	Flank pain *  [3]1/30 (3.33%)	the primary trial recorded 4 life-threatening adverse events.	[1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 5/19 (26.32%)	Pain 3/19 (15.79%)	White blood cells (WBC) 5/19 (26.32%)	Hemoglobin (Hgb) 1/19 (5.26%)	Absolute neutrophil count (ANC) 5/19 (26.32%)	Platelets 3/19 (15.79%)	Elevated Aspartate Aminotransferase (AST) 1/19 (5.26%)	Elevated Alanine Aminotransferase (ALT) 1/19 (5.26%)	Dyspnea 3/19 (15.79%)	the primary trial monitors the occurrence of anemia in its adverse events.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 10/30 (33.33%)	Hemoglobin decreased 2/30 (6.67%)	Abdominal pain 1/30 (3.33%)	Colitis 1/30 (3.33%)	Diarrhea 7/30 (23.33%)	Nausea 2/30 (6.67%)	Rectal hemorrhage 1/30 (3.33%)	Fatigue 1/30 (3.33%)	Skin infection 1/30 (3.33%)	Neutrophil count decreased 1/30 (3.33%)	Platelet count decreased 3/30 (10.00%)	Dehydration 1/30 (3.33%)	Hyperglycemia was the most common adverse event in cohort 1 of the primary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Clinical Benefit Rate (CR + PR + SD > 6 Months).	To determine the clinical benefit rate (Complete Response + Partial Response + Stable Disease > 6 months) per Response Evaluation Criteria in Solid tumors (RECIST version 1.0). of MPA monotherapy and MPA + low dose oral cyclophosphamide and methotrexate (ldoCM) in patients with refractory hormone receptor negative metastatic breast cancer. This will show the percent of patients who had Clinical Benefit and the Exact 95% Confidence Interval.	Time frame: baseline through end of study, up to 3 years	Results 1:	Arm/Group Title: Cohort I: MPA-Alone	Arm/Group Description: Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.	Overall Number of Participants Analyzed: 14	Measure Type: Number	Unit of Measure: Percent of Participants  7.1        (0.2 to 33.9)	Results 2:	Arm/Group Title: Cohort 2: MPA+IdoCM	Arm/Group Description: Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.	Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week.	Overall Number of Participants Analyzed: 16	Measure Type: Number	Unit of Measure: Percent of Participants  6.3        (0.2 to 30.2)	the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure, and use a 6 month time frame.	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Outcome Measurement:	Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort	Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.	Time frame: After 24 weeks of treatment	Results 1:	Arm/Group Title: Alpelisib + Letrozole	Arm/Group Description: Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.	Overall Number of Participants Analyzed: 60	Measure Type: Number	Unit of Measure: Percentage of Participants  1.7        (0.2 to 6.3)	Results 2:	Arm/Group Title: Placebo + Letrozole	Arm/Group Description: Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.	Overall Number of Participants Analyzed: 67	Measure Type: Number	Unit of Measure: Percentage of Participants  3.0        (0.8 to 7.7)	the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure, and use a 6 month time frame.	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Arm I	See Detailed Description	tipifarnib: Given orally	paclitaxel: Given IV	doxorubicin hydrochloride: Given IV	cyclophosphamide: Given IV	pegfilgrastim: Given SC	conventional surgery: surgical procedures performed on patients	axillary lymph node dissection: correlative study	Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV, but only a subset of participants undergo axillary lymph node dissection.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)	OIRR is the percentage of participants with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. CR is measurable target lesions, the disappearance of all central nervous system (CNS) target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum longest duration (LD) of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. Stable disease (SD) is less than (<)30% decrease relative to baseline but <20% increase in sum LD relative to nadir. Progressive disease (PD) is greater than or equal to (  ) 20% increase in sum LD relative to nadir and a relative increase of 20%, 1 lesion must increase by absolute value of 5 millimeter (mm).	Time frame: Baseline to Objective Disease Progression (Up to 36 Months)	Results 1:	Arm/Group Title: Part A Abemaciclib: HR+, HER2+ Breast Cancer	Arm/Group Description: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.	Overall Number of Participants Analyzed: 23	Measure Type: Number	Unit of Measure: percentage of participants  0	Results 2:	Arm/Group Title: Part B Abemaciclib: HR+, HER2- Breast Cancer	Arm/Group Description: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET).	Participants may continue to receive treatment until discontinuation criteria are met.	Overall Number of Participants Analyzed: 52	Measure Type: Number	Unit of Measure: percentage of participants  5.8	There were no participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 57/57 (100.00%)	Dry eyes  13/33 (39.39%)	Heartburn  9/33 (27.27%)	Nausea after the CT (before day 7)  57/57 (100.00%)	Herpetic eruption  0/33 (0.00%)	Dry skin  15/33 (45.45%)	Alopecia  57/57 (100.00%)	Adverse Events 2:	Total: 23/23 (100.00%)	Dry eyes  2/11 (18.18%)	Heartburn  2/11 (18.18%)	Nausea after the CT (before day 7)  23/23 (100.00%)	Herpetic eruption  3/11 (27.27%)	Dry skin  9/11 (81.82%)	Alopecia  23/23 (100.00%)	A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 18/364 (4.95%)	Febrile neutropenia 3/364 (0.82%)	Atrial fibrillation 1/364 (0.27%)	Cardio-respiratory arrest 1/364 (0.27%)	Sinus bradycardia 1/364 (0.27%)	Ventricular extrasystoles 0/364 (0.00%)	Enterocolitis 0/364 (0.00%)	Faecaloma 0/364 (0.00%)	Gastric ulcer perforation 0/364 (0.00%)	Gastrointestinal toxicity 0/364 (0.00%)	Pancreatitis acute 0/364 (0.00%)	Adverse Events 2:	Total: 5/361 (1.39%)	Febrile neutropenia 0/361 (0.00%)	Atrial fibrillation 0/361 (0.00%)	Cardio-respiratory arrest 0/361 (0.00%)	Sinus bradycardia 0/361 (0.00%)	Ventricular extrasystoles 0/361 (0.00%)	Enterocolitis 0/361 (0.00%)	Faecaloma 0/361 (0.00%)	Gastric ulcer perforation 0/361 (0.00%)	Gastrointestinal toxicity 1/361 (0.28%)	Pancreatitis acute 0/361 (0.00%)	Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial.	[1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Adverse Events 1:	Total: 6/25 (24.00%)	Neutropenia *3/25 (12.00%)	Anemia *0/25 (0.00%)	Febrile Neutropenia *0/25 (0.00%)	Chest Pain *0/25 (0.00%)	Diarrhea *1/25 (4.00%)	Fatigue *1/25 (4.00%)	Liver Tests *0/25 (0.00%)	Neuropathy *0/25 (0.00%)	Syncope *0/25 (0.00%)	Hand and Foot Syndrome *1/25 (4.00%)	Adverse Events 2:	Total: 11/26 (42.31%)	Neutropenia *3/26 (11.54%)	Anemia *1/26 (3.85%)	Febrile Neutropenia *1/26 (3.85%)	Chest Pain *1/26 (3.85%)	Diarrhea *1/26 (3.85%)	Fatigue *0/26 (0.00%)	Liver Tests *1/26 (3.85%)	Neuropathy *1/26 (3.85%)	Syncope *1/26 (3.85%)	Hand and Foot Syndrome *1/26 (3.85%)	Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial.	[1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Arm I	See Detailed Description	tipifarnib: Given orally	paclitaxel: Given IV	doxorubicin hydrochloride: Given IV	cyclophosphamide: Given IV	pegfilgrastim: Given SC	conventional surgery: surgical procedures performed on patients	axillary lymph node dissection: correlative study	Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Fraction of Patients With Increased Levels of Circulating Endothelial Cells	An exact 95% confidence interval (CI) will be calculated for the CEC response rate. With 26 patients, this CI will be no wider than 40% (e.g., if 13 of 26 patients respond, the CI is 30% to 70%).	Time frame: After 3 weeks of treatment	Results 1:	Arm/Group Title: Treatment (Cediranib Maleate)	Arm/Group Description: Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.	Overall Number of Participants Analyzed: 26	Measure Type: Number	Unit of Measure: percentage of participants  30	30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer	Participants who are undergoing breast cancer surgery with lumpectomy or mastectomy	Participants with planned axillary sentinel node biopsy procedure	Exclusion Criteria:	Participants with cancer > 3 cm	Participants with clinically positive nodes	Participants with prior surgery for breast cancer in the index breast	Participants who have had bilateral breast surgeries	Thyroid dysfunction	Hypersensitivity to iodine	Hepatic insufficiency	Renal insufficiency	Patients with HER2 + breast cancer stage 1-4  are eligible for both the primary trial and the secondary trial.	[1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Stage IIIB, IIIC, or IV erbB2 (HER2) positive breast cancer	Prior use of Herceptin (trastuzumab), and a taxane	Adequate cardiac and renal function	Exclusion Criteria:	More than 2 prior Herceptin (trastuzumab) regimens or prior use of Xeloda (capecitabine) and / or Tykerb (lapatinib) [Tyverb]	Bone as the only site of disease	Active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)	Significant gastrointestinal disorder with diarrhea as major symptom	Patients with HER2 + breast cancer stage 1-4  are eligible for both the primary trial and the secondary trial.	[1, 1, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	- Female  18 years, 70 years. ECOG 0-1 with no deterioration over previous 2 weeks Minimum life expectancy 3 months Histological confirmation of hormone receptor-high expressed breast cancer(IHC:ER 60% and PR  60%) on primary tumour at diagnosis/on biopsy of metastasis Histological confirmation of HER2 negative breast cancer on primary tumour at diagnosis/on biopsy of a metastasis The disease-free time of relapsed patients is more than 12 months Once received standard hormone treatment and progressed Clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection At least one evaluative focus according to RECIST creterion or non-measurable disease but only bone metastasis Adequate bone marrow and organ function Progressive disease whilst receiving endocrine therapy for locally advanced or metastatic BC or relapsed with metastatic disease whilst receiving endocrine therapy Radiological or objective clinical evidence of recurrence or progression on or after last systemic therapy prior to enrolment	4 prior lines of endocrine therapy for ABC	3 line of cytotoxic chemotherapy for ABC Suitable for further endocrine therapy Availability of archival tumour sample or fresh biopsy Informed consent Normal organ function	Exclusion Criteria:	Last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour embolisation <21 days prior to study treatment Last dose of palliative radiotherapy <7 days prior to study treatment Rapidly progressive visceral disease not suitable for further endocrine therapy Spinal cord compression or brain/meningeal metastases unless asymptomatic, treated and stable and not requiring steroids for  4 weeks study treatment Creatinine clearance <30 ml/min. Patients with creatinine clearance <50 mL/min will start at a permanently reduced vandetanib dose of 200 mg.	Major surgery (excluding placement of vascular access) within 4 weeks before study treatment Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone metastasis Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent Participation in another study with investigational product during last 30 days Inability or unwillingness to comply with study procedures, including inability to take regular oral medication	Sharone had a hip replacement 3 weeks prior, she is not elgible for the primary trial.	[0, 0, 0, 0, 1, 0, 1]
primary trial Inclusion Criteria:	Postmenopausal women, Stage III or axillary node positive	Currently disease free of breast cancer and other invasive malignancies at the time of registration	No concurrent use of bisphosphonates	Exclusion Criteria:	Metastatic disease	Adequate blood, kidney, and hepatic function are required to participate in the secondary trial, however this condition is not specified in the primary trial.	[1, 1, 1, 1, 1, 1]
secondary trial Inclusion Criteria:	Pathologically confirmed HER2-positive MBC	Progression of or new brain metastases after completion of whole-brain radiotherapy or stereotactic radiosurgery	Completion of whole-brain radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollment	Stable systemic disease	Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1	LVEF at least 50%	Adequate hematologic, renal, and hepatic function	Life expectancy more than 12 weeks	Exclusion Criteria:	Progression of systemic disease at Screening	Leptomeningeal disease	History of intolerance or hypersensitivity to study drug	Use of certain investigational therapies within 21 days prior to enrollment	Current anthracycline use	Unwillingness to discontinue ado-trastuzumab emtansine or lapatinib use	Active infection	Pregnant or lactating women	Significant history or risk of cardiac disease	Symptomatic intrinsic lung disease or lung involvement	History of other malignancy within the last 5 years	Adequate blood, kidney, and hepatic function are required to participate in the secondary trial, however this condition is not specified in the primary trial.	[1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	Female and male patients 18 years of age.	Histologically confirmed adenocarcinoma of the breast.	Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-T3, N1-N2, M0). (T1N0M0 lesions are excluded.)	Patients who have no clearly defined palpable breast mass or axillary lymph nodes but are radiographically measurable are eligible. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. In these patients, radiographic tumor measurements need to be repeated after 3 cycles and prior to surgery.	Positive HER2 status (overexpression and/or amplification of HER2 in the primary tumor) as defined by: IHC 3+ or fluorescence in situ hybridization (FISH) positive (ratio >2.2) testing. Documentation of the HER2 results must be available at the time of study enrollment.	An ECOG (Eastern Cooperative Oncology Group) performance score of 2	Normal bone marrow function as defined by:	absolute neutrophil count (ANC) >1,500/µL;	platelets >100,000/µL;	hemoglobin >10 g/dL.	Normal hepatic and renal function.	Left ventricular ejection fraction (LVEF) within the institutional limits of normal, whichever is lower, as measured by multi-gated acquisition (MUGA) scan or echocardiogram (ECHO).	Life expectancy > 12 weeks.	Estrogen and progesterone (or estrogen alone) receptor status in the primary tumor known or pending at the time of study enrollment.	For women of childbearing potential, negative serum pregnancy test within 7 days prior to starting treatment.	For women of childbearing potential, agreement to use a method of contraception that is acceptable to their physician from time of first signing the informed consent until at least 3 months after the last dose of study drug. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. Patient agreement to discontinue breast-feeding, if applicable, during study treatment. Men enrolled in the study must also agree to use a method of contraception that is acceptable to their physician during their study participation.	For patients with previous invasive cancers (including breast cancer) treated with curative intent, completion of chemotherapy or radiation therapy more than 5 years prior to enrollment for this study and no evidence of recurrent disease. Patients may be receiving anti-estrogen hormonal therapy prescribed for previous invasive breast cancer as long as the diagnosis of invasive cancer was made more than 5 years prior to study enrollment. Patients may be using anti-estrogen hormonal therapy at the time of current diagnosis but must discontinue this therapy before beginning study treatment.	For patients who had, or will have sentinel lymph node and/or axillary dissection prior to initiation of study treatment, completion at least 4 weeks prior to starting study treatment and well-healed wound.	Ability to understand and willingness to sign a written informed consent document.	Exclusion Criteria:	Previous treatment for this breast cancer.	Evidence of metastatic disease.	Prior radiation that included 30% of major bone marrow-containing areas.	Women who are pregnant or breastfeeding.	Neuropathy (motor or sensory) grade 1 at study entry.	History of significant cardiac disease or cardiac risk factors or the following:	uncontrolled arrhythmias	poorly controlled hypertension (e.g., systolic blood pressure [BP]> 150 mmHg or diastolic BP >100 mmHg) in spite of optimal medical management	angina pectoris requiring antianginal medication or unstable angina within the previous 6 months	history of documented congestive heart failure (CHF)	any documented myocardial infarction within the previous 6 months	clinically significant valvular heart disease	current use of medications (e.g., digitalis, beta-blockers, calcium channel-blockers) that alter cardiac conduction, if these medications are administered for the management of cardiac arrhythmia, angina, or CHF. If these medications are administered for other reasons (e.g., hypertension), the patient may be eligible.	patients with cardiomegaly on chest x-ray or ventricular hypertrophy on ECG unless ECHO or MUGA scan within the last 3 months demonstrates that the LVEF is  institutional lower limit of normal.	Symptomatic intrinsic lung disease.	Active malignancy, other than superficial basal cell carcinoma, superficial squamous (skin) cell carcinoma, carcinoma in situ, or non-invasive breast cancer, within the past 5 years.	Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection >grade 2.	Mental condition or psychiatric disorder rendering the subject unable to understand the nature, scope, and possible consequences of the study or that would limit compliance with study requirements.	Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving a reasonable suspicion of a disease or condition that contraindicates the use of a study agent or that may affect the interpretation of the results or renders the subjects at high risk from treatment complications.	Chronic use of CYP3A4 inhibitors and use of the following strong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, amprenavir, indinavir, nelfinavir, delavirdine, and voriconazole. Use of these agents must be discontinued at least 72 hours prior to initiation of study treatment.	Received chemotherapy for any indication within the 5 years preceding study enrollment.	Prior treatment with trastuzumab or any other anti-HER2 agent for any indication.	Concurrent treatment with any other anti-cancer therapy.	Concurrent radiation therapy during neoadjuvant study treatment.	Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment must be stopped prior to study enrollment.	Current therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention of breast cancer. These agents must be discontinued prior to study enrollment.	Participation within the previous 30 days in a study with an experimental drug.	Known or suspected allergy to Cremophor EL (polyoxyethylated castor oil), a drug formulated in Cremophor EL such as paclitaxel, or any other agent given in the course of this trial.	Inability or unwillingness to comply with study procedures including those for follow-up.	Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for the primary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	No known soy intolerance	At increased risk of developing breast cancer in >= 1 previously unaffected breast, as defined by any of the following:	Estimated 5-year risk of developing breast cancer using the Gail model, as defined by 1 of the following:	Gail score >= 1.66%	Gail score >= 0.1% for women age 20-29 years	Gail score >= 1.0% for women age 30-39 years	Estimated 5-year risk of developing breast cancer using the Claus model:	Claus score >= 1.66%	Claus score >= 0.1% for women age 20-29 years	Claus score >= 1.0% for women age 30-39 years	Prior diagnosis of unilateral in situ or invasive breast cancer OR history of atypical hyperplasia, BRCA 1 and/or BRCA 2 positivity	History of lobular carcinoma in situ	No evidence of breast cancer, as determined by a negative mammogram within the past 6 months and a history and physical	No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago	Pre- or postmenopausal	ECOG performance status 0-1	Hemoglobin > 10.0 g/dL	Platelet count > 100,000/mm^3	Absolute neutrophil count > 1,000/mm^3	Creatinine < 2.0 mg/dL	SGPT < 82 U/L	SGOT < 68 U/L	Bilirubin < 3 mg/dL* [Note: * Patients with a higher level of bilirubin due to a familial metabolism may be eligible at the discretion of the investigator]	Life expectancy > 2 years	Not pregnant or nursing	Negative pregnancy test	Fertile patients must use effective barrier contraception	Must be willing to keep a dietary diary	No venous thrombosis within the past year	No unrecognized or poorly controlled thyroid disease	No other cancer within the past 5 years except nonmelanomatous skin cancer or noninvasive cervical cancer	No other medical condition that, in the opinion of the investigator, would jeopardize either the patient or the integrity of the data obtained	None of the following for >= 2 weeks before the first random fine needle aspiration and during study participation:	Oral contraceptives	Soy supplements	High soy-containing foods	Fish oil supplements	Multivitamins	Vitamins C and E	Daily aspirin or nonsteroidal	Anti-inflammatory drugs	No other concurrent investigational agents	No concurrent warfarin or other blood thinners	Female patient	Exclusion Criteria:	Women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously	Currently pregnant, or planning to become pregnant during the study period	History of venous thrombosis within past year	Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained	History of other cancer within the past five years, excluding non-melanomatous skin cancer, and non-invasive cervical cancer	Known soy intolerance	Unrecognized or uncontrolled thyroid disease, subjects may be on synthroid, but thyroid function must be in normal range or the patient's physician must document that the patient's thyroid is controlled.	Currently receiving any other investigational agents	Currently on coumadin, or other blood thinners	History of breast augmentation implants.	Rusults from patients who have <4000 epithelial cells in either the first or the second random Fine-needle aspiration (rFNA) will not be included in the study.	Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Female aged  18 years.	Patients with pathologically documented metastatic triple negative breast cancer (TNBC), eligible for treatment with paclitaxel. Paraffin-embedded tissue must be available from metastatic sites, if reasonably accessible, or from the primary tumor, to confirm the diagnosis of TNBC and for correlative studies (only on metastatic tissue). Fifteen slides can be obtained if the full block is not available to be sent or released.	TNBC will be defined as breast cancer with <1% ER+ and <1% PgR+ cells, and HER2 immunohistochemistry score of 0 or 1+ and/or in situ hybridization (ISH) with HER2 gene copy number <4 or a ratio of less than 2 between HER2 gene copy number and centromere of chromosome 17. Patients whose metastatic disease is TNBC are eligible even when their primary tumor expressed hormone receptors and/or HER2.	Patients must be newly diagnosed metastatic or must have relapsed following a prior (neo)adjuvant chemotherapy regimen. If a taxane (i.e., paclitaxel or docetaxel) was administered as part of the (neo)adjuvant regimen, PD must have occurred > 12 months from the end of previous (neo)adjuvant treatment. For non-taxane (neo)adjuvant regimen, PD must have occurred > 6 months from the end of previous (neo)adjuvant treatment	Patients with at least one baseline measurable lesion according to RECIST criteria version 1.1.	Zubrod (Eastern Co-operative Oncology Group [ECOG]) Performance Status (PS) of 0-1.	Life expectancy of at least three months.	Patients must be able to swallow and retain oral medication (intact tablet).	Able to undergo all screening assessments outlined in the protocol.	Adequate organ function (defined by the following parameters):	Serum creatinine < 140 μmol/L (< 1.6 mg/dL) or creatinine clearance > 60 mL/min.	Serum hemoglobin  9 g/dL; absolute neutrophil count  1.5 x 109/L; platelets  100 x 109/L.	Serum bilirubin  1.5 x upper normal limit (UNL) except patients with Gilbert's syndrome	Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST)  2.5 x UNL but  5.0 x UNL in case of liver metastases; alkaline phosphatase (ALP)  UNL but i)  2.5 x UNL in case of liver metastases and ii)  5 UNL in case of bone metastases; albumin  2.5 g/dl.	No history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease.	No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus-I and -II positive status.	Dated and signed IEC/IRB-approved informed consent.	Exclusion Criteria:	Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological therapy), Patients may receive bisphosphonates and other therapies to treat bone metastases, however if used, bone lesions will not be considered as measurable disease.	Less than four weeks since last radiotherapy (excluding palliative radiotherapy).	Pregnancy or lactation or unwillingness to use adequate method of birth control.	Neurological or psychiatric disorders which may influence understanding of study and informed consent procedures.	Active or uncontrolled infection.	Malabsorption syndrome, disease significantly affecting gastrointestinal function.	G>1 pre-existing peripheral neuropathy	Any other invasive malignancy from which the patient has been disease-free for less than 5 years with the exception of curatively treated basal or squamous cell skin cancer	Hypersensitivity to:	paclitaxel	ibuprofen or to more than one non-steroidal anti-inflammatory drug.	medications belonging to the class of sulfonamides, with the exception of sulfanilamides (e.g., sulfamethoxazole).	Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 18/52 (34.62%)	Anaemia 2/52 (3.85%)	Febrile Neutropenia 1/52 (1.92%)	Haemolytic Uraemic Syndrome 1/52 (1.92%)	Leukopenia 1/52 (1.92%)	Neutropenia 1/52 (1.92%)	Thrombocytopenia 1/52 (1.92%)	Cardiac Failure Congestive 1/52 (1.92%)	Cardio-Respiratory Arrest 1/52 (1.92%)	Abdominal Pain 1/52 (1.92%)	Constipation 1/52 (1.92%)	Diarrhoea 1/52 (1.92%)	More patients with a Low Platelet Count where found in the primary trial than in the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 14/54 (25.93%)	anaemia 2/54 (3.70%)	Febrile neutropenia 7/54 (12.96%)	Neutropenia 2/54 (3.70%)	Thrombocytopenia 6/54 (11.11%)	Atrial fibrillation 1/54 (1.85%)	Cardiac failure congestive 1/54 (1.85%)	Pericardial effusion 1/54 (1.85%)	Nausea 2/54 (3.70%)	Vomiting 3/54 (5.56%)	Catheter site erythema 1/54 (1.85%)	Chest discomfort 1/54 (1.85%)	Adverse Events 2:	Total: 5/20 (25.00%)	anaemia 0/20 (0.00%)	Febrile neutropenia 2/20 (10.00%)	Neutropenia 0/20 (0.00%)	Thrombocytopenia 0/20 (0.00%)	Atrial fibrillation 0/20 (0.00%)	Cardiac failure congestive 0/20 (0.00%)	Pericardial effusion 0/20 (0.00%)	Nausea 0/20 (0.00%)	Vomiting 0/20 (0.00%)	Catheter site erythema 0/20 (0.00%)	Chest discomfort 0/20 (0.00%)	More patients with a Low Platelet Count where found in the primary trial than in the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Change in Tumor Size (CTS) From Baseline to the End of Cycle 2	The log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant, where the tumor size is the sum of the target lesion measurements at each assessment.	Time frame: Baseline up to end of Cycle 2 (Day 42)	Results 1:	Arm/Group Title: LY2523355 + Pegfilgrastim or Filgrastim	Arm/Group Description: LY2523355 administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Dosage determined by calculating participant's body surface area (5 milligrams per meter squared per day [mg/m^2/day]).	Pegfilgrastim or filgrastim administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. Dosage is determined by standard of care.	If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.	Overall Number of Participants Analyzed: 17	Mean (Standard Deviation)	Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.0         (0.08)	Results 2:	Arm/Group Title: Ixabepilone	Arm/Group Description: Ixabepilone administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles.	Dosage determined by calculating participant's body surface area (40 mg/m^2).	If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.	Overall Number of Participants Analyzed: 11	Mean (Standard Deviation)	Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.1         (0.37)	the primary trial reports the changes in tumor size for patients in its cohorts.	[1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	Pre-menopausal women aged 18 years or over with histologically/cytologically-confirmed oestrogen receptor positive (ER +ve) breast cancer	World Health Organization (WHO) performance status of 0, 1, or 2	Provided written informed consent	Exclusion Criteria:	Treatment with tamoxifen or other hormonal therapies as early breast cancer (EBC) adjuvant in the previous 24 weeks	Received radiotherapy within the past 4 weeks	History of systemic malignancy other than breast cancer within the previous 3 years	Estimated survival less than 24 weeks	the primary trial and the secondary trial use ECOG to evaluate potential candidates' performance status.	[0, 0, 1, 0, 0, 0, 0, 0, 0]
secondary trial Inclusion Criteria:	Recurrent or residual metastatic breast carcinoma	Zubrod performance status less than 2	18-60 years old	Related donor human leukocyte antigen (HLA)-compatible for allogeneic transplantation or unrelated HLA-compatible donor.	No major organ dysfunction or active infection	Exclusion Criteria: None	the primary trial and the secondary trial use ECOG to evaluate potential candidates' performance status.	[0, 0, 1, 0, 0, 0, 0]
primary trial Outcome Measurement:	1. Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR)	PFS was defined as the time from randomization to progressive disease, or death, whichever occurs first. Response was assessed according to RECIST 1.1 by BICR. According to RECIST 1.1, progressive disease (PD) was defined as a 20% relative increase in the sum of diameters (SOD) of target lesions, taking as reference the nadir SOD and an absolute increase of >5 mm in the SOD, or the appearance of new lesions. PFS was analyzed using the Kaplan-Meier method and median PFS (95% confidence interval [CI]) in weeks was reported for each treatment arm. Per protocol, participants remained on assigned treatment until disease progression. Participants who discontinued study treatment for reasons other than disease progression continued to be assessed by imaging until objective documentation of progression. All participants (including participants who discontinued study treatment) were followed for survival until investigator notification to discontinue.	Time frame: From Day 1 through last post-study efficacy follow-up (up to ~19 months)	Results 1:	Arm/Group Title: Ridaforolimus + Dalotuzumab + Exemestane	Arm/Group Description: Participants received ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity.	Overall Number of Participants Analyzed: 40	Median (95% Confidence Interval)	Unit of Measure: Weeks  23.29        (8.71 to 38.43)	Results 2:	Arm/Group Title: Ridaforolimus + Exemestane	Arm/Group Description: Participants received ridaforolimus 30 mg PO QD x 5 plus exemestane 25 mg PO QD treatment in 28-day cycles until documented disease progression or unacceptable toxicity.	Overall Number of Participants Analyzed: 40	Median (95% Confidence Interval)	Unit of Measure: Weeks  31.86        (16.00 to 39.29)	The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 38.43 months.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Treatment (Tivantinib)	Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.	Laboratory Biomarker Analysis: Correlative studies	Tivantinib: Given PO	the primary trial and the secondary trial are testing completely different modalities of interventions, but utilising the same 21 day cycle.	[1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Prone	Prone position	INTERVENTION 2:	Supine	Supine position	the primary trial and the secondary trial are testing completely different modalities of interventions, but utilising the same 21 day cycle.	[1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 30/98 (30.61%)	NEUTROPENIA 1/98 (1.02%)	ATRIAL FIBRILLATION 1/98 (1.02%)	CARDIAC FAILURE 1/98 (1.02%)	TACHYCARDIA 0/98 (0.00%)	ACUTE VESTIBULAR SYNDROME 1/98 (1.02%)	VERTIGO 0/98 (0.00%)	ABDOMINAL PAIN 0/98 (0.00%)	COLITIS 0/98 (0.00%)	DIARRHOEA 2/98 (2.04%)	FEMORAL HERNIA 0/98 (0.00%)	HAEMATEMESIS 0/98 (0.00%)	ILEUS 0/98 (0.00%)	NAUSEA 0/98 (0.00%)	Adverse Events 2:	Total: 46/102 (45.10%)	NEUTROPENIA 0/102 (0.00%)	ATRIAL FIBRILLATION 0/102 (0.00%)	CARDIAC FAILURE 0/102 (0.00%)	TACHYCARDIA 2/102 (1.96%)	ACUTE VESTIBULAR SYNDROME 0/102 (0.00%)	VERTIGO 1/102 (0.98%)	ABDOMINAL PAIN 2/102 (1.96%)	COLITIS 1/102 (0.98%)	DIARRHOEA 8/102 (7.84%)	FEMORAL HERNIA 1/102 (0.98%)	HAEMATEMESIS 1/102 (0.98%)	ILEUS 1/102 (0.98%)	None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 46/170 (27.06%)	Anaemia 1/170 (0.59%)	Febrile neutropenia 1/170 (0.59%)	Cardiac tamponade 1/170 (0.59%)	Myocarditis 1/170 (0.59%)	Pericardial effusion 2/170 (1.18%)	Pericarditis 1/170 (0.59%)	Colitis 1/170 (0.59%)	Constipation 1/170 (0.59%)	Diarrhoea 0/170 (0.00%)	Gastroenteritis eosinophilic 0/170 (0.00%)	Intestinal obstruction 0/170 (0.00%)	Adverse Events 2:	Total: 0/1 (0.00%)	Anaemia 0/1 (0.00%)	Febrile neutropenia 0/1 (0.00%)	Cardiac tamponade 0/1 (0.00%)	Myocarditis 0/1 (0.00%)	Pericardial effusion 0/1 (0.00%)	Pericarditis 0/1 (0.00%)	Colitis 0/1 (0.00%)	Constipation 0/1 (0.00%)	Diarrhoea 0/1 (0.00%)	Gastroenteritis eosinophilic 0/1 (0.00%)	Intestinal obstruction 0/1 (0.00%)	Nausea 0/1 (0.00%)	It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2  the primary trial, despite the difference in cohort size.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 12/538 (2.23%)	Hypertension 0/538 (0.00%)	Acoustic Neuroma 1/538 (0.19%)	Diarrhea 0/538 (0.00%)	Colitis 1/538 (0.19%)	Elevated ALT or AST enzyme 7/538 (1.30%)	Diagnosis of Uterine Cancer 0/538 (0.00%)	Motorcycle accident 0/538 (0.00%)	Fall 0/538 (0.00%)	Surgery 3/538 (0.56%)	Adverse Events 2:	Total: 8/537 (1.49%)	Hypertension 1/537 (0.19%)	Acoustic Neuroma 0/537 (0.00%)	Diarrhea 1/537 (0.19%)	Colitis 0/537 (0.00%)	Elevated ALT or AST enzyme 0/537 (0.00%)	Diagnosis of Uterine Cancer 2/537 (0.37%)	Motorcycle accident 1/537 (0.19%)	Fall 1/537 (0.19%)	Surgery 2/537 (0.37%)	It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2  the primary trial, despite the difference in cohort size.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Rate of Breast Related Adverse Events	Investigators evaluated each subject and each reconstructed breast for the occurrence of an adverse event from the first stage of reconstruction through the final follow-up visit. A breast related adverse event was defined as any untoward medical occurrence related to a reconstructed breast.	Time frame: 18 months	Results 1:	Arm/Group Title: Meso BioMatrix Acellular Peritoneum Matrix	Arm/Group Description: All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction. After tissue expansion, the tissue expander was replaced with a breast implant during the second stage of reconstruction.	Overall Number of Participants Analyzed: 25	Overall Number of Units Analyzed	Type of Units Analyzed: Reconstructed breasts  Measure Type: NumberUnit of Measure: Reconstructed breasts affected: 12	several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	LBH589 With Capecitabine	MTD, LBH589 with Capecitabine	LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.	Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.	INTERVENTION 2:	LBH589 and Lapatinib	LBH589 and Lapatinib	LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.	Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.	the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with patients body weight.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial INTERVENTION 1:	Radiotherapy/Supportive Care (A)	Patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapy	INTERVENTION 2:	Control ARM (B)	Patients receive radiotherapy and sham healing touch therapy from a sham healing-touch therapist once a week for the duration of their radiotherapy	Radiotherapy is used in all cohorts of the primary trial and the secondary trial.	[1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	Participants With Stage 0-III Breast Cancer	Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.	Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.	Radiotherapy is used in all cohorts of the primary trial and the secondary trial.	[1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 3/6 (50.00%)	Febrile neutropenia 0/6 (0.00%)	Leukopenia 0/6 (0.00%)	Neutropenia 0/6 (0.00%)	Thrombocytopenia 0/6 (0.00%)	Cardio-respiratory arrest 0/6 (0.00%)	Cardiopulmonary failure 0/6 (0.00%)	Vertigo 0/6 (0.00%)	Visual impairment 0/6 (0.00%)	Abdominal pain 0/6 (0.00%)	Diarrhoea 0/6 (0.00%)	Dysphagia 0/6 (0.00%)	Gastric ulcer 0/6 (0.00%)	Adverse Events 2:	Total: 6/17 (35.29%)	Febrile neutropenia 0/17 (0.00%)	Leukopenia 0/17 (0.00%)	Neutropenia 0/17 (0.00%)	Thrombocytopenia 0/17 (0.00%)	Cardio-respiratory arrest 1/17 (5.88%)	Cardiopulmonary failure 0/17 (0.00%)	Vertigo 0/17 (0.00%)	Visual impairment 0/17 (0.00%)	Abdominal pain 0/17 (0.00%)	Diarrhoea 1/17 (5.88%)	Dysphagia 0/17 (0.00%)	Gastric ulcer 1/17 (5.88%)	There were more than 3 cases of Febrile neutropenia, Leukopenia and Neutropenia across all cohorts in the primary trial.	[1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 59/373 (15.82%)	Neutropenia 14/373 (3.75%)	Febrile neutropenia 10/373 (2.68%)	Leukopenia 1/373 (0.27%)	Anaemia 2/373 (0.54%)	Lymphadenopathy 0/373 (0.00%)	cardiac failure 2/373 (0.54%)	Atrial fibrillation 1/373 (0.27%)	Pericardial effusion 2/373 (0.54%)	Cardiac failure congestive 1/373 (0.27%)	Cardiomyopathy 0/373 (0.00%)	Adverse Events 2:	Total: 69/377 (18.30%)	Neutropenia 17/377 (4.51%)	Febrile neutropenia 10/377 (2.65%)	Leukopenia 4/377 (1.06%)	Anaemia 2/377 (0.53%)	Lymphadenopathy 1/377 (0.27%)	cardiac failure 1/377 (0.27%)	Atrial fibrillation 1/377 (0.27%)	Pericardial effusion 0/377 (0.00%)	Cardiac failure congestive 0/377 (0.00%)	Cardiomyopathy 1/377 (0.27%)	There were more cases of Febrile neutropenia than eukopenia observed in the primary trial, but less cases of Febrile neutropenia than Neutropenia.	[1, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Treatment (Pazopanib Hydrochloride)	Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	pazopanib hydrochloride: Given orally	pharmacological study: Correlative studies	laboratory biomarker analysis: Correlative studies	 Patients in the primary trial receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity.	[1, 1, 1, 1, 1, 1]
primary trial Outcome Measurement:	Fraction of Patients With Increased Levels of Circulating Endothelial Cells	An exact 95% confidence interval (CI) will be calculated for the CEC response rate. With 26 patients, this CI will be no wider than 40% (e.g., if 13 of 26 patients respond, the CI is 30% to 70%).	Time frame: After 3 weeks of treatment	Results 1:	Arm/Group Title: Treatment (Cediranib Maleate)	Arm/Group Description: Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.	Overall Number of Participants Analyzed: 26	Measure Type: Number	Unit of Measure: percentage of participants  30	30% of the primary trial participants had an increased level of CECs after 42 days of treatment.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 47/254 (18.50%)	Anaemia 1/254 (0.39%)	Febrile neutropenia 1/254 (0.39%)	Lymphadenopathy 1/254 (0.39%)	Acute myocardial infarction 1/254 (0.39%)	Angina pectoris 0/254 (0.00%)	Angina unstable 0/254 (0.00%)	Bundle branch block left 0/254 (0.00%)	Cardiac failure 4/254 (1.57%)	Coronary artery disease 0/254 (0.00%)	Coronary artery stenosis 1/254 (0.39%)	Adverse Events 2:	Total: 56/269 (20.82%)	Anaemia 1/269 (0.37%)	Febrile neutropenia 0/269 (0.00%)	Lymphadenopathy 0/269 (0.00%)	Acute myocardial infarction 0/269 (0.00%)	Angina pectoris 3/269 (1.12%)	Angina unstable 1/269 (0.37%)	Bundle branch block left 1/269 (0.37%)	Cardiac failure 1/269 (0.37%)	Coronary artery disease 1/269 (0.37%)	Coronary artery stenosis 0/269 (0.00%)	There are four types of adverse events in the primary trial, for which one occurence is recorded.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Outcome Measurement:	Number of Participants With Dose Limiting Toxicities (DLT)	Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD). Important Limitations and Caveats are provided in the respective section.	Time frame: 28 days	Results 1:	Arm/Group Title: Afatinib 20mg + Herceptin	Arm/Group Description: Patients received continuous daily dosing with Afatinib 20mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit. This group includes patients from the dose-escalation cohort and from the expansion cohort.	Overall Number of Participants Analyzed: 13	Measure Type: Number	Unit of Measure: Participants  4	Results 2:	Arm/Group Title: Afatinib 30mg + Herceptin	Arm/Group Description: Patients received continuous daily dosing with Afatinib 30mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit.	Overall Number of Participants Analyzed: 2	Measure Type: Number	Unit of Measure: Participants  2	100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 13/34 (38.24%)	Anemia 3/34 (8.82%)	Diarrhea 7/34 (20.59%)	Nausea 2/34 (5.88%)	Sepsis 1/34 (2.94%)	Urinary tract infection 1/34 (2.94%)	Alkaline phosphatase increased 1/34 (2.94%)	Neutrophil count decreased 2/34 (5.88%)	Dehydration 1/34 (2.94%)	Headache 1/34 (2.94%)	Thromboembolic event 1/34 (2.94%)	One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Anemia.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	At least 18 years of age	Willing and able to provide informed consent	Reporting daily hot flashes	Able to read, write, and speak English	Postmenopausal to limit sample variability (> 12 months amenorrhea)	Greater then 1 month but < 5 years post-treatment (surgery, radiation, chemotherapy) for non-metastatic breast cancer.	These criteria allow inclusion of women successfully treated for recurrent breast cancer since there is no known reason to exclude them. Menopausal status is assessed using self-reports due to problems in reliably measuring follicle-stimulating hormone levels and estradiol in tamoxifen users.	Exclusion Criteria:	Exclusion criteria are current depression, history of migraines or hepatitis, abnormal chemistry profile (e.g., sodium, potassium, glucose), or a positive urine drug screen for illegal substances.	Clinically anxious patients are not able to participate in the primary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 1, 1]
primary trial DISEASE CHARACTERISTICS:	Diagnosis of localized breast cancer	Stage I-IIIA disease	Adequately treated breast cancer	No clinical or radiological evidence of recurrent or metastatic disease	Baseline total lumbar spine or femoral neck bone mineral density T-score < -2.0 standard deviation (e.g., a patient with a T score of -2.1 is eligible)	Hormone-receptor status:	Estrogen receptor and/or progesterone receptor-positive breast cancer	PATIENT CHARACTERISTICS:	Female	Postmenopausal, defined by 1 of the following criteria:	Age > 55 years with cessation of menses	Age  55 years with spontaneous cessation of menses for > 1 year	Age  55 years with spontaneous cessation of menses for  1 year, but amenorrheic (e.g., spontaneous or secondary to hysterectomy), AND has postmenopausal estradiol levels	Bilateral oophorectomy	ECOG performance status 0-2	Life expectancy  5 years	WBC  3,000/mm³ OR granulocyte count  1,500/mm³	Platelet count  100,000/mm³	Alkaline phosphatase  3 times upper limit of normal (ULN)	AST  3 times ULN	Creatinine < 2.0 mg/dL	Creatinine clearance  45 mL/min	No hypercalcemia (i.e., calcium level > 1 mg/dL above ULN) OR hypocalcemia (i.e., calcium level > 0.5 mg/dL below lower limit of normal) within the past 6 months	No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix	No other nonmalignant systemic diseases, including any of the following:	Uncontrolled infection	Uncontrolled diabetes mellitus	Uncontrolled thyroid dysfunction	Disease affecting bone metabolism (hyperparathyroidism, hypercortisolism, Paget's disease, osteogenesis imperfecta)	Malabsorption syndrome	No uncontrolled seizure disorders associated with falls	No known hypersensitivity to zoledronate or other bisphosphonates, letrozole, calcium, or vitamin D	No concurrent active dental problems, including any of the following:	Infection of the teeth or jawbone (maxillary or mandibular)	Dental or fixture trauma	Prior or current diagnosis of osteonecrosis of the jaw	Exposed bone in the mouth	Slow healing after dental procedures	No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following:	History of surgery at the lumbosacral spine, with or without implantable devices	Scoliosis with a Cobb angle > 15 degrees at the lumbar spine	Immobility, hyperostosis, or sclerotic changes at the lumbar spine, or evidence of sclerotic abdominal aorta sufficient to interfere with DXA scan	Disease of the spine that would preclude the proper acquisition of a lumbar spine DXA	No condition that would preclude study follow-up or compliance	No psychiatric illness that would preclude giving informed consent	PRIOR CONCURRENT THERAPY:	More than 3 weeks since prior and no other concurrent oral bisphosphonates	No prior intravenous bisphosphonates	No prior aromatase inhibitor therapy	More than 6 months since prior anabolic steroids or growth hormone	More than 2 weeks since prior and no concurrent inhibitor of osteoclastic bone resorption (e.g., calcitonin, mithramycin, or gallium nitrate)	More than 30 days since prior systemic investigational drug and/or device	More than 7 days since prior topical investigational drug	More than 6 weeks since prior and no concurrent dental or jaw surgery (e.g., extraction, implants)	Concurrent short-term corticosteroid therapy allowed	No concurrent sodium fluoride, parathyroid hormone, or tibolone	No other concurrent investigational drug or device	Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these would interfere with the necessary CT and MRI scans for the study.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Outcome Measurement:	Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24	Bone mineral density (BMD) by DXA at lumbar spine (L2-L4); DXA assessments of the BMD at dual hips. (BMD). Two X-ray beams with different energy levels are aimed at the patient's bones. When soft tissue absorption is subtracted out, the BMD can be determined from the absorption of each beam by bone.	Time frame: baseline, month 24	Results 1:	Arm/Group Title: Placebo	Arm/Group Description: Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).	Overall Number of Participants Analyzed: 36	Mean (Standard Deviation)	Unit of Measure: Z-score  -0.075         (0.041)	Results 2:	Arm/Group Title: Zometa	Arm/Group Description: Zoledronic Acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).	Overall Number of Participants Analyzed: 34	Mean (Standard Deviation)	Unit of Measure: Z-score  0.037         (0.042)	In the primary trial patients in the test group had better health outcomes than the control group.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial DISEASE CHARACTERISTICS:	Diagnosis of localized breast cancer	Stage I-IIIA disease	Adequately treated breast cancer	No clinical or radiological evidence of recurrent or metastatic disease	Baseline total lumbar spine or femoral neck bone mineral density T-score < -2.0 standard deviation (e.g., a patient with a T score of -2.1 is eligible)	Hormone-receptor status:	Estrogen receptor and/or progesterone receptor-positive breast cancer	PATIENT CHARACTERISTICS:	Female	Postmenopausal, defined by 1 of the following criteria:	Age > 55 years with cessation of menses	Age  55 years with spontaneous cessation of menses for > 1 year	Age  55 years with spontaneous cessation of menses for  1 year, but amenorrheic (e.g., spontaneous or secondary to hysterectomy), AND has postmenopausal estradiol levels	Bilateral oophorectomy	ECOG performance status 0-2	Life expectancy  5 years	WBC  3,000/mm³ OR granulocyte count  1,500/mm³	Platelet count  100,000/mm³	Alkaline phosphatase  3 times upper limit of normal (ULN)	AST  3 times ULN	Creatinine < 2.0 mg/dL	Creatinine clearance  45 mL/min	No hypercalcemia (i.e., calcium level > 1 mg/dL above ULN) OR hypocalcemia (i.e., calcium level > 0.5 mg/dL below lower limit of normal) within the past 6 months	No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix	No other nonmalignant systemic diseases, including any of the following:	Uncontrolled infection	Uncontrolled diabetes mellitus	Uncontrolled thyroid dysfunction	Disease affecting bone metabolism (hyperparathyroidism, hypercortisolism, Paget's disease, osteogenesis imperfecta)	Malabsorption syndrome	No uncontrolled seizure disorders associated with falls	No known hypersensitivity to zoledronate or other bisphosphonates, letrozole, calcium, or vitamin D	No concurrent active dental problems, including any of the following:	Infection of the teeth or jawbone (maxillary or mandibular)	Dental or fixture trauma	Prior or current diagnosis of osteonecrosis of the jaw	Exposed bone in the mouth	Slow healing after dental procedures	No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following:	History of surgery at the lumbosacral spine, with or without implantable devices	Scoliosis with a Cobb angle > 15 degrees at the lumbar spine	Immobility, hyperostosis, or sclerotic changes at the lumbar spine, or evidence of sclerotic abdominal aorta sufficient to interfere with DXA scan	Disease of the spine that would preclude the proper acquisition of a lumbar spine DXA	No condition that would preclude study follow-up or compliance	No psychiatric illness that would preclude giving informed consent	PRIOR CONCURRENT THERAPY:	More than 3 weeks since prior and no other concurrent oral bisphosphonates	No prior intravenous bisphosphonates	No prior aromatase inhibitor therapy	More than 6 months since prior anabolic steroids or growth hormone	More than 2 weeks since prior and no concurrent inhibitor of osteoclastic bone resorption (e.g., calcitonin, mithramycin, or gallium nitrate)	More than 30 days since prior systemic investigational drug and/or device	More than 7 days since prior topical investigational drug	More than 6 weeks since prior and no concurrent dental or jaw surgery (e.g., extraction, implants)	Concurrent short-term corticosteroid therapy allowed	No concurrent sodium fluoride, parathyroid hormone, or tibolone	No other concurrent investigational drug or device	Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these constitute contraindications to spine dual energy x-ray absorptiometry (DXA).	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial INCLUSION CRITERIA	PART 1:	confirmed pathologic diagnosis of a solid tumor not curable with available therapies for which neratinib plus capecitabine is a reasonable treatment option.	PART 2:	confirmed histologically and/or cytologically confirmed diagnosis of breast cancer, metastatic or locally advanced.	erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation), based on local testing, or based on centralized FISH testing prior to day 1.	disease progression on or following at least 1 prior trastuzumab containing treatment regimen (at least 6 weeks) for metastatic or locally advanced disease. (Prior adjuvant trastuzumab is allowed but not required). A 2 week period is required between the last dose of trastuzumab treatment and first dose of the test article.	Prior treatment with a taxane in the neoadjuvant, adjuvant, locally advanced, and/or metastatic disease treatment setting.	PARTS 1 and 2:	At least 1 measurable lesion as defined by RECIST criteria.	LVEF within institutional range of normal as measured by multi-gated acquisition (MUGA) or echocardiogram (ECHO).	EXCLUSION CRITERIA	PART 2:	prior treatment with capecitabine, lapatinib (20 subjects with prior lapatinib exposure will be enrolled) or any erbB-2 targeted agents except trastuzumab. Treatment with erbB-2 targeted therapy must exceed 2 weeks (14 days) in order to be exclusionary.	prior treatment with anthracyclines with a cumulative dose of doxorubicin of greater than 400 mg/m², epirubicin dose of greater than 800 mg/m², or the equivalent dose for other anthracyclines.	PARTS 1 and 2:	Subjects with bone as the only site of disease.	Active uncontrolled or symptomatic central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Subjects with a history of CNS metastases or cord compression are allowable if they have been considered definitively treated and are off anticonvulsants and steroids for at least 4 weeks before the first dose of test article.	Any other cancer within 5 years prior to screening with the exception of adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin.	Patients with HER2 positive tumors are ineligible for the primary trial.	[1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Exemestane	Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period.	INTERVENTION 2:	Tamoxifen	Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period.	The patient groups in the primary trial each receive different oral medication, either Tamoxifen or Exemestane.	[1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Female and male patients 18 years of age.	Histologically confirmed adenocarcinoma of the breast.	Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-T3, N1-N2, M0). (T1N0M0 lesions are excluded.)	Patients who have no clearly defined palpable breast mass or axillary lymph nodes but are radiographically measurable are eligible. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. In these patients, radiographic tumor measurements need to be repeated after 3 cycles and prior to surgery.	Positive HER2 status (overexpression and/or amplification of HER2 in the primary tumor) as defined by: IHC 3+ or fluorescence in situ hybridization (FISH) positive (ratio >2.2) testing. Documentation of the HER2 results must be available at the time of study enrollment.	An ECOG (Eastern Cooperative Oncology Group) performance score of 2	Normal bone marrow function as defined by:	absolute neutrophil count (ANC) >1,500/µL;	platelets >100,000/µL;	hemoglobin >10 g/dL.	Normal hepatic and renal function.	Left ventricular ejection fraction (LVEF) within the institutional limits of normal, whichever is lower, as measured by multi-gated acquisition (MUGA) scan or echocardiogram (ECHO).	Life expectancy > 12 weeks.	Estrogen and progesterone (or estrogen alone) receptor status in the primary tumor known or pending at the time of study enrollment.	For women of childbearing potential, negative serum pregnancy test within 7 days prior to starting treatment.	For women of childbearing potential, agreement to use a method of contraception that is acceptable to their physician from time of first signing the informed consent until at least 3 months after the last dose of study drug. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. Patient agreement to discontinue breast-feeding, if applicable, during study treatment. Men enrolled in the study must also agree to use a method of contraception that is acceptable to their physician during their study participation.	For patients with previous invasive cancers (including breast cancer) treated with curative intent, completion of chemotherapy or radiation therapy more than 5 years prior to enrollment for this study and no evidence of recurrent disease. Patients may be receiving anti-estrogen hormonal therapy prescribed for previous invasive breast cancer as long as the diagnosis of invasive cancer was made more than 5 years prior to study enrollment. Patients may be using anti-estrogen hormonal therapy at the time of current diagnosis but must discontinue this therapy before beginning study treatment.	For patients who had, or will have sentinel lymph node and/or axillary dissection prior to initiation of study treatment, completion at least 4 weeks prior to starting study treatment and well-healed wound.	Ability to understand and willingness to sign a written informed consent document.	Exclusion Criteria:	Previous treatment for this breast cancer.	Evidence of metastatic disease.	Prior radiation that included 30% of major bone marrow-containing areas.	Women who are pregnant or breastfeeding.	Neuropathy (motor or sensory) grade 1 at study entry.	History of significant cardiac disease or cardiac risk factors or the following:	uncontrolled arrhythmias	poorly controlled hypertension (e.g., systolic blood pressure [BP]> 150 mmHg or diastolic BP >100 mmHg) in spite of optimal medical management	angina pectoris requiring antianginal medication or unstable angina within the previous 6 months	history of documented congestive heart failure (CHF)	any documented myocardial infarction within the previous 6 months	clinically significant valvular heart disease	current use of medications (e.g., digitalis, beta-blockers, calcium channel-blockers) that alter cardiac conduction, if these medications are administered for the management of cardiac arrhythmia, angina, or CHF. If these medications are administered for other reasons (e.g., hypertension), the patient may be eligible.	patients with cardiomegaly on chest x-ray or ventricular hypertrophy on ECG unless ECHO or MUGA scan within the last 3 months demonstrates that the LVEF is  institutional lower limit of normal.	Symptomatic intrinsic lung disease.	Active malignancy, other than superficial basal cell carcinoma, superficial squamous (skin) cell carcinoma, carcinoma in situ, or non-invasive breast cancer, within the past 5 years.	Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection >grade 2.	Mental condition or psychiatric disorder rendering the subject unable to understand the nature, scope, and possible consequences of the study or that would limit compliance with study requirements.	Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving a reasonable suspicion of a disease or condition that contraindicates the use of a study agent or that may affect the interpretation of the results or renders the subjects at high risk from treatment complications.	Chronic use of CYP3A4 inhibitors and use of the following strong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, amprenavir, indinavir, nelfinavir, delavirdine, and voriconazole. Use of these agents must be discontinued at least 72 hours prior to initiation of study treatment.	Received chemotherapy for any indication within the 5 years preceding study enrollment.	Prior treatment with trastuzumab or any other anti-HER2 agent for any indication.	Concurrent treatment with any other anti-cancer therapy.	Concurrent radiation therapy during neoadjuvant study treatment.	Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment must be stopped prior to study enrollment.	Current therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention of breast cancer. These agents must be discontinued prior to study enrollment.	Participation within the previous 30 days in a study with an experimental drug.	Known or suspected allergy to Cremophor EL (polyoxyethylated castor oil), a drug formulated in Cremophor EL such as paclitaxel, or any other agent given in the course of this trial.	Inability or unwillingness to comply with study procedures including those for follow-up.	Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from the primary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion criteria:	Inclusion Criteria:	Female patients age 18 years or older	Histologically proven breast cancer after failure or relapse of no more than three lines of chemotherapy including adjuvant, irrespective of prior hormone therapy metastatic disease (stage IV);	HER2-negative patients (HER2 1+ or negative, or HER2 2+ and FISH negative)	At least one measurable tumour lesion (RECIST);	Availability of tumour samples	Written informed consent that is consistent with ICH-GCP guidelines and local law	Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0 - 2.	Exclusion criteria:	Exclusion Criteria:	Active infectious disease	Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhoea	Serious illness, concomitant non-oncological disease or mental problems considered by the investigator to be incompatible with the protocol	Active/symptomatic brain metastases	Cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal)	ANC less than 1500/mm3 platelet count less than 100 000/mm3	Bilirubin greater than 1.5 mg /dl (>26 and#61549 mol /L, SI unit equivalent)	AST and ALT greater than 2.5 times the upper limit of normal or greater 5 times the upper limit of normal in case of known liver metastases	Serum creatinine greater than 1.5 mg/dl (>132 and#61549 mol/L, SI unit equivalent)	Patients who are sexually active and unwilling to use a medically acceptable method of contraception	Pregnancy or breast-feeding	Concomitant treatment with other investigational drugs or other anti-cancer-therapy during this study and/or during the past two/four weeks, prior to the first treatment with the trial drug. Concurrent treatment with biphosphonates is allowed	Previous treatment with trastuzumab, EGFR-, or EGFR/HER2-inhibitors patients unable to comply with the protocol	Active alcohol or drug abuse	Other malignancy within the past 5 years	Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger 	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Premenopausal women 55 years of age or younger with regular menstrual cycles (at least four cycles in the last six months). Women with fewer than 4 menses in the last 6 months or who have had a hysterectomy with ovaries intact will be considered premenopausal if FSH level < 20.	Women with breast density  25% (scattered fibroglandular densities or greater) are eligible.	Prior Treatment	Patients who are currently receiving hormone replacement therapy (estrogen or progesterone); or are taking tamoxifen or raloxifene are not eligible. Women who have taken these medications must have stopped for at least 4 months prior to study entry.	Topical estrogen (eg, transdermal patches and vaginal estrogens) is allowed.	Patients who are currently using hormonal contraception, should be taking it for at least 4 months prior to study entry.	Vitamin D Use	Patients who are taking regular vitamin D supplementation (above 400 IUs daily) and refuse or are unable to stop use are not eligible. Women who agree to stop will need to do so for at least 6 months prior to registration.	Patients may not start vitamin D supplementation after registration (regardless of results of vitamin D testing) but they may continue vitamin D if they are already taking 400 IUs daily or less and have been taking vitamin D for at least 6 months prior to baseline mammogram.	Patients with a history of breast cancer (including DCIS) or ovarian cancer are not eligible.	Patients with a history of breast implants or breast reduction are not eligible.	Patients with two or more bone fractures in the past five years are not eligible.	Patients with a diagnosis of osteoporosis with physician recommendation for treatment of low bone mass are not eligible.	Patients known to have hyperparathyroid disease or other serious disturbances of calcium metabolism requiring intervention in the past 5 years are not eligible.	Patients with a history of kidney stones (unless documented not to have been a calcium stone) are not eligible.	Patients participating in a concurrent breast cancer chemoprevention trial are not eligible.	Required initial laboratory values - Calcium < 10.5 mg/dL	Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger 	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Adverse Events 1:	Total: 103/1408 (7.32%)	Anaemia 1/1408 (0.07%)	Angina pectoris 1/1408 (0.07%)	Myocardial infarction 1/1408 (0.07%)	Atrial fibrillation 0/1408 (0.00%)	Sinus tachycardia 0/1408 (0.00%)	Tachycardia 0/1408 (0.00%)	Vertigo 0/1408 (0.00%)	Diarrhoea 22/1408 (1.56%)	Vomiting 12/1408 (0.85%)	Nausea 4/1408 (0.28%)	Abdominal pain 2/1408 (0.14%)	Pancreatitis 2/1408 (0.14%)	Adverse Events 2:	Total: 85/1408 (6.04%)	Anaemia 1/1408 (0.07%)	Angina pectoris 0/1408 (0.00%)	Myocardial infarction 1/1408 (0.07%)	Atrial fibrillation 1/1408 (0.07%)	Sinus tachycardia 1/1408 (0.07%)	Tachycardia 1/1408 (0.07%)	Vertigo 1/1408 (0.07%)	Diarrhoea 1/1408 (0.07%)	Vomiting 1/1408 (0.07%)	Nausea 1/1408 (0.07%)	Abdominal pain 0/1408 (0.00%)	Pancreatitis 1/1408 (0.07%)	the primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial had 0.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial Adverse Events 1:	Total: 46/170 (27.06%)	Anaemia 1/170 (0.59%)	Febrile neutropenia 1/170 (0.59%)	Cardiac tamponade 1/170 (0.59%)	Myocarditis 1/170 (0.59%)	Pericardial effusion 2/170 (1.18%)	Pericarditis 1/170 (0.59%)	Colitis 1/170 (0.59%)	Constipation 1/170 (0.59%)	Diarrhoea 0/170 (0.00%)	Gastroenteritis eosinophilic 0/170 (0.00%)	Intestinal obstruction 0/170 (0.00%)	Adverse Events 2:	Total: 0/1 (0.00%)	Anaemia 0/1 (0.00%)	Febrile neutropenia 0/1 (0.00%)	Cardiac tamponade 0/1 (0.00%)	Myocarditis 0/1 (0.00%)	Pericardial effusion 0/1 (0.00%)	Pericarditis 0/1 (0.00%)	Colitis 0/1 (0.00%)	Constipation 0/1 (0.00%)	Diarrhoea 0/1 (0.00%)	Gastroenteritis eosinophilic 0/1 (0.00%)	Intestinal obstruction 0/1 (0.00%)	Nausea 0/1 (0.00%)	the primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial had 0.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	Cases with Stage II-IIIA Breast Cancer that have completed adjuvant treatment with anthracyclines and/or taxanes + or -Radiation therapy within past 6 months(+/- 7 days) (subjects on concurrent endocrine therapy (TAM, Aromatase inhibitors are also eligible to participate as this is standard of care for this patient population)	Able to understand and sign the informed consent	Fluent in reading, comprehension and communication in the English language	No evidence of dementia - Mini Mental State Examination (MMSE) >=23 but some evidence of cognitive impairment	Must be aware of the nature of his current medical condition and must be willing to give consent after being informed of the experimental nature of therapy, alternatives, potential benefits, side-effects, risks and discomforts	Eastern Cooperative Oncology Group (ECOG) performance status of 0- 2 (Karnofsky score >60%)	Acceptable hemoglobin and hematocrit level based on complete blood count (CBC)	Must be willing to be monitored for adequacy of nutritional intake during the intervention, as is the current standard of clinical practice	Exclusion Criteria:	Use of estrogens (oral, dermal or vaginal), progesterone (oral or topical), androgens, Raloxifene or Tamoxifen during the previous 3 months	Use of over the counter steroid hormonal supplements including dehydroepiandrosterone (DHEA)	Patients with advanced or Stage IIIIB or IV breast cancer or other cancers	Use of n-3 fatty acids or high dose antioxidant supplements other than what is provided in the trial	History of known allergy to components of the study supplements	Renal or liver disease	Concurrent participation in another chemoprevention trial	Evidence of bleeding diathesis or coagulopathy	Metabolic abnormalities (e.g. thyroid disorders, insulin dependent diabetes, rheumatologic disease etc.)	Known claustrophobia, presence of pacemaker and/or ferromagnetic material in their body that would prohibit MRI imaging	Medical history of concussions	Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase risk associated with study participation or study drug administration, or may interfere with interpretation of study results, and in the judgment of the investigator would make the potential participant inappropriate for entry into this study	Patients with irrational fear of confined spaces are not elligible for the primary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]
primary trial Outcome Measurement:	Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])	DFS=interval between the date of randomization and the date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause. The date of the event is the earliest date of the occurrence of any of the following: local recurrence (LR) following mastectomy; LR in ipsilateral breast following lumpectomy; regional recurrence; distant recurrence; contralateral breast cancer, including ductal carcinoma in situ; other second primary cancer (excluding squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, or lobular carcinoma in situ of the breast); death from any cause without a prior event. Par. who started additional anti-cancer adjuvant therapy prior to the recurrence of their disease were to be censored. Par. who did not withdraw from the study and did not experience a specified event or death were to be censored (follow-up ongoing) at the last visit date available at which progression was assessed.	Time frame: From randomization until date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause (assessed up to 6 years; 1 year of treatment, 5 years of follow-up [median of 5.3 years for final analysis])	Results 1:	Arm/Group Title: Lapatinib 1500 mg	Arm/Group Description: Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal.	Overall Number of Participants Analyzed: 1571	Measure Type: Number	Unit of Measure: Participants  Any recurrence or death: 252	Censored, New Anti-cancer Agent/Radiotherapy: 1	Censored, Follow-up Ended: 1318	Results 2:	Arm/Group Title: Placebo	Arm/Group Description: Participants received matching placebo orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal.	Overall Number of Participants Analyzed: 1576	Measure Type: Number	Unit of Measure: Participants  Any recurrence or death: 290	Censored, New Anti-cancer Agent/Radiotherapy: 1	Censored, Follow-up Ended: 1285	the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely to achieve DFS at 5 years than placebo patients.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion criteria:	Female patients  18 years of age.	Written informed consent given.	Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed.	Previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months.	Eastern Cooperative Oncology Group (ECOG) performance status 2 .	Life expectancy  1 year.	Exclusion criteria:	More than 3 months since last infusion of Zoledronic Acid (Zometa®).	Treatments with other bisphosphonate than Zoledronic Acid (Zometa®) at any time prior to study entry.	Serum creatinine > 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) < 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85	Corrected (adjusted for serum albumin) serum calcium < 8 mg/dl (2 mmol/L) or > 12 mg/dL ( 3.0 mmol/L).	Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.	Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants).	Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients. Women of childbearing potential not using effective methods of birth control (e.g. abstinence, oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide).	History of non-compliance to medical regimens or potential unreliable behavior.	Known sensitivity to study drug(s) or class of study drug(s).	Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study	Use of any other investigational agent in the last 30 days.	Patients must have a Life expectancy of at least 1 year to enroll in the primary trial	[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Adverse Events 1:	Total: 57/57 (100.00%)	Dry eyes  13/33 (39.39%)	Heartburn  9/33 (27.27%)	Nausea after the CT (before day 7)  57/57 (100.00%)	Herpetic eruption  0/33 (0.00%)	Dry skin  15/33 (45.45%)	Alopecia  57/57 (100.00%)	Adverse Events 2:	Total: 23/23 (100.00%)	Dry eyes  2/11 (18.18%)	Heartburn  2/11 (18.18%)	Nausea after the CT (before day 7)  23/23 (100.00%)	Herpetic eruption  3/11 (27.27%)	Dry skin  9/11 (81.82%)	Alopecia  23/23 (100.00%)	A total of 3 patients in the primary trial experience a Herpes related adverse event.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
primary trial Inclusion Criteria:	History of biopsy-proven HER-2-overexpressing breast cancer and radiographic evidence of metastatic disease. The HER-2 status can be determined either by immunohistochemistry (score, 3+) or by fluorescence in situ hybridization.	History of trastuzumab resistance, defined as the development of progressive disease after trastuzumab-based therapy for metastatic breast cancer. Patient may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen (either as single agent or in combination with chemotherapy)for metastatic breast cancer. Patients who develop metastatic disease during or after adjuvant or neoadjuvant trastuzumab are eligible.	Performance status 0-2 (by Eastern Cooperative Oncology Group (ECOG) scale).	Absolute neutrophil count (ANC) 1500/µl or higher; Platelets 100,000/µl or higher; Hemoglobin 9.0 gm/dL or higher; Serum creatinine 2.0 mg/dL or lower; Total bilirubin 1.5 mg/dL or lower; Serum glutamic pyruvic transaminase (SGPT) up to 3* upper limit of normal; Alkaline phosphatase up to 3* upper limit of normal; Calcium 11.0 mg/dL or lower.	Age 18 years or older.	Patients must not be pregnant. A pregnancy test will be obtained if the patient is a woman of child-bearing potential, defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses at any time in the preceding 24 consecutive months).	Patients must have signed an informed consent document stating that they understand the investigational nature of the proposed treatment.	Patients must have measurable disease using Response Evaluation Criteria in Solid Tumors (RECIST). Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension with longest diameter >/= 20 mm using conventional techniques or >/= 10 mm with spiral computed tomography (CT) scan.	Patients may not be receiving any other investigational agents, and must not have received investigational agents within 15 days of enrollment.	Left ventricular ejection fraction determined by echocardiogram or multigated acquisition (MUGA) (cardiac scan) must be 50% or higher.	Exclusion Criteria:	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements	Prior treatment with any investigational drug within the preceding 15 days	Chronic treatment with systemic steroids or another immunosuppressive agent	Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases, and patients diagnosed with brain mets or leptomeningeal disease (LMD) within 3 months.	Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.	A known history of HIV seropositivity	Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)	Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin)	Patients who have received prior treatment with an mTor inhibitor.	History of noncompliance to medical regimens.	Patients unwilling to or unable to comply with the protocol.	Patients who are receiving any other investigational agents	Patients exhibiting confusion, disorientation, or having a history of major psychiatric illness that may impair the understanding of the informed consent.	Patients must have at least 3 prior treatments with trastuzumab to be eligible for the primary trial.	[1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial Inclusion Criteria:	Histologically confirmed breast cancer with evidence of metastatic disease	HER2 3+ or FISH (fluorescent in situ hybridization)+	Age  18 years	No prior trastuzumab, except as given in the adjuvant or neoadjuvant setting.	No prior chemotherapy in the metastatic setting.	Exclusion Criteria:	CNS (central nervous system) metastases	Prior radiation therapy within the last 4 weeks	Pregnant (positive pregnancy test) or lactating women	Major surgical procedure, open biopsy, non-healing wounds, or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study	Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study.	Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for either the primary trial or the secondary trial.	[1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]
secondary trial DISEASE CHARACTERISTICS:	Histologically confirmed invasive breast cancer meeting the following criteria:	Primary tumor  3 cm by mammography, ultrasound, or palpation AND/OR palpable axillary lymph nodes > 1 cm	Survivin- and/or carcinoembryonic antigen-positive by IHC	Tumor must be localized by exam or ultrasound to allow tumor injection	No stage IV or metastatic disease	HER2/neu-negative tumor by IHC	If 2+ or in the indeterminate range, further testing of HER2/neu overexpression by fluorescent in situ hybridization (FISH) is required	Hormone receptor status known	PATIENT CHARACTERISTICS:	Female	Pre-, peri-, or postmenopausal	ECOG performance status 0-1	Not pregnant or nursing	Negative pregnancy test	Fertile patients must use effective contraception during and for up to 6 months following completion of study therapy	ANC  1,500/mm³	Platelet count  100,000/mm³	Alkaline phosphatase  1.5 times upper limit of normal (ULN)	Total bilirubin  1.5 times ULN	AST and ALT  1.5 times ULN	Creatinine < 1.5 times ULN	No active serious infections	No prior malignancy except adequately treated basal cell or squamous cell skin cancer, noninvasive carcinoma, or other cancer from which the patient has been disease free for 5 years	No comorbidity or condition that would interfere with study assessments and procedures or preclude study participation	PRIOR CONCURRENT THERAPY:	No prior chemotherapy or radiotherapy	Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for either the primary trial or the secondary trial.	[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]
primary trial Outcome Measurement:	LDex Change-	Bioimpedance measured by units of LDex. As extracellular fluid accumulates (i.e. lymphedema develops) the LDex value increases.	Time frame: Bioimpedance at baseline and end of treatment with the average number of treaments being 9 conducted over a median of up to 4 weeks.	Results 1:	Arm/Group Title: Laser Therapy Alone	Arm/Group Description: therapist administered laser treatment	laser: therapist administered laser	Overall Number of Participants Analyzed: 15	Median (Inter-Quartile Range)	Unit of Measure: LDex  28.0        (17 to 35)	Results 2:	Arm/Group Title: Mld Alone	Arm/Group Description: therapist administered manual lymphatic drainage	manual lymphatic drainage: therapist administered massage therapy	Overall Number of Participants Analyzed: 16	Median (Inter-Quartile Range)	Unit of Measure: LDex  17.8        (3 to 38)	the secondary trial and the primary trial do not record the same metrics in their results section	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
secondary trial Outcome Measurement:	Overall Survival (OS) of Patients	To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC). Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients will be followed until their date of death or until final database closure. Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis.	Time frame: Within 3 years from study start	Results 1:	Arm/Group Title: NKTR-102	Arm/Group Description: In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.	Overall Number of Participants Analyzed: 92	Median (95% Confidence Interval)	Unit of Measure: months  7.8        (6.1 to 10.2)	Results 2:	Arm/Group Title: Treatment of Physician's Choice (TPC)	Arm/Group Description: In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.	Overall Number of Participants Analyzed: 86	Median (95% Confidence Interval)	Unit of Measure: months  7.5        (5.8 to 10.4)	the secondary trial and the primary trial do not record the same metrics in their results section	[1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]
primary trial INTERVENTION 1:	Treatment (Neoadjuvant Therapy, Adjuvant Therapy)	See Detailed Description.	doxorubicin hydrochloride: Given IV	cyclophosphamide: Given PO	paclitaxel: Given IV	filgrastim: Given SC	capecitabine: Given PO	methotrexate: Given IV	vinorelbine tartrate: Given IV	needle biopsy: Correlative studies	therapeutic conventional surgery: Undergo definitive breast surgery	immunohistochemistry staining method: Correlative studies	trastuzumab: Given IV	tamoxifen citrate: Given PO	letrozole: Given PO	laboratory biomarker analysis: Correlative studies	IV is used as route of administration by the interventions in the primary trial and the secondary trial.	[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]
secondary trial INTERVENTION 1:	100 mg Q-122	Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.	INTERVENTION 2:	200 mg Q-122	Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.	IV is used as route of administration by the interventions in the primary trial and the secondary trial.	[1, 1, 1, 0, 0, 0]
